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AJCC American Joint Committee on Cancer 
BMCA bisulphite melting curve analysis 
BRAF B-Raf proto-oncogene, serine/threonine kinase 
BrdU 5-bromo-2´-deoxyuridine 
BSA bisulphite sequencing analysis 
C10rf106 chromosome 1 open reading frame 106 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 
CDKN2A cyclin-dependent kinase inhibitor 2A 
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CPSF6 cleavage and polyadenylation specific factor 6,68kDa 
D176A aspartic acid at amino acid 176 replaced by alanine, MAPK13 mutant 
DNMT DNA (cytosine-5-)-methyltransferase 
EFCAB1 EF-hand calcium binding domain 1 
EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit 
F324S phenylalanine at amino acid 324 replaced by serine, MAPK13 mutant 
FAMMM familial atypical multiple mole melanoma 
HDAC histone deacetylase 
HIST1H3E histone cluster 1, H3e 
HOXA9 homeobox A9 
LEP leptin 
MAGEA melanoma antigen family A 
MAGEB melanoma antigen family B 
MAPK13 mitogen-activated protein kinase 13 
MBD methyl-CpG-binding domain proteins 
MCHR1 melanin-concentrating hormone receptor 1 
MeCP2 methyl CpG binding protein 2 
MeDIP methylated DNA immune precipitation 
MITF microphthalmia-associated transcription factor 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 
OIS oncogene-induced senescence 
p38δ p38 MAP kinase protein, isoform δ 
PLEKHG6 pleckstrin homology domain containing, family G (with RhoGef domain) member 6 
PPP1R3C protein phosphatase 1, regulatory subunit 3C 
RASEF RAS and EF-hand domain containing 
Rb retinoblastoma protein 
ROS reactive oxygen species 
SYNPO2 synaptopodin 2 (myopodin) 
TBP TATA box binding protein 
TIMP3 TIMP metallopeptidase inhibitor 3 
TNM tumor depth (T), lymph node status (N), and distant metastasis (M) classification 


























Clinical aspects of melanoma 
Cutaneous melanoma is a type of cancer that originates from melanocytes residing in the 
skin. It is characterized by a propensity to metastasize and resistance to chemotherapy. 
The majority of cutaneous melanoma can be divided into four subtypes: superficial 
spreading, nodular, lentigo maligna, and acral lentiginous melanoma
1
. A prediction of the 
course of disease and the survival rate depends largely on the extent of the cancer at the 
time of diagnosis in the patient. The American Joint Committee on Cancer (AJCC) staging 
system is generally applied in the clinic to categorize melanoma into defined stages based 
on TNM classification
2
. Melanoma is divided into four stage categories, where stage I is a 
thin localized tumor, stage II a thick localized tumor, stage III the presence of regional 
lymph node metastases and stage IV the presence of distant metastases. The 5-year 
overall survival rate for stage I is approximately 90%, for stage II 70%, stage III 60% and 
stage IV 20%
2
. In a proportion of patients the sentinel node procedure is performed to 
examine the presence of nodal micrometastases. In addition to the presence of nodal 
micrometastases, the prognosis of melanoma patients without apparent metastatic 
disease is determined by tumor thickness, microscopic ulceration, mitotic rate, tumor site, 
sex and age of the patient
1
. For a localized tumor, surgical resection is the principle 
therapy. For melanoma that has metastasized to distant sites, the two main treatment 
modalities are molecular targeted therapy, developed and tested in clinical trials for BRAF, 
MEK and KIT mutant melanoma, and immune-based therapy that have lead to a better 




Epidemiology of melanoma 
The incidence of cutaneous melanoma in the Netherlands for men and women was 9.0 
and 12.2 per 100.000 person-years respectively over a five-year period of 1989-1993. For 
the period of 2004-2008, the incidence for males and females was 17.9 and 21.5 per 
100.000 person-years respectively. The ten-year relative survival rate of cutaneous 
melanoma for men and women in the Netherlands was 77% and 88% respectively over 
2004-2008. The mortality rate, standardized for age, was 2.2 per 100.000 person-years in 
1989 and has since increased to 3.9 per 100.000 person-years in 2009. The mortality rate 
for individuals between 0-44 years however has remained stable; a significant increase has 
been observed for individuals older than 45 years, with the largest increase in mortality 




Risk factors for melanoma 
Environmental melanoma risk factors include intermittent exposure to sunlight, sunburn 
and the use of tanning beds. Protection from sunlight exposure can reduce the risk of 
developing melanoma
5,6
. Aside from these environmental factors, several phenotypic 




markers include the presence of more than 100 naevi or more than five dysplastic naevi 
on the body, a fair skin type, red or blond hair color, blue eye color, freckles, the presence 
of actinic keratosis or lentigines and a history of basal cell carcinoma or squamous cell 
carcinoma
7-9
. In addition to phenotypic characteristics, genetic variants that predispose to 
the development of melanoma have been identified using genome-wide association 
studies. The variations often occur in genes that are implicated in the pigmentation 
response and in naevus development
10,11
. In approximately 10% of cases there is familial 
clustering of melanoma. This autosomal dominantly inherited genetic condition is termed 
familial melanoma, hereditary melanoma or familial atypical multiple mole melanoma 
(FAMMM) syndrome; generally defined as melanoma occurring in 3 or more members of a 
family, with a first-degree relationship between at least two affected members. An 
estimated 40% of patients with familial melanoma carry a mutation in CDKN2A, a gene 




 tumor suppressor proteins. A founder mutation in 
CDKN2A has also been identified in familial melanoma kindreds known as the p16-Leiden 
deletion
12
. Individuals with melanoma predisposition by CDKN2A mutation who live at 
lower latitudes have a higher melanoma incidence, suggesting a correlation with sunlight 
exposure
13
. The life-time risk to develop melanoma of individuals that carry a CDKN2A 





Melanoma develops from melanocytes, the melanin-producing cells localized in the basal 
layer of the epidermis and in the hair follicles. A melanoma can develop de novo, or from 
an existing common naevus or dysplastic naevus. Melanocytic naevi, both common and 
dysplastic, are important in relation to melanoma because they can be regarded as 





Common naevus and dysplastic naevus 
A common naevus, or mole, is a benign melanocytic neoplasm that consists of clusters of 
melanocytes that underwent limited rounds of proliferation. A common naevus is often 
smaller than 5 millimeters in diameter and round or oval in shape, with a distinct edge. A 
dysplastic naevus is generally larger than 5 millimeters in diameter and may differ in color, 
surface, symmetry and border from a common naevus
16,17
. A dysplastic naevus can be 
distinguished from a common naevus based on the presence of architectural disorder and 
cytologic atypia which can be mild to severe
15,18
. Dysplastic naevus cells have been 
observed to produce more reactive oxygen species (ROS) than normal melanocytes in the 
skin
19
. Compared to common naevus cells, dysplastic naevus cells showed abnormalities in 
pathway components involved in the processes of cell proliferation and apoptosis
20-23
. 








There are clinical and histopathological criteria to distinguish a common naevus 
and dysplastic naevus from melanoma. However, substantial inter-observer variability in 
separating melanocytic naevi from melanoma remains
25
. Especially the differentiation 
between melanoma in its early stages and a dysplastic naevus remains challenging since 
the histological features used as criteria for dysplastic naevus overlap to some extent with 
those for early-stage melanoma
16
. 
The majority of common naevi demonstrate maturation, a histological feature 
indicative of a benign lesion, with a decrease in the pigmentary activity and size of the 
naevus cells at the periphery of the lesion in the dermis. In line with this are findings that 
melanocytic naevi very rarely develop into melanoma in the general population, the 
estimated annual transformation rate of a common naevus into melanoma is 1 in 200.000 
for men and women younger than 40 years, and 1 in 33.000 for men older than 60 years
26
. 
Despite the low transformation frequency of naevi into melanoma, both common and 
dysplastic naevi are associated with an increased melanoma risk. Additionally, individuals 




A model of melanoma progression 
Melanocytic naevi are also important in relation to melanoma because they are potential 
precursors of melanoma. Cutaneous melanoma develops in over half of the cases de novo, 
but in an estimated 20%-50% of cases from a common or dysplastic naevus. Observations 
have been made of individuals with pre-existing naevi that underwent malignant change, 
next to patients that had histological dysplasia in contiguity to their melanoma
15
. Common 
naevi harbor frequent mutation of BRAF and mutations in NRAS or KRAS at lower 
frequencies, while dysplastic naevi were found to harbor BRAF mutation and allelic 
deletion at chromosome 9p21
27-29
. These genetic alterations have also been frequently 
found in melanoma, sometimes in cases where a melanoma and adjacent naevus in the 
same patient were examined
30-32
. Melanocytes in the skin are assumed to undergo initial 
rounds of proliferation as a result of the aberrant activity of a mutated oncogene such as 
BRAF. This initial growth is followed by a stable cell cycle arrest that is part of the 
oncogene-induced senescence (OIS) response, an important mechanism that acts to 
prevent further malignant activity of the melanocytes and gives rise to a benign 
melanocytic lesion, a common naevus
33
.  
The model of melanoma development and progression as proposed by Clark 
describes the histologic changes that accompany the development of a common naevus, 
dysplastic naevus and the different stages of melanoma (Figure 1)
34
. In this process, 
benign melanocytes acquire a variety of increasingly malignant phenotypic features that 




phenotypic change of normal melanocytes in the skin, placing the common naevus at the 
start of the melanoma development and progression model. The development of a 
dysplastic naevus is generally regarded as an intermediate step between common naevus 
and melanoma. In the stage of melanoma, the melanoma cells of a localized tumor display 
an increasing loss of cellular differentiation and have the ability of unlimited proliferation. 
In the radial-growth phase, the tumor expands mainly in a horizontal direction in the 
epidermis of the skin. In the vertical-growth phase, melanoma cells cross the basement 
membrane and grow further into the dermis of the skin. The capacity of melanoma cells to 
invade the dermis is significantly correlated with their capacity to metastasize. In the stage 
of metastatic melanoma, cells dissociate from the primary tumor and migrate through 
surrounding stroma to invade lymph or blood vessels. From there, melanoma cells can 
spread via lymph or blood to distant body sites and form secondary tumors (Figure 1). 
 
 
Figure 1. Schematic representation of different stages in the development of melanoma. (Adapted 
from reference 34 with permission of Massachusetts Medical Society, copyright 2006.) 
 
Genetic alterations in melanoma 
Research through the years has identified a multitude of genes that are affected in 
melanoma by genetic alterations, leading to aberrant signaling of cellular pathways that 
contribute to the malignant phenotype of melanoma cells. Table 1 lists the melanoma 
oncogenes and tumor suppressor genes that have been extensively studied, some of 
which will be described here. 
Activating mutations in BRAF occur in approximately 50% of all melanomas, they 
are most commonly found in cutaneous melanoma of intermittently sun-exposed skin and 
rare in mucosal and acral melanoma. Most frequently, valine at amino acid 600 is replaced 
by glutamic acid (V600E) by mutation of a single nucleotide (GTG to GAG) in the kinase-




mutation at the same site substitutes lysine for valine (V600K) by mutation of two 
nucleotides (GTG to AAG)
35,36
. 
NRAS mutations are also found in cutaneous melanoma, including those that 
arise in intermittently sun-exposed skin and other types of melanoma, at a frequency of 
approximately 20%. NRAS mutations occur most frequently in codon 61 and have also 
been identified in codon 12, 13 and 18
37
. NRAS and BRAF mutations are almost never 
found simultaneously in melanoma. Similar to BRAF mutation, NRAS mutation leads to 
hyperactivation of the MEK/ERK signaling pathway
38,39
. 





, from two transcript variants that differ in their first exons. CDKN2A 





 binds to and inhibits G1 cyclin-dependent kinase (Cdk) 4 and 6. 
Cdk4/6 phosphorylate and inactivate the retinoblastoma protein (Rb) to allow progression 
of the cell cycle into the S-phase. Loss of p16
INK4A
 therefore promotes Rb inactivation, 
leading to uncontrolled cell proliferation. It has been proposed that disruption of the 
p16
INK4A
-Rb pathway, mainly by CDKN2A inactivation, may be an important next step in the 
melanoma progression model. Together with the activation of hTERT to maintain minimal 
telomere length and other additional molecular alterations, disruption of the p16
INK4A
-Rb 
pathway allows neval melanocytes to overcome senescence and acquire the ability for 
unrestrained proliferation
35
. Often melanomas that harbor BRAF mutation also have 




 is known to stabilize p53, a tumor suppressor 
protein that responds to a variety of cellular stresses and regulates the expression of 
target genes to induce a tumor restrictive response such as cell cycle arrest, apoptosis or 
DNA repair. Mutations in the encoding gene, TP53, were found in 19% of melanoma 
cases
40
. Germline CDKN2A mutation occurs in an estimated 40% of patients with familial 
melanoma. 
The PTEN (phosphatase and tensin homolog) tumor suppressor is inactivated by 
deletion or mutation in 25% and 12% of melanoma cases respectively
40
. PTEN mutations 
are often found together with BRAF mutation
41,42
. The loss of PTEN in some melanomas, 
especially in melanomas that also harbor BRAF mutation, leads to consecutive activation 
of the PI3K pathway. Experiments conducted in mice showed that deletion of PTEN or 
CDKN2A alone in mouse melanocytes did not lead to development of melanoma
43,44
. 
However, the combination of either PTEN or CDKN2A deletion with a mutation such as 
BRAF
V600E
 can give rise to melanoma
45
. This underscores the understanding that loss of 
CDKN2A or PTEN alone is only one event in the process and that additional molecular 
alterations are needed for full melanoma development. 
As the melanocyte master regulator, MITF (microphthalmia-associated 




maintains melanocyte progenitor cells in adults. Amplification of MITF has been found in 
4% of melanomas. In addition a rare inherited MITF gene variant is known to predispose 
to familial melanoma
46
. Many melanomas are dependent on MITF as a survival factor and 
loss of MITF activity renders melanoma cells sensitive to chemotherapeutic agents
38,39
. 
Melanomas that arise on chronically sun-exposed skin, on mucous membrane 
(mucosal melanoma) and on palms, soles and nail bed (acral melanoma) show relatively 
low frequency of BRAF mutation but harbor alterations in other genes. Activating 
mutations and amplifications of the tyrosine kinase KIT have been found in these 
melanomas. Activation of KIT results in proliferation and survival advantages via induction 
of the MAPK and PI3K pathways. Alterations in components of the p16
INK4A
-Rb pathway 
that impact cell cycle regulation have also been identified, such as amplification of cyclin 




Table 1. Genes affected by mutation, amplification or deletion in melanoma as adapted from 
references 38 and 39. M, mutation; A, amplification; D, deletion. 
 
Gene Alteration Frequency Affected pathways/processes 
Kinases or signaling factors   
BRAF M 50% MAPK 
NRAS M 20% MAPK, PI3K and RALGDS 
KIT M or A 3% M; 6% A MAPK and PI3K 
CDK4 A 3% Cell cycle 
CCND1 A 10% Cell cycle 
PPP6C M 9% Cell cycle 
RAC1 M 5% PAK 
STK19 M 4% unknown 
MAP3K5, MAP3K9 M 24% JNK, p38 MAPK 
Transcription factors   
MITF A 4% Melanocyte lineage,  cell cycle 
Tumor suppressors   
CDKN2A M or D 19% M; 38% D Cell cycle 
TP53 M 19% Cell cycle 
ARF M 12% Cell cycle 
PTEN M or D 12% M; 25% D PI3K 
Epigenetic regulators 
ARID2 M 9% Chromatin remodeling 
EZH2 M 3% Chromatin remodeling 
 
Recently new genes with somatic mutations have been identified through exome 
sequencing in melanoma, these include PPP6C and RAC1, encoding a phosphatase 
involved in cell cycle regulation and a GTPase involved in regulating cell adhesion and 
migration respectively, and the kinase-encoding STK19
40
 (Table 1). Somatic mutations 









Human DNA is organized into 23 chromosome pairs that together contain over 25.000 
protein-coding genes. DNA is stored in a condensed form in the nucleus of the cell. In 
order to achieve such condensed packaging, the DNA molecule is wrapped around 
histones, highly conserved proteins that are present in the nucleus of all eukaryotic cells. 
Histones are grouped into five classes (H1, H2A, H2B, H3 and H4). Two sets of histone 
classes H2A, H2B, H3 and H4 bind to 147 DNA base pairs as an octamere to form a 
repeating unit known as the nucleosome (Figure 2). The fifth histone class H1 serves as a 
linker histone and binds to the nucleosome to enable the organization of the nucleosomes 
into a higher-order structure, the 30-nm filament
49
 (Figure 2). Together the DNA molecule 
and histone proteins form a DNA-protein polymer known as chromatin. 
 
Epigenetic regulation of gene expression  
Chromatin is a dynamic macromolecular structure that can exist in different 
configurations. The structure of chromatin can differ in packaging density that ranges from 
a relatively loose form known as euchromatin where active gene transcription can take 
place, to a highly condensed form known as heterochromatin where transcriptional 
activity is silenced, such as at the centromeres and telomeres of chromosomes. 
Euchromatin consists in large part of coding sequences and makes up less than 4% of the 
genome in mammals. Some heterochromatic structures remain permanently silent 
(constitutive heterochromatin) and genes that are located in such regions will rarely be 
expressed in any cell type, while other heterochromatic structures (facultative 
heterochromatin) can be found at the coding regions of the genome and function to 
silence only in certain cells during a specific cell cycle or stage in development
50-52
.The 
range of variation that exists in chromatin structure can be introduced via different 
mechanisms, including chromatin remodeling, histone modifications and DNA methylation 
which will be briefly introduced here.  
 
Chromatin remodeling  
Chromatin remodeling is one of the mechanisms by which changes in chromatin structure 
can be introduced. In chromatin remodeling, protein complexes hydrolyze ATP in order to 
bring about non-covalent modifications in the chromatin structure. This ATP-dependent 
remodeling includes the replacement of a regular histone protein with another histone 
variant, the moving of a histone octamere along the DNA strand (nucleosome sliding), the 
removal of a histone octamere (nucleosome eviction) and the creation of a DNA loop on 
the surface of the histone octamere (DNA looping). Through these chromatin remodeling 
processes, DNA regions that were previously occluded or ‘tucked away’ in the chromatin 








The second mechanism by which changes in chromatin structure are introduced is the 
addition of posttranslational modifications to histone proteins within the nucleosome. 
Several different types of posttranslational histone modifications have been identified so 
far, including histone acetylation, methylation and phosphorylation. The presence of such 
a modification results in an altered electrostatic charge or structure of a histone protein. 
This in turn induces changes in the contact between nucleosome units, leading to a 






Another well-known epigenetic mechanism of inducing alterations in the chromatin 
structure is DNA methylation. With this modification, a methyl group is added to a 
cytosine nucleotide of the DNA to yield 5’-methylcytosine (Figure 3). In mammals, DNA 
methylation takes place at CpG dinucleotides in the linear DNA sequence. CpG 
dinucleotides are non-randomly distributed in the human genome in focused, CpG-rich 
regions known as CpG islands. CpG islands can be found at the 5’end region of over half of 
all human genes consisting of the promoter, untranslated region and the first exon. DNA 
methylation is known to have an important role in developmental processes such as X-
chromosome inactivation and genomic imprinting. DNA methylation patterns in mammals 
are established during embryonic development and they are maintained in each cell 
division. Specialized enzymes, DNA methyltransferases (DNMTs), catalyze the de novo 
addition of methyl groups or function to maintain existent DNA methylation. In the 
genome of higher eukaryotes, an enrichment of methylated DNA is found in regions that 





DNA methylation also functions to silence gene transcription. One way is through the 
interaction of methylcytosine with methyl-CpG-binding domain proteins (MBDs). In 
humans, the methyl-CpG-binding protein MeCP2 binds to methylcytosine in order to 
recruit histone deacetylases (HDACs), specialized enzymes that deacetylate the lysine 
residues of histone proteins. This histone deacetylation subsequently induces alterations 
of the nucleosome to mediate repression of transcriptional activity. The presence of 
methylcytosine can also prevent binding of transcription factors which only bind to CpG 
sequences in the DNA that are not methylated, leading to the inhibiton of gene 
transcription
57
. Other forms of modifications to cytosine within the CpG dinucleotide have 
also been found that are believed to be involved in regulation of gene expression, 







Together the before mentioned mechanisms make chromatin a dynamic DNA-organizing 
entity that determines when and which genes are expressed. Epigenetics is therefore 
defined as changes in gene transcription caused by modulation of chromatin, which are 
not caused by changes in the DNA sequence. Epigenetics is important for establishing and 
maintaining a healthy state of an organism as aberrant alterations in the epigenetic 
machinery cause a variety of diseases in humans, including developmental and 
neurological disorders
59-61
. Moreover, it has become increasingly clear from the 
substantial number of studies performed in the past two decades that cancer is a disease 
that is caused by not only genetic alterations, but also epigenetic alterations that involve 





Figure 2. Organization of chromatin
63
:
1. A short region of the DNA double 
helix 2. A DNA strand wrapped around a 
histone octamere to comprise a 
nucleosome 3. 30-nm chromatin fibre 
of stacked nucleosomes 4. A section of 
the chromosome in an extended form 
5. A condensed section of the 
chromosome 6. An entire mitotic 
chromosome. (Adapted from reference
63 with permission of American Society 





Figure 3. DNA methyltransferase catalyzes 
the addition of a methyl group to the fifth 
carbon atom within the pyrimidine ring of 
the cytosine base to yield 5’-methylcytosine. 
 
DNA methylation in cancer 
Since the discovery of 5’-methylcytosine in DNA, studies have observed differences in the 
DNA methylation pattern between normal cells and cancer cells. Cancer cells were found 
to have a global loss of the 5’-methyl modification (hypomethylation) across the 
genome
64,65
. Global genomic hypomethylation has been observed in a number of human 
cancer types such as B-cell chronic lymphocytic leukemia, cervical cancer, prostate cancer 
and metastatic hepatocellular cancer
66-69
. Since stable DNA methylation in the genome 
functions to maintain chromosomal integrity, a loss of this modification contributes to 
genomic instability, a hallmark of cancer
70,71
. Additionally, the loss of repressive 
methylation marks may lead to aberrant transcriptional activity of oncogenes that 
contribute to the malignant transformation of normal cells to cancer cells
72
. In contrast to 
most of the genome, CpG islands located in the promoter region in normal human cells 
are largely unmethylated, with methylation of only a very small percentage of the 
cytosines
73,74
. In cancer cells, often an aberrant increase of methylation 
(hypermethylation) at these promoter CpG island regions has been observed that 
correlates with transcriptional silencing of the genes involved
75
 (Figure 4). Aberrant 
promoter hypermethylation has also been found in cutaneous melanoma. Some of the 
genes that have been identified as promoter hypermethylated are known to be involved in 
a variety of cellular processes (Table 2). Known tumor suppressor genes that are 
inactivated by mutation have also been observed to be inactivated by hypermethylation in 
cutaneous melanoma such as CDKN2A, CDH1, PTEN and ARF
76-79
. Promoter CpG island 
hypermethylation can therefore contribute to melanoma development through the 
inactivation of tumor suppressor genes. 
 
DNA methylation alterations in cutaneous melanoma 
Several studies have investigated DNA methylation alterations in cutaneous melanoma so 
far. Initial studies of methylation in cutaneous melanoma have focused on the 
investigation of promoter methylation of one candidate gene at a time. Promoter 
hypermethylation of P27Kip1, RASSF1A, Maspin and APC has been found in this way
80-83
. 
Other studies have analyzed a selected group of candidate genes and observed the 
presence of methylation
84-88
. The global demethylating agent 5'-aza-2'-deoxycytidine 
(Decitabine) has often been used in methylation studies. When added to cells, 5'-aza-2'-




Figure 4. Schematic 
representation of a gene 
promoter region in a 
normal cell (left) versus a 
cancer cell (right). 
Hypermethylation in the 
cancer cell leads to 
transcriptional silencing 
of the gene. 
inhibit cytosine methylation in subsequent rounds of DNA synthesis during cell 
replication
89,90
. 5'-aza-2'-deoxycytidine is therefore applied to investigate associations 
between promoter hypermethylation and transcriptional repression, with the assumption 
that erasing methylation will lead to re-activation of gene expression. A number of studies 
have applied the gene re-activation principle of 5'-aza-2'-deoxycytidine treatment to 
screen for methylation alterations in cutaneous melanoma. These studies subjected 5'-
aza-2'-deoxycytidine-treated melanoma cell lines to microarray analysis, subsequently 
analyzing the methylation status of those genes that showed significant upregulated 
expression in the treated cell lines
91,92
. Other screening approaches have aimed to directly 
analyze methylation, such as methylated DNA immune precipitation (MeDIP). MeDIP uses 
methyl-binding proteins to precipitate methylated sequences in the genome. The 
obtained sequences are subsequently hybridized to CpG island arrays in order to identify 
the genes involved
93,94
. Hypermethylation of COL1A2, NPM2, HSPB6, DDIT4L and MT1G 
has been found in this way
95
. DNA methylation screening based on direct hybridization of 
sample DNA eliminated the need for methyl-binding antibodies and circumvented the 
issues associated with MeDIP. The HumanMethylation27K Beadchip array, consisting of 
oligonucleotide-coated beads for hybridization of bisulphite-treated DNA, has been used 
for the analysis of cultured melanoma cell lines and resulted in the identification of 
WNT10B, TUB, ALOX12B and SLC6A11
96,97
. Using the GoldenGate methylation array, 1505 
CpG loci across 807 cancer-related genes have been analyzed in biopsy tissue from benign  
 
Table 2. Genes that have previously been found to be hypermethylated in cutaneous melanoma. 
Hypermethylated genes in cutaneous melanoma 
Apoptosis:  RASSF1A,  TNFRSF10C,  TP53 
Cell Cycle:  CDKN1B,  CDKN1C,  CDKN2A 
Cell fate determination:  APC, WIF1 
Differentiation:  HOXB13 
Extracellular matrix:  COL1A2 
Immune response:  HLA class I,  MAGE1,  MAGEA2, A3, A4 
Invasion / Metastasis:  CDH1,  CDH8,  CDH13,  SERPINB5,  TFPI-2,  TIMP3,  SYK 




naevi and invasive melanomas, where hypermethylation of FRZB was found, together with 
hypomethylation of EMR3 and RUNX3 in melanoma
98
. Table 3 gives a summary of the 
methylation studies that have been performed prior to the genome-wide methylation 
study described in this thesis; they are categorized according to applied analysis method 
and type of studied material. 
 
Table 3. Overview of methylation studies performed prior to the genome-wide methylation study 
described in Chapter 2 of this thesis with reference numbers to respective papers. 
 
  Reference 







 CG x x x x x x x x x x x x x       
DM              x x     
IP                x    








CL x x  x x x x x x x x  x x x x x x  
BT x x x  x x x x  x x  x      x 
S   x         x        
 
                                                            
1
method applied: 
CG: candidate gene(s), methylation status analysis of a single gene or a group of genes 
DM: demethylation, expression profiling after 5’-aza treatment 
IP: immuno-precipitation, precipitation of methylated sequences with methyl-binding proteins 




CL: melanoma cell lines 






Studies of DNA methylation alterations in melanoma that have been performed thus far 
provide a scattered view on the methylation alterations that are present in cutaneous 
melanoma. In most studies a selection of candidate genes has been analyzed. Those 
studies aimed at a more broad analysis of DNA methylation in the genome, have been 
performed on cultured melanoma cell lines or metastatic melanoma biopsies. In one study 
DNA methylation was analyzed in primary biopsy samples on only 807 selected cancer-
related genes, but a study of promoter CpG island methylation alterations at a genome-
wide level was still lacking. The analyses performed in this study have been permitted by 
the introduction of reliable beadchip technology (Illumina’s Infinium platform) capable of 
analyzing methylation at high resolution with high reproducibility on a genome-wide scale, 
and the availability for these studies of fresh-frozen primary melanoma tumor samples. 
Our aims were to perform genome-wide promoter CpG island methylation 
profiling of primary cutaneous melanoma biopsy specimens using Illumina’s 
HumanMethylation27K Beadchip technology, in order to identify novel genes that are 
affected by aberrant promoter methylation in primary melanoma in comparison to 
common naevus (described in Chapter 2). In addition we asked whether genes that are 
affected by DNA hypermethylation in primary melanoma may have a tumor suppressive 
role in the development of melanoma. This question is addressed in Chapter 2 and 
Chapter 3. Still relatively little is known about methylation alterations in dysplastic naevi 
and it remains challenging to distinguish dysplastic naevus from early-stage primary 
melanoma. In Chapter 4 we aimed to examine promoter CpG island hypermethylation in 
dysplastic naevi and to investigate the diagnostic value of the methylation status of a five-
gene panel in distinguishing primary melanoma from dysplastic naevus. In Chapter 5, gene 
expression differences between melanocytes from dysplastic naevus and melanocytes 
from normal skin are examined. Up to now only few (epi)genetic alterations have been 
identified that confer the capacity to melanoma cells for invasion and dissemination. 
Much of the genetic and epigenetic basis of the metastatic capacity of melanoma remains 
unknown. Our aim in Chapter 6 was to investigate differential methylation events in 
primary melanoma with and without metastatic capacity and whether these events have 
prognostic value in predicting metastatic disease. Finally in Chapter 7, the results 
described in Chapters 2 to 6 are summarized and put into perspective with existent 
literature. It is also discussed to which extent the set aims at the start of this thesis have 
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The involvement of epigenetic alterations in the pathogenesis of melanoma is increasingly 
recognized. Here, we performed genome-wide DNA methylation analysis of primary 
cutaneous melanoma and benign melanocytic naevus interrogating 14,495 genes using 
BeadChip technology. This genome-wide view of promoter methylation in primary 
cutaneous melanoma revealed an array of recurrent DNA methylation alterations with 
potential diagnostic applications. Among 106 frequently hypermethylated genes, there 
were many novel methylation targets and tumor suppressor genes. Highly recurrent 
methylation of the HOXA9, MAPK13, CDH11, PLEKHG6, PPP1R3C, and CLDN11 genes was 
established. Promoter methylation of MAPK13, encoding p38δ, was present in 67% of 
primary and 85% of metastatic melanomas. Restoration of MAPK13 expression in 
melanoma cells exhibiting epigenetic silencing of this gene reduced proliferation, 
indicative of tumor suppressive functions. This study demonstrates that DNA methylation 
alterations are widespread in melanoma and suggests that epigenetic silencing of MAPK13 
contributes to melanoma progression. 
 
Introduction 
Cutaneous melanoma is a malignancy arising from melanocytes residing in the skin. The 
mortality rate of melanoma is high due to its propensity to metastasize and resistance to 
chemotherapy. The pathological diagnosis, especially distinction of early stage melanoma 
from benign melanocytic naevus, can be difficult. Also determination of the prognosis and 
prediction whether metastatic disease will develop is often troublesome. In spite of the 
recent advent of kinase inhibitors and immunomodulatory treatments, the prognosis of 
patients with disseminated disease remains poor. Recent years have seen major advances 
in our understanding of the genetics of melanoma with the identification of recurrent 
somatic mutations in multiple oncogenes and tumor suppressor genes
1,2
. Mutations in the 
BRAF and NRAS oncogenes are the most important drivers of melanoma development, 
activating the mitogen-activated protein kinase (MAPK) pathway that mediates 
proliferative signals. This signaling pathway is additionally disrupted in melanoma by 
recurrent mutations in MAP2K1, MAP2K2, MAP3K5, and MAP3K9
3,4
. 
Cancer genomes are not only characterized by the presence of mutations and 
chromosomal aberrations, but also by epigenetic alterations. Aberrant methylation of CpG 
islands located in gene promoters is an epigenetic mechanism with an essential role in 
tumorigenesis. Promoter hypermethylation is associated with transcriptional 
downregulation affecting a multitude of genes in cancer cells. DNA methylation often 
manifests in tumor type-specific patterns and in melanoma several established tumor 
suppressor genes are affected by promoter hypermethylation. Conversely, tumor 
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Melanoma cells acquire the capacity for unrestrained proliferation, escape from 
cellular senescence, evasion of apoptosis, and metastatic dissemination during disease 
progression. There is increasing appreciation for the impact of DNA methylation 
alterations in conferring these malignant characteristics to incipient tumor cells
7
. Hence, 
the delineation of epigenetic alterations in melanoma could be applied in the molecular 
diagnosis and prognosis of melanoma. In addition, there are possible therapeutic 
implications as epigenetic alterations, as opposed to genetic abnormalities, can be 
pharmacologically reversed. Furthermore, recent findings showing the significant loss of 
DNA hydroxymethylation in melanoma as well as occurrence of mutations in IDH1, EZH2, 
ARID2, and other SWI/SNF complex members underscore the role of epigenetic 
deregulation in melanoma tumorigenesis
2,8
. 
Studies on DNA methylation in melanoma published thus far have mostly 
employed candidate gene approaches on melanoma metastatic lesions or cell lines
6
. In 
this study, we characterized promoter methylation on a genome-wide scale by generating 
epigenomic maps with BeadChip technology that quantifies the methylation levels of 
14,495 human genes in primary cutaneous melanomas and benign melanocytic naevi. This 
approach enabled the identification of many novel and highly recurrent hypermethylated 
genes in primary melanoma. Our results show that melanoma is characterized by 
widespread epigenetic alterations, with multiple genes selectively affected by methylation 
at high frequency. Several hypermethylated genes have tumor suppressive properties, 





Fresh-frozen biopsy specimens were obtained from primary cutaneous melanoma tumors 
of 24 patients. Detailed clinicopathological characteristics of these primary cutaneous 
melanoma biopsies can be found in Table S1A. As controls, fresh-frozen biopsy specimens 
from benign nevoid lesions of five individuals were obtained. Handling and review of 
melanoma and naevus samples were performed as previously described
9
. Briefly, frozen 
naevus and primary melanoma excision samples were sectioned, and the percentage of 
naevus or melanoma cells were assessed on an H&E-stained section. Only cases in which 
at least 70% of the cells were naevus or melanoma cells were included. Subsequently, four 
10 μm thick sections were cut, and finally, another H&E section was made and analyzed to 
confirm the percentage of naevus or melanoma cells. All 29 samples were subjected to 



















 mutations on a CFX384 
Real-Time Detection System (Bio-Rad, Hercules, CA, USA) as previously described
10
. For 
validation of identified methylation targets, an independent sample set of BFPE (fixed in 
Boonfix and embedded in paraffin) biopsy specimens from primary cutaneous melanoma 
tumors of 15 patients and fresh-frozen biopsy samples from benign nevoid lesions of 10 
individuals was used. All skin biopsy specimens were required to contain at least 70% 
melanocytic cells. For additional validation analyses of methylation status, an extra sample 
set of fresh-frozen biopsy specimens from melanoma cutaneous metastases of seven 
patients and cultured melanoma cell lines was used. To obtain the cell lines, melanoma 
cells were isolated from melanoma metastases of 13 patients and cultured briefly in 
DMEM+ GlutaMax-I (Gibo, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum 
(Thermo Scientific, Waltham, MA, USA), 100 units/ml penicillin, and 0.1 mg/ml 
streptomycin (Gibco). Clinical information on the patients of which the cell lines were 
derived can be found in Table S1B. DNA from all samples was extracted using either the 
Genomic Tip kit (Qiagen, Hilden, Germany) or RecoverAll Nucleic Acid kit (Ambion, 
Carlsbad, CA, USA), followed by bisulfite conversion with the EZ DNA methylation kit 
(Zymo Research, Orange, CA, USA). Completeness of conversion was tested for each 
sample by direct bisulfite sequencing analysis of three gene promoters with known 
methylation status. 
 
Illumina Infinium methylation assay and statistical analysis 
The Infinium methylation assay was performed at a certified Illumina service provider 
(Service XS, Leiden, The Netherlands). Bisulfite-converted DNA was hybridized onto 
Infinium HumanMethylation27 BeadChips (Illumina, San Diego, CA, USA) following 
manufacturer’s protocol. Resulting β-values from the Infinium methylation assay, ranging 
from 0 to 1, were quantile normalized to correct for unequal distributions within and 
between samples due to technical variation. Average β-values were calculated for the 
primary melanoma and naevus sample groups. To find differential methylation 
distributions, we applied a statistical test that was able to detect both consistent as 
sporadically occurring differential methylation alterations across the melanoma and 
naevus sample groups
11
. P values for this test were robustly calculated by permutations. 
Multiple testing correction was performed with Benjamini and Hochberg’s False Discovery 
Rate method
12
. To generate Heatmap colors, relative β-values were calculated by scaling 
β-values per sample to the existing range of β-values over all samples for each individual 
probe plotted. 
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Bisulphite melting curve analysis (BMCA) and bisulphite sequencing analysis (BSA) 
Bisulfite primer sequences were designed to amplify CpG islands located in the promoter 
region of the genes of interest, encompassing or in close proximity of the corresponding 
50-mer probe sequence on the BeadChip (Table S2A, Figure S1). Sensitivity of each 
bisulfite primer set was validated using mixtures, 1:1, 1:3, 1:9, and 1:9.5, of completely 
methylated CpGenome universal methylated DNA (Chemicon, Hampshire, UK) and 
unmethylated semen DNA, respectively. This showed that methylation could accurately be 
detected whether at least 10% of total analyzed DNA was methylated. In BMCA, melting 
curves were generated for CpG island amplicons of candidate gene promoters. A promoter 
was considered methylated if the melting temperature peak corresponding to methylated 
DNA had a height of 0.5 or more relative to the melting curve peak corresponding to 
unmethylated DNA for this sample. For BSA, promoter methylation was defined as a 
density of methylated CpG dinucleotides in the CpG island amplicon of 15% or more, a 





Melanoma cell lines 06.24 and 94.13 were used for demethylation experiments where 
cells seeded at 15% confluency were treated with 2 μM 5-aza-2′-deoxycytidine 
(Decitabine; Sigma, St. Louis, MO, USA) for 96 hrs. Culture medium was replaced with 
medium containing freshly prepared 5-aza-2′-deoxycytidine every 24h. Cells were 
harvested for RNA extraction with the RNeasy Mini kit (Qiagen). RNA was DNase treated 
with RQ1 RNase-free DNase (Promega, Madison, WI, USA) before cDNA was generated 
using the iScript cDNA synthesis kit (Bio-Rad). qRT-PCR was performed with iQ SYBR Green 
Supermix on a MyiQ Real-Time PCR Detection System (Bio-Rad). qRT-PCR primers were 
designed to span exon-exon barriers (Table S2B). Expression of the reference genes TBP 




Viral transduction of human melanoma cells, fibroblasts, and melanocytes 
The pcDNA3.1-HA, pcDNA3.1-HA-MAPK13-WT, pcDNA3.1-HAMAPK13-D176A, and 
pcDNA3.1-HA-MAPK13-F324S constructs were kindly provided by Dr. D. Engelberg and 
subcloned into the Moloney murine leukemia virus (MoMuLV)-based pBABE retroviral 
vector with a puromycin expression cassette (pBABE-puro)
16
. The melanoma cell lines 634, 
453A0, 93.08, 9304C, and 04.07 (Table S1B), the human fibroblast cell line TIG-3 
(expressing the ecotropic receptor, hTERT, and shRNA targeting p16
INK4A
), Phoenix, and 
HEK293T cells were cultured in DMEM (Gibco) supplemented with 9% fetal bovine serum 
(PAA Laboratories GmbH, Pasching, Austria), 2 mM glutamine, 100 U/ml penicillin, and 0.1 
mg/ml streptomycin (Gibco). Human melanocytes were isolated from the epidermis of 
neonatal foreskins
17
, and cultured in Medium 254 (Cascade Biologics) supplemented with 




mg/ml streptomycin (Gibco). For retroviral transduction, Phoenix cells were used as 
producers of retrovirus. Production of retrovirus was performed as described 
(http://www.stanford.edu/group/nolan/retroviral_systems/phx.html). For proliferation 
assays of the melanoma cell lines, cells were transduced with retrovirus encoding either of 
the pBABE-puro-p38δ expression constructs, selected for successful proviral integration by 
puromycin, and seeded at equal numbers for either incubation with BrdU for 1.5h 9–12 
days post-infection, fixed and stained with crystal violet 15–19 days post-infection or 
counted every 3–4 days starting at 3 days post-infection for at least 3 weeks. Samples 
were harvested for Western blot analysis 9 days post-infection. For proliferation assays of 
the fibroblast cell line TIG-3, cells were transduced with shRNA-encoding retrovirus, 
selected with puromycin, and plated at equal densities for transduction with BRAF
V600E
-
encoding retrovirus, followed by blasticidin selection. Cells were subsequently seeded at 
equal numbers and either incubated for 1.5h with BrdU 3 days post-infection or fixed and 
stained with crystal violet 3-7 days post-infection. Samples were harvested for Western 
blot analysis 2 days post-infection. For lentiviral transduction, HEK293T cells were used as 
producers of lentivirus; production of lentivirus was performed as previously described
18
. 
Human melanocytes were transduced with shRNA-encoding lentivirus, cultured for one 
week, and transduced with BRAF
V600E
-encoding lentivirus followed by selection with 
blasticidin. Cells were seeded at equal numbers, analyzed for BrdU incorporation, fixed 
and stained with crystal violet, and harvested for Western blot analysis 15 days post-
infection. For Western blot, antibodies against BRAF (sc-5284; Santa Cruz Biotechnology, 
Dallas, TX, USA), MAPK13 (AF1519; R&D Systems, Abingdon, UK), β-actin (AC-74; Sigma), 
and α-tubulin (T5168; Sigma) were used. 
 
Database Accession numbers 
The data discussed in this publication have been deposited in NCBI’s Gene Expression 
Omnibus
19




Genome-wide DNA methylation profiling of primary cutaneous melanomas and 
naevi 
DNA methylation profiles of 24 primary cutaneous melanomas and five benign naevi were 
generated with Infinium BeadChip technology that interrogates 27,578 CpG loci in the 
promoter regions of 14,495 genes at single-nucleotide resolution. Normalized β-values 
were used as a measure of methylation and showed a bimodal distribution indicating the 
presence of a distinct subset of methylated CpG loci in the investigated samples among a 
large number of unmethylated CpG loci (Figure 1A). Detailed information on each 
melanoma and naevus sample can be found in Table S1A. The DNA methylation profiles of 
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the primary melanomas and benign naevi showed an almost complete separation with the 
exception of one naevus sample (N3) that segregated with a primary melanoma sample 
(PM6) (Figure 1B). We suspect that aberrant clustering of this naevus sample is due to 
non-biological sources of variation in methylation BeadChip results, as the methylation 
pattern of this benign naevus for the most differentially methylated genes is distinct from 
those of primary melanomas and similar to those of other naevus samples (Figure 2A). We 
calculated and used the average β-value difference to represent methylation differences 
occurring between the primary melanomas and naevi. Figure 1C visualizes the average β-
values of all interrogated probes and shows the presence of statistically significant probes 
with average β-value difference exceeding 0.2 or less than 0.2 between the primary 
melanomas and naevi, indicating the presence of hyper- and hypomethylated CpG loci, 
respectively, between the two sample groups. 
We sought to identify genes aberrantly methylated in primary melanoma when 
compared with naevus; CpG probes that showed a significant methylation difference by 
comparative statistical analysis (P < 0.05) and had an absolute average β-value difference 
between the primary melanomas and naevi exceeding 0.2 were considered differentially 
methylated. Using these criteria, 120 probes corresponding to 106 unique genes were 
found to be hypermethylated in primary melanoma (Figure 2A); 46 probes corresponding 
to 44 unique genes were hypomethylated (Figure 2B). The Heatmaps in Figure 2A, B 
illustrate that despite heterogeneity of methylation among the primary melanoma 
samples, multiple gene promoters demonstrate highly recurrent and selective methylation 
alterations in primary melanoma. We found HOXA9, C1orf106, HIST1H3E, MAPK13, and 
LEP as the most frequently hypermethylated in primary melanoma. Among the 106 
differentially hypermethylated genes, five were imprinted; CYP1B1, GPT, KCNQ1, MEST, 
and NNAT. In addition, we identified HLA-DRA, SLC1A2, MGC35206, PRSS2, and SIRPB1 as 
the most frequently differentially hypomethylated genes. Several identified genes have 
previously been reported to be aberrantly methylated in melanoma or in other cancer 
types as indicated in the columns on the right (Figure 2A, B). All significantly hyper- and 
hypomethylated genes prioritized by average β-value difference can be found in Table 
S3A, B. 
 
Further analysis of genes aberrantly methylated in primary melanoma 
To categorize methylation events aggregating in genes of particular classes or in the same 
signaling pathway, we performed gene ontology analysis using the DAVID bioinformatics 
resource
20
. Functional classification of the 106 hypermethylated genes showed 
enrichment for homeobox genes (HOXA9, HOXD12, OTP, VSX1, FOXD2, MSX1), G-protein-
coupled receptor genes, and genes with sulfotransferase and kinase activity. Homeobox 




be co-regulated with DNA methylation. Genes hypermethylated in cancer are more 
frequently targets of polycomb complexes
21,22
. Correspondingly, we observed that 22 of 
106 (21%) genes within our set of hypermethylated genes were validated polycomb 
targets
23
, corresponding to a 1.8-fold enrichment for polycomb target genes. In colorectal 
cancer, mutant BRAF and NRAS have been found to associate with a CpG island 
methylator phenotype. However, the subset of BRAF and NRAS mutant melanomas did 
not exhibit a higher degree of CpG island methylation (average β-value for all interrogated 
CpG loci) and did not cluster separately, consistent with previous findings on candidate 
genes in melanoma cell lines
24
. We assessed whether the mitotic rate may correlate with 
methylation patterns, but found no significant association when analyzing hierarchical 
clustering data and the set of frequently hypermethylated genes in melanoma samples 
with high and with low mitotic rates. 
Recently, exome and whole genome sequence analyses have characterized the 
mutational landscape of melanoma. As genetic and epigenetic mechanisms often 
commonly affect cancer genes, we sought to integrate our epigenetic findings with results 
from these studies. Among the 50 most frequently mutated genes identified in an exome 
sequencing study of 147 melanomas, the COL14A1 and SLC15A2 genes also emerged from 
our study as frequently hypermethylated
25
. Among the 100 genes with the most 
significant functional mutation burden determined by exome sequencing of 121 
melanoma samples, the PDE4DIP gene overlapped with our set of frequently 
hypermethylated genes
2
. There were several genes found to be affected by genomic 
rearrangements in a whole genome sequencing study of 25 melanomas, including the 
ANKDD1A, CRB1, EFCAB1, HLA-G, NDST4, PDE4DIP, and SERPINB5 genes that we found to 
be frequently hypermethylated in melanoma
1
. In particular, the PDE4DIP gene appears to 
be inactivated by genetic mechanisms as well as through promoter hypermethylation in 
melanoma. 
Among the identified aberrantly methylated genes, we sought to delineate genes 
whose epigenetic deregulation might contribute to the malignant phenotype of melanoma 
cells. Several genes we found to be hypermethylated in melanoma are annotated by the 
CancerGenes resource
26
 as tumor suppressor genes, including CDH11, CHFR, GNMT, 
NR4A1, RARB, and SERPINB5. Among the 44 hypomethylated genes, RUNX1 and RUNX3 
have been established as oncogenes, albeit in different tumor types. 
 
Validation of identified hypermethylated genes in primary melanoma by 
bisulphite melting curve analysis and bisulphite sequencing analysis 
Among the 106 genes identified as differentially hypermethylated in primary melanoma, 
we selected HOXA9, MAPK13, CDH11, PLEKHG6, PPP1R3C, and CLDN11 for validation by 
analysis of promoter methylation status. HOXA9, MAPK13, and CDH11 were selected  
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Figure 1. Distribution of genome-wide DNA 
methylation data in primary melanoma and 
naevus samples. (A) The frequency (vertical axis) 
of normalized, logit-transformed β-values at a 
range from 0 to 1 (horizontal axis) across all CpG 
probes on the BeadChip in all samples. Normalized 
β-values were used as a measure of methylation 
with a β-value of 0 corresponding to complete 
absence of methylation and a β-value of 1 
corresponding to the presence of full methylation. 
(B) Hierarchical clustering of the 24 primary 
melanoma and five benign naevus samples. 
Clustering analysis was based on correlation 
distance and average linkage of the normalized β-
values of all interrogated CpG probes. PM, primary 
melanoma; N, naevus. (C) The average β-values of 
all interrogated CpG probes in the primary 
melanoma sample group (vertical axis) and naevus 
sample group (horizontal axis) plotted as individual 
gray dots. CpG probes showing statistically 
significant differential methylation between the 
primary melanomas and benign naevi are depicted 
as black dots (P <0.05). CpG probes with average 
β-value difference between the melanoma and 
naevus sample groups exceeding 0.2 or less than 































































































































































































































































































































































































































































Figure 2. Comparative analysis of the genome-wide DNA methylation data. (A) Heatmap highlighting the 120 
CpG probes corresponding to 106 unique genes that were identified as hypermethylated in the primary 
melanomas (P <0.05 and average β-value difference >0.2) when compared to naevi. Genes previously reported 
as hypermethylated in melanoma or other cancer types are marked with ‘x’ in columns on the right side. PM, 
primary melanoma; N, naevus. 








































































































































































Figure 2. Comparative analysis of the genome-wide DNA methylation data. (B) Heatmap highlighting the 46 
CpG probes corresponding to 44 unique genes that were found hypomethylated in primary melanomas (P <0.05 
and average β-value difference <0.2) as compared to naevi. Genes previously reported as hypomethylated in 
melanoma or other cancer types are marked with ‘x’ in columns on the right side. Heatmap colors were created 
by scaling the β-values per sample to the existing range of β-values over all 29 investigated samples for each 




based on their position in the top 10 of the most frequently hypermethylated genes; 
PLEKHG6, PPP1R3C, and CLDN11 were selected based on their potential functional 
relevance in melanoma. Bisulfite melting curve analysis (BMCA) was used for validation on 
two sample sets; the first consisted of the 24 primary melanomas and five benign naevi 
originally subjected to genome-wide methylation analysis, the second was an independent 
set of 15 primary melanoma and 10 naevus biopsy specimens. Melting temperatures 
corresponding to the unmethylated and methylated amplicons of the six genes can be 
found in Table S2A. For each gene at least one primary melanoma biopsy, one melanoma 
cell line and one naevus biopsy were additionally analyzed with bisulfite sequencing 
analysis (BSA) in order to assess methylation density of the interrogated CpG island 
amplicons. 
BMCA showed that the analyzed CpG regions of the HOXA9, MAPK13, CDH11, 
PLEKHG6, PPP1R3C, and CLDN11 promoters were frequently methylated in the primary 
melanomas (Figure 3A, top graphs). In contrast, promoter methylation of CDH11, 
PLEKHG6, PPP1R3C, and CLDN11 was absent in the naevi (Figure 3A, bottom graphs). For 
MAPK13, four naevi showed small melting curve elevations at an intermediary melting 
temperature, corresponding to methylation of a few single CpG dinucleotides within a 
further unmethylated promoter as demonstrated by BSA (Figure 3B). The HOXA9 gene 
showed promoter methylation in a subset of naevus samples. Bisulfite sequencing results 
confirmed that the analyzed promoter regions of HOXA9, MAPK13, CDH11, PLEKHG6, 
PPP1R3C, and CLDN11 contained a high density of methylated CpG dinucleotides in 
primary melanomas (Figure 3B). In summary, we found that HOXA9, MAPK13, CDH11, 
PLEKHG6, PPP1R3C, and CLDN11 were methylated in 85, 67, 44, 67, 51, and 28% of 
primary melanomas, respectively, whereas significant promoter methylation of MAPK13, 
CDH11, PLEKHG6, PPP1R3C, and CLDN11 could not be detected in the naevi (Table 1). 
Methylation of HOXA9, MAPK13, CDH11, PLEKHG6, PPP1R3C, and CLDN11 was 
additionally analyzed in cutaneous melanoma metastases biopsy specimens and early 
passage melanoma cell lines using BMCA and BSA (Figure S2), showing that an even higher 
percentage of these samples was hypermethylated for the analyzed genes (Table 1). In 
one of the early passage melanoma cell lines, methylation of MAPK13 was mono-allelic, 
whereas methylation was bi-allelic in 12 of 13 melanoma cell lines. For tumor biopsies, 
which contain admixed skin-resident cells, mono-allelic cannot be reliably distinguished 
from bi-allelic methylation using BMCA. 
 
MAPK13 is epigenetically silenced in melanoma cells  
Next, we analyzed whether promoter methylation of MAPK13, CDH11, and PLEKHG6 was 
associated with gene silencing. Melanoma cell lines 06.24 and 94.13 were included in our 
panel of 13 melanoma cell lines used for validation experiments and demonstrated  
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Figure 3. Bisulfite melting curve analysis and direct bisulfite sequencing analysis of HOXA9, MAPK13, CDH11, 
PLEKHG6, PPP1R3C, and CLDN11. (A) Bisulfite melting curve profiles of 39 primary melanomas plotted together 
in one graph (top) and of 15 naevi plotted overlapping in one graph (bottom) for each gene. The primary 
melanomas show a peak in their melting curve patterns at the melting temperatures (Tms) for methylated DNA 
(85.6, 86.0, 82.6, 85.2, 85.0, and 83.2°C for HOXA9, MAPK13, CDH11, PLEKHG6, PPP1R3C, and CLDN11, 
respectively), an additional peak at the Tm for unmethylated DNA (80.8, 81.8, 79.6, 81.6, 81.4, and 80.4°C for 
HOXA9, MAPK13, CDH11, PLEKHG6, PPP1R3C, and CLDN11, respectively) and peaks at intermediate Tms. In 
contrast, the naevi show only a peak at the Tm for unmethylated DNA while a peak at the Tm for methylated 
DNA is absent. Methylated DNA peaks in the melting curve pattern with a height of 0.5 or more relative to the 
unmethylated DNA peaks were considered indicative of methylation for the investigated CpG island amplicon. (B) 
Bisulfite sequencing analysis of CpG dinucleotides in the HOXA9, MAPK13, CDH11, PLEKHG6, PPP1R3C, and 
CLDN11 promoter regions in a selected number of primary melanomas (PM) and naevi (N). An unmethylated 
cytosine of an interrogated CpG dinucleotide is depicted as a white circle, a methylated cytosine as a black circle, 
a partially methylated cytosine as a gray circle. An investigated CpG island amplicon was considered methylated 
if the density of methylated CpG dinucleotides was 15% or more. (C) The effect of demethylation on MAPK13, 
CDH11, and PLEKHG6 expression in the 06.24 and 94.13 melanoma cell lines cultured in the presence or absence 
of 2μM 5-aza-2′-deoxycytidine for 96h. Data are representative of duplicate treatment experiments, error bars 
indicate standard deviation from triplicate qRT-PCR experiments. The fold induction in expression upon 
treatment with 5-aza-2′-deoxycytidine is indicated above the bars. A two-sided t-test was applied for statistical 




Table 1. Overview of the validation results performed in naevi, primary melanoma, and metastatic melanoma for 
six genes identified as hypermethylated with genome-wide DNA methylation profiling. Numbers indicate the 





























HOXA9 47 88 80 85 100 92 95 
MAPK13 0 67 67 67 86 85 85 
CDH11 0 46 40 44 43 85 70 
PLEKHG6 0 71 60 67 86 85 85 
PPP1R3C 0 54 47 51 57 54 55 
CLDN11 0 29 27 28 43 46 45 
 
promoter methylation for MAPK13, CDH11, and PLEKHG6. Both cell lines were treated 
with 5-aza-2’-deoxycytidine, and effect on gene expression was analyzed by qRT-PCR. 
Expression of all three genes, which was nearly undetectable to low in untreated 
melanoma cells, was increased significantly upon treatment with 5-aza-2′- deoxycytidine 
(Figure 3C). These results suggest that expression of MAPK13, CDH11, and PLEKHG6 is 
epigenetically regulated and that the observed promoter methylation in melanoma is 
associated with transcriptional downregulation. We proceeded to examine whether 
MAPK13 protein expression correlated with promoter methylation status in human 
melanocytes, fibroblasts, and our panel of melanoma cell lines. Western blot analysis 
showed that melanoma cells with MAPK13 promoter methylation (94.13, 607B, 93.08, 
Mz7.4, 634, 05.06, 06.24, 453A0, and 94.07) did not express significant levels of MAPK13 
(Figure 4A). In contrast, expression was observed in fibroblasts, in melanocytes, and in 
melanoma cell lines with unmethylated MAPK13 promoters (9304C and 04.07) or with 
mono-allelic methylation (518A2). MAPK13 protein levels were higher in the 
unmethylated melanoma cells compared with melanocytes. This can be explained by the 
BRAF
V600E
-mutation that melanoma cell lines 9304C and 04.07 harbor, as we observed in 
fibroblasts that ectopic expression of BRAF
V600E
 increased MAPK13 protein expression 
(Figure S4A). 
 
MAPK13 acts cytostatically in melanoma cells  
We found that MAPK13 was among the most frequently methylated genes in primary 
cutaneous melanoma and that promoter hypermethylation was associated with gene 
silencing. In addition, MAPK13 promoter methylation was present in primary melanomas 
and melanoma cell lines carrying either BRAF mutations, NRAS mutations, as well as in 
primary melanomas lacking mutations in these oncogenes (Table S1A, B). Furthermore, we 
found that this gene was expressed in human melanocytes and fibroblasts, but silenced in  
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Figure 4. Restoration of MAPK13 
expression in melanoma cells with 
MAPK13 promoter methylation 
attenuates proliferation. (A) Thirteen 
melanoma cell lines, human melanocytes, 
and fibroblasts (TIG-3) were analyzed for 
MAPK13 protein expression with α-tubulin 
serving as loading control. The MAPK13 
promoter methylation status of each cell 
line is depicted; M, methylated (gray); U, 
unmethylated (white); m, mono-allelic 
methylation (striped). (B) Melanoma cell 
lines 634, 453A0, 93.08, 9304C, and 04.07 










and selected for integration of the 
construct. Empty vectors were used as 
controls (c). Samples were seeded at equal 
densities and stained with crystal violet 
15-19 days post-infection. MAPK13 
promoter methylation status is indicated 
for each cell line; M, methylated (left); U, 
unmethylated (right). (C) Samples of 
transduced melanoma cell lines 634, 
453A0, 93.08, 9304C, and 04.07 were 
seeded at equal numbers and analyzed for 
BrdU incorporation 9-12 days post-
infection. The percentage of BrdU-positive 
cells was normalized to empty vector 
controls (c). Error bars indicate standard 
deviation from triplicate measurements; 
two-tailed t-test was applied for statistical 
analysis. MAPK13 promoter methylation 
status is indicated for each cell line; M, 
methylated (top row); U, unmethylated 
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melanoma cells with MAPK13 promoter hypermethylation. Previous reports suggested a 
tumor suppressive role of MAPK13 
27
. Therefore, we asked whether MAPK13 could have a 
tumor suppressive role in melanoma. MAPK13 encodes p38δ, one of four p38 isoforms of 
the p38 MAPK family of proteins. The p38 MAPK signaling pathway is activated upon 
environmental and genotoxic stress, and its activation affects cellular proliferation, 
differentiation, survival, and migration
28
. The observed methylation and transcriptional 
shutdown of MAPK13 in melanoma would predict that re-establishment of its expression 
affects an essential tumor property. To investigate whether restoration of MAPK13 
expression changed melanoma cell behavior, five melanoma cell lines, three of which 
(634, 453A0, and 93.08) with MAPK13 methylation and two (9304C and 04.07) without, 
were retrovirally transduced with vectors expressing either wild-type MAPK13 
(MAPK13
WT
) or variants mutated at either Asp176 (MAPK13
D176A
) or Phe324 (MAPK13
F324S
); 
these kinase mutants were previously shown to have constitutive activity and to 
phosphorylate ATF2
29
. Retroviral transduction led to comparable expression levels of the 
three different MAPK13 constructs across the five cell lines (Figure S3A). 
Interestingly, in melanoma cell lines 634 and 453A0 and somewhat less 
pronounced in 93.08, all exhibiting MAPK13 promoter methylation, proliferation was 
suppressed upon overexpression of MAPK13, particularly when the constitutively active 
form was used (Figure 4B, left panel). In contrast, proliferation of 9304C and 04.07 
melanoma cells, in which MAPK13 is not epigenetically silenced, was only marginally 
affected upon ectopic expression of MAPK13, even when the active form was used (Figure 
4B, right panel). Extending these proliferation assays, long-term growth curves also 
illustrate that the reduction in population doublings after restoration of MAPK13 
expression is more pronounced in melanoma cell lines in which MAPK13 is epigenetically 
silenced (Figure S3B, top versus bottom panels). 
Consistent with this, bromodeoxyuridine (BrdU) incorporation assays showed 
that expression of wild-type MAPK13 or activated mutants reduced BrdU uptake more 
profoundly in the melanoma cell lines in which MAPK13 was epigenetically silenced 
(Figure 4C, top versus bottom panels). Together, these results suggest that restoration of 
either wild-type or kinase mutant MAPK13 expression in melanoma cells with MAPK13 
promoter methylation can reduce the proliferative capacity of these cells. Our results raise 
the intriguing possibility that during progression of melanoma, loss of MAPK13 expression 
due to promoter methylation confers a selective advantage, which would be consistent 
with its previously proposed tumor suppressor function
27
. Lastly, considering the 
cytostatic effect that MAPK13 elicits in melanoma cells and the involvement of MAPK14 
(p38α) and MAPK12 (p38γ) in oncogene-induced senescence
30,31
, we asked whether 
MAPK13 might be involved in this tumor suppressive mechanism. For this, we examined 
whether MAPK13 depletion allowed human fibroblasts (TIG-3) to bypass the cell cycle 
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arrest that typically accompanies the senescence response induced by BRAF
V600E
. Similar 
experiments have been reported recently, uncovering a critical role for PTEN in this 
setting
18
. Although shRNAs no. 1 and no. 3 significantly reduced MAPK13 expression 
(Figure S4A), it failed to result in a bypass from BRAF
V600E
-induced cell cycle arrest (Figure 
S4B, C). Taken together, these results suggest that MAPK13 may act as a tumor suppressor 
that is selected against during melanomagenesis, at least in part because of its role in 
regulating the proliferative potential of melanoma cells. 
 
Discussion 
Aberrant DNA methylation is a key epigenetic event associated with tumorigenesis, as it 
results in deregulated expression of genes with a critical function in fundamental cellular 
processes. This study provides the first genome-wide view of promoter methylation in 
primary cutaneous melanoma. Detection of methylation at 27,578 CpG loci spread across 
14,495 genes in fresh-frozen primary melanoma and melanocytic naevus samples revealed 
the presence of many highly recurrent and novel methylation events that were validated 
using independent techniques. Our results show that melanoma is characterized by 
widespread and heterogeneous epigenetic deregulation with many genes showing tumor-
selective aberrant methylation. The multitude of DNA methylation events in melanoma 
might be related to the recently observed genomic loss of 5-hydroxymethylcytosine and 
decreased activity of IDH2 and TET family enzymes in this tumor type
8
. Epigenomic studies 
previously performed on breast cancer and glioblastoma using similar BeadChip 
technology have revealed a large number of de novo-methylated promoter regions that 
differ substantially from those identified in melanoma, confirming tumor type specificity 
of promoter hypermethylation
32,33
. Most of the genes we identified as hypermethylated in 
primary melanoma are novel methylation targets. Eleven of the 106 genes identified as 
most frequently hypermethylated in melanoma in this study have previously been 
reported to be hypermethylated in melanoma, while 32 genes have been found to be 
hypermethylated in other cancer types. Among the genes frequently hypermethylated in 
melanoma were several established tumor suppressor genes, including CDH11 and 
SERPINB5 (Maspin). Interestingly, epigenetic silencing of these genes has been 
demonstrated to enhance metastatic behavior of melanoma cells
34,35
. The most frequently 
methylated gene in primary melanoma was HOXA9, showing methylation in over 80% of 
melanoma samples analyzed, but also in a subset of benign naevi. Methylation of HOXA9 
has previously been demonstrated in a melanoma cell line as well as in other cancer 
types
36,37
. Among gene promoters hypermethylated in melanoma, there was enrichment 
for other homeobox genes, which are attracting increasing attention for their contribution 
to oncogenesis
38






. In most of these studies, metastatic melanoma samples 
or cell lines were analyzed using candidate gene approaches. RASSF1A, SOCS2, RAR-
β2,TNFSF10C, and TNFSF10D are among genes shown to display promoter 
hypermethylation in metastatic melanoma in multiple studies
39,40
. Whereas RAR-β2 is also 
represented in the 106 most frequently methylated genes that we identified in primary 
melanoma, several previously reported methylation targets were not detected in this 
study as frequently hypermethylated in primary melanoma. In the few published genome-
wide methylation analyses of melanoma, immunoprecipitation-based MeDIP and 
demethylation gene reactivation methods were applied to melanoma cell lines
41,42
. One of 
the few studies aimed at primary cutaneous melanoma employed a BeadChip assay that 
analyzed methylation of 807 cancer-related genes on formalin-fixed paraffin-embedded 
tumor samples
43
. In this study, six genes were identified as hypermethylated and 16 genes 
as hypomethylated in melanoma, with one hypermethylated gene (COL1A2) and two 
hypomethylated genes (EMR3, RUNX3), showing overlap with our results. Discrepancies of 
our findings with those of other studies can be explained by differences in the applied 
methylation assay, statistical analysis as well as in the sample size of the studies. 
Additionally, some of the reported methylation events in metastatic melanoma cells and 
not detected in this study of primary melanoma might be acquired during metastatic 
progression or melanoma cell culture
44
. 
Among the most frequently hypermethylated genes in primary melanoma was 
MAPK13, a gene encoding the p38δ isoform. The MAPK13 gene was hypermethylated in 
26 of 39 primary melanomas (67%) and in 17 of 20 metastatic melanoma samples (85%). 
Promoter hypermethylation of MAPK13 was previously demonstrated in a subset of 
malignant pleural mesothelioma cases
45
. Mouse embryonic fibroblasts lacking MAPK13 
(p38δ) have been found to proliferate and migrate faster and to have diminished cell 
contact inhibition than their wild-type counterparts, suggesting tumor suppressive 
properties of this gene
27
. We show here that MAPK13 promoter hypermethylation is 
associated with silencing of its transcript and protein expression in melanoma cells. 
Previous gene expression profiling showed that treatment of melanoma cells with the 
demethylating agent 5- aza-2′-deoxycytidine resulted in increased MAPK13 expression, 
supporting the observation that promoter hypermethylation of this gene is associated 
with transcriptional repression
41
. Importantly, restoration of MAPK13 expression in 
melanoma cells with epigenetically silenced MAPK13 resulted in suppression of 
proliferation, the effect being more pronounced when a constitutively active form of 
MAPK13 was expressed. In contrast, for two melanoma cell lines that were not affected by 
MAPK13 promoter methylation and that expressed the protein, ectopic expression of wild 
type or constitutively active MAPK13 only marginally affected proliferation. These 
observations suggest that MAPK13 has cytostatic functions in melanoma cells and that 
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epigenetic silencing of MAPK13 expression confers a growth advantage to melanoma cells. 
MAPK13 has been reported to contribute to delayed cell cycle progression through its 
capacity to phosphorylate p53 on serine 33, providing a possible mechanism for the 
cytostatic properties we observed in melanoma cells
46
. A critical tumor suppressive 
mechanism in melanocytic neoplasia is oncogene-induced senescence where expression 
of mutant BRAF or RAS elicits a stable cell cycle arrest from which incipient melanoma 
cells can escape through acquisition of additional genetic and epigenetic events
47
. 
Signaling through the MAPK14 (p38α) and MAPK12 (p38γ) isoforms has been shown to be 
required for mutant RAS-induced senescence
30,39
. We therefore examined whether 
MAPK13 could be involved in the senescence response but observed that its depletion in 
human fibroblasts did not prevent the proliferative arrest induced by expression of 
mutant BRAF. Although our results point to a tumor suppressive role of MAPK13 in 
melanoma, in cutaneous squamous cell carcinoma MAPK13 has been proposed to have 
oncogenic properties
48
. Similar paradoxical observations regarding oncogenic properties 
have been made for p38α
28
. The apparently contradicting functions of MAPK13 and other 
p38 proteins in tumorigenesis as either a tumor suppressor gene or oncogene appear to 
be dependent on cell type, pattern of oncogenic mutations, and stage of tumor 
development. Recently, genetic events that affect p38 signaling have been identified in 
melanoma, including inactivating mutations in the MAP3K5 gene that mediates sustained 
activation of p38 and JNK proteins in response to cytotoxic stresses in melanoma 
samples
4
. In addition, a point mutation in MAPK13 was detected in melanoma in a recent 
exome sequencing study
25
. Our finding of frequent epigenetic silencing of MAPK13 further 
implicates disruption of p38 signaling in the pathogenesis of melanoma. 
Clinical application of aberrant DNA methylation as a molecular biomarker in the 
diagnosis of melanoma is attractive as early stage melanoma and benign melanocytic 
lesions such as dysplastic naevi can be difficult to discriminate for clinical pathologists 
based on histomorphological grounds. Methylation targets identified in this study as 
frequently and selectively methylated in melanoma may be used as new diagnostic 
biomarkers for melanoma. The diagnostic discriminatory value of the epigenetic 
melanoma biomarkers in clinical practice should be validated in a large set of benign 
melanocytic tumors, including dysplastic and Spitz naevi, which we are currently 
addressing. In addition, the epigenomic maps of primary melanoma may reveal crucial 
information for the identification of specific epigenetic patterns associated with 
metastatic propensity and an unfavorable prognosis. The high degree of promoter 
methylation observed in melanoma could also have implications for melanoma therapy, as 
it might be associated with sensitivity to demethylating agents. Demethylating agents such 
as decitabine have pleiotropic effects affecting expression of hundreds of genes 




it was shown that inhibition of STAT3 acetylation in melanoma results in demethylation 
and reactivation of multiple tumor suppressor genes, which indicates the feasibility of 
targeted therapeutic reversal of melanoma suppressor gene hypermethylation through 
interference with a common epigenetic silencing mechanism
49
. 
This study illustrates the multitude of epigenetic events that occur in primary 
cutaneous melanoma. In this assessment of promoter methylation, many novel genes 
were found that show highly recurrent, selective hypermethylation in melanoma that 
might be applied as molecular diagnostic markers in the clinic. Restoration of expression 
of the MAPK13 gene, which is epigenetically silenced in the majority of melanoma 
samples, was shown to inhibit the proliferative capacity of melanoma cells, compatible 
with a tumor suppressive function of this gene. Indeed, several other genes affected by 
promoter hypermethylation in melanoma are established tumor suppressors. We feel that 
this study merits further analysis of the oncogenic role and diagnostic applications of the 
methylated genes identified. 
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Supplementary Table S1 (A) Fresh-frozen biopsies of naevus, primary cutaneous melanoma and melanoma 
metastases. MA, sample used for genome-wide methylation analysis; VA, sample used for validation of identified 
methylation targets; DBN, dermal benign naevus; CBN, compound benign naevus; PT, primary tumor; CM, 
cutaneous metastasis. Ulceration was identified according to EORTC criteria (Spatz A, Cook MG, Elder DE, 
Piepkorn M, Ruiter DJ, Barnhill RL. Interobserver reproducibility of ulceration assessment in primary cutaneous 
melanomas. Eur J Cancer. 2003 Sep;39(13):1861-1865). Mitotic rate was determined using the "hot-spot" 
method which identifies the maximum number of dermal mitotic figures in a 1-mm
2
 area of the invasive part of 
the melanoma according to American Joint Committee on Cancer (AJCC) recommendations for diagnosis and 
treatment of malignant melanoma (Gershenwald JE, Soong S, Balch CM. 2010 TNM staging system for cutaneous 
melanoma… and beyond. Ann Surg Oncol. 2010;17:1475-1477). 
Naevus             
Code ID Application Type Mutation Site Gender Age      
N1 K22691 MA/VA DBN BRAFV600E Leg F 29      
N2 K23142 MA/VA DBN/CBN BRAFV600E Trunk F 43      
N3 K23342 MA/VA DBN BRAFV600E Upper leg M 55      
N4 K24383 MA/VA DBN BRAFV600E Trunk F 40      
N5 K24848 MA/VA DBN BRAFV600E Trunk F 38      
- LUMC-N01 VA DBN - - F 31      
- LUMC-N03 VA DBN - - M 46      
- LUMC-N04 VA DBN - - F 39      
- LUMC-N05 VA DBN - - F 27      
- LUMC-N06 VA DBN - - M 21      
- LUMC-N07 VA DBN - - M 57      
- LUMC-N09 VA DBN - - F 52      
- LUMC-N10 VA DBN - - F 24      
- LUMC-N11 VA DBN - - F 30      
- LUMC-N13 VA DBN - - F 30      
             
Primary melanoma           
Code ID Application Type Mutation Site Breslow Clark Ulcer Mitoses Diagnosis Gender Age 
PM1 K5940 MA/VA PT wt Lower leg 1,67 IV - 3 SSMM F 53 
PM2 K7206 MA/VA PT BRAFV600E Lower leg 2,08 IV + 6 SSMM M 68 
PM3 K7376 MA/VA PT wt Foot 4,48 V + 13 ALMM M 65 
PM4 K14294 MA/VA PT wt Trunk 2,05 IV - 2 SSMM F 65 
PM5 K17504 MA/VA PT wt Foot 3,88 IV - 5 ALMM F 60 
PM6 K17716 MA/VA PT wt Ear 0,81 III - 1 SSMM M 58 
PM7 K12832 MA/VA PT BRAFV600K Back 0,91 IV - 0 SSMM F 42 
PM8 K8269 MA/VA PT wt Shoulder 0,94 IV - 2 SSMM F 34 
PM9 K17155 MA/VA PT BRAFV600E Back 1,06 IV - 2 SSMM M 36 
PM10 K10454 MA/VA PT BRAFV600E Buttock 0,73 III - 0 SSMM F 35 
PM11 K5666 MA/VA PT NRASG12D Nailbed Toe 1,70 IV + 2 ALMM F 59 
PM12 K5912 MA/VA PT wt Foot 3,36 IV + 6 ALMM F 73 
PM13 K7393 MA/VA PT wt Neck 15,60 V - 2 Desmopl MM M 85 
PM14 K14277 MA/VA PT wt Scalp 3,46 IV - 4 SSMM M 54 
PM15 K15582 MA/VA PT NRASQ61K Thigh 9,20 V + 10 SSMM F 48 
PM16 K20015 MA/VA PT BRAFV600E Lower leg 18,00 V + 12 SSMM M 82 
PM17 K21160 MA/VA PT wt Buttock 6,29 IV + 8 SSMM F 62 
PM18 K4554 MA/VA PT wt Back 1,28 IV - 1 SSMM F 65 
PM19 K24091 MA/VA PT BRAFV600K Scalp 17,2 V + 9 NMM M 79 
PM20 K9900 MA/VA PT wt Back 3,04 IV + 4 SSMM F 45 
PM21 K6386 MA/VA PT wt Lower leg 2,02 IV + 4 SSMM M 78 
PM22 K5557 MA/VA PT wt Axilla 12,2 V - 7 SSMM M 70 
PM23 K16334 MA/VA PT wt Vulva 10,1 IV + 8 SSMM F 56 
PM24 K20506 MA/VA PT BRAFV600E Foot 2,08 IV - 7 SSMM F 75 
             
Melanoma metastasis           
Code ID Application Type Mutation Site Gender Age      
MM1 K5317 VA CM BRAFV600E Thigh M 68      
MM2 K9600 VA CM BRAFV600E Neck M 76      
MM3 K14772 VA CM wt Lower leg F 75      
MM4 K17323 VA CM NRASQ61R Lower leg F 48      
MM5 K19394 VA CM wt Shoulder F 56      
MM6 K23602 VA CM BRAFV600E Trunk M 69      




Supplementary Table S1 (B) Early-passage melanoma cell lines, isolated from metastatic lesions of patients 
treated at Leiden University Medical Center. MA, sample used for genome-wide methylation analysis; VA, 
sample used for validation of identified methylation targets; LN, Lymph Node; SC, subcutaneous; Stage AJCC III, 
local / loco-regional metastasis; Stage AJCC IV, distant metastasis; M, methylated; U, unmethylated; m, mono-
allelic methylation. 
Cell line Application Passage Mutation Pigment Site Stage Gender Age MAPK13 promoter 
05.06 VA 8 BRAFV600E No LN IV M 59 M 
06.24 VA 7 NRASQ61R No LN IV F 60 M 
518A2 VA 8 BRAFV600E No LN III M 19 m 
453A0 VA 5 BRAFV600E No SC IV M 42 M 
9304C VA 10 BRAFV600E Yes SC III F 37 U 
94.07 VA 7 BRAFV600E No Mesenterial IV M 39 M 
94.13 VA 10 BRAFV600E No Omentum IV F 47 M 
9903A VA 13 BRAFV600E No LN III F 31 M 
04.07 VA 8 BRAFV600E No SC IV F 59 U 
607B VA 36 NRASQ61K No SC IV F 51 M 
93.08 VA 32 BRAFV600E No SC IV M 30 M 
Mz7.4 VA 30 BRAFV600E No na na na na M 
634 VA 27 NRASQ61R No SC IV F 52 M 
 
Supplementary Table S2 (A) Bisulphite primers. No. of CpG’s, position relative to TSS, size (bp) and Tm (°C) in 
regard to respective amplicon. 













HOXA9 ATGGTTATTATTGGGGTTTTGGGTAA 38 74 + 416 + 343 74 + 80,8 85,6 
 
TAAACTCCAACCAAAAACGCATATAC 
       
MAPK13 GAGGGAATTGGGAAGTATTGTTTT 18 273 - 90 - 184 99 + 81,8 86 
 
AACCTATCCAACCCTACGCTCC 
       
CDH11 GTCGTTGATTTGTGAATGGGAT 8 35 + 153 + 119 443 + 79,6 82,6 
 
CACCTCACCTAAAACCCTTAAAAAT 
       
PLEKHG6 AGGGTATCGTTACGTGAGTTGTTTT 20 103 + 316 + 214 149 + 81,6 85,2 
 
CCCGATACCCAACCTAAAACTAAAAT 
       
PPP1R3C GTTTTAGTTGGGCGTTGGTTG 14 84 - 77 + 161 133 + 81,4 85 
 
AACCACAACTCCAAACCTTACCC 
       
CLDN11 GTATTTGGGTAGGTATTGTTTAGTTTAGG 10 112 + 291 + 180 191 + 80,4 83,2 
 
CAAATCACCACCCAATCATTAATAAA 
       
 
Supplementary Table S2 (B) qPCR primers. 
cDNA Primer sequence 5'> 3 Accession No. Exonic Location Amplicon size (bp) 
HOXA9 GAGAATGAGAGCGGCGGA NM_152739 1, 2 90 
 
CCGCTTTTTCCGAGTGGA 
   
MAPK13 GGCTGTATCATGGCAGAGATG NM_002754 8, 9 85 
 
CTTTCAGGATCTGGGTCAGC 
   
CDH11 CGCCTGCATCGTCATTCT NM_001797 12, 13 101 
 
CACGGACATCTTCTTCCTCAA 
   
BMP4 AGGAGCTTCCACCACGAAG NM_001202 3, 4 92 
 
GGGATGCTGCTGAGGTTAAA 
   
PLEKHG6 CTCTATCGGGACCAGGACAGG NM_018173 14, 15 112 
 
GGATAATGGTCGAGAACTCAGGAG 
   
 
Supplementary Table S2 (C) BRAF and NRAS sequencing primers. 
Gene Sequence Exonic location Interrogated codon 
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Supplementary Table S3 (A) List of the 106 unique genes (P <0.05 and average β-value difference >0,20) 
identified as hypermethylated in primary melanoma. Validated genes are highlighted. 









HOXA9 Homeobox A9 0.386483234 0.012 x x 
C1orf106 Chromosome 1 open reading frame 106 0.322837474 0 
  
HIST1H3E Histone cluster 1, H3e 0.316605725 0 
 
x 
MAPK13 Mitogen-activated protein kinase 13 0.311837229 0.034 
 
x 
LEP Leptin (obesity homolog, mouse) 0.311563859 0 
  
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) 0.298408797 0.016 x x 
C4orf8 Chromosome 4 open reading frame 8 0.297335994 0 
  
EFCAB1 EF-hand calcium binding domain 1 0.283580672 0.029 
  
CNTN1 Contactin 1 0.282425828 0 
  
GNMT Glycine N-methyltransferase 0.281172377 0 
 
x 
ABCA3 ATP-binding cassette, sub-family A (ABC1), member 3 0.279902377 0.023 
  
PLEKHG6 
Pleckstrin homology domain containing, family G (with 
RhoGef domain) member 6 
0.271057913 0.026 
  
HIST1H3G Histone cluster 1, H3g 0.269972293 0 
  
PDE4DIP Phosphodiesterase 4D interacting protein (myomegalin) 0.269764956 0 
  
PPP1R3C Protein phosphatase 1, regulatory (inhibitor) subunit 3C 0.269496395 0 x 
 
ME3 Malic enzyme 3, NADP(+)-dependent, mitochondrial 0.268329645 0 
  
MYL9 Myosin, light chain 9, regulatory 0.267168652 0.034 
 
x 
HOXD12 Homeobox D12 0.266988536 0 x 
 
NDST4 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 4 0.265946667 0 
  
HLA-G HLA-G histocompatibility antigen, class I, G 0.263079106 0 x x 
SLC6A6 
Solute carrier family 6 (neurotransmitter transporter, 
taurine), member 6 
0.262815719 0 
  
CLDN11 Claudin 11 (oligodendrocyte transmembrane protein) 0.259287545 0.04 
 
x 
LCAT Lecithin-cholesterol acyltransferase 0.258877843 0 
  
TRIM50C Tripartite motif containing 74 0.258660963 0 
  
CLDN7 Claudin 7 0.257209464 0.038 
 
x 
OVOL1 Ovo-like 1(Drosophila) 0.255892223 0.048 
  
GPR135 G protein-coupled receptor 135 0.255310147 0.033 
  
DCDC2 Doublecortin domain containing 2 0.251983999 0.046 
  
CDK3 Cyclin-dependent kinase 3 0.250844565 0 
  
MEST Mesoderm specific transcript homolog (mouse) 0.249726168 0 
 
x 
ALDH2 Aldehyde dehydrogenase 2 family (mitochondrial) 0.249604266 0 
 
x 
GBGT1 Globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 0.248456228 0 
  
LOXL1 Lysyl oxidase-like 1 0.248370347 0 
 
x 
FAM3B Family with sequence similarity 3, member B 0.247974455 0.036 
  
SERPINB5 Serpin peptidase inhibitor, clade B (ovalbumin), member 5 0.24599395 0 
 
x 
GPT Glutamic-pyruvate transaminase (alanine aminotransferase) 0.244655194 0 
  
COL1A2 Collagen, type I, alpha 2 0.244446308 0.029 x x 
ALOX12 Arachidonate 12-lipoxygenase 0.243363656 0 
 
x 
COL14A1 Collagen, type XIV, alpha 1 (undulin) 0.240319162 0.014 
 
x 
HAAO 3-hydroxyanthranilate 3,4-dioxygenase 0.239623765 0 
 
x 
RARB Retinoic acid receptor, beta 0.238093203 0 x x 
FLJ36070 




RNF43 Ring finger protein 43 0.235797878 0 
  
OTP Orthopedia homeobox 0.235315488 0.014 
 
x 
PRDM14 PR domain containing 14 0.235166177 0 
  
IL20RA Interleukin 20 receptor, alpha 0.234413165 0 
 
x 
GPR109B G protein-coupled receptor 109B 0.234166841 0 
  
LOC222171 Proline rich 15 0.233727994 0 
  
PPP1R13L Protein phosphatase 1, regulatory (inhibitor) subunit 13 like 0.233637254 0.019 
  
DES Desmin 0.232837864 0.013 
  
UNQ2446 Neuritin 1-like 0.232180459 0 
  
CCL27 Chemokine (C-C motif) ligand 27 0.231546716 0 
  
ZNF710 Zinc finger protein 710 0.231358867 0 
  
MSX1 Msh homeobox 1 0.230475548 0 
 
x 
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 0.230267325 0 x x 
CHFR Checkpoint with forkhead and ring finger domains 0.229806888 0 
 
x 
CENTB5 Centaurin, beta 5 0.229121547 0 
  
PRTFDC1 Phosphoribosyl transferase domain containing 1 0.227675219 0 
 
x 
NNAT Neuronatin 0.227436253 0 
 
x 
LRRC8C Leucine rich repeat containing 8 family, member C 0.225715702 0 
  














PAX3 Paired box 3 0.223214654 0 x x 
PLXNB1 Plexin B1 0.22538469 0.021 
  
ARHGAP8 Rho GTPase activating protein 8 0.225166562 0 
  
ABHD9 Abhydrolase domain containing 9 0.222971815 0 x x 
ANGPTL5 Angiopoietin-like 5 0.221433652 0 
  
KCTD12 Potassium channel tetramerisation domain containing 12 0.221238936 0 
  
P2RY6 Pyrimidinergic receptor P2Y, G-protein coupled, 6 0.221209139 0.038 
  
DISP1 Dispatched homolog 1 (Drosophila) 0.21881343 0.014 
  
VSX1 Visual system homeobox 1 0.218541035 0.032 
  
DDR1 Discoidin domain receptor family, member 1 0.217786303 0 
  
PDK4 Pyruvate dehydrogenase kinase, isozyme 4 0.216572648 0.023 
  
WISP2 WNT1 inducible signaling pathway protein 2 0.215433672 0 
  
GAL3ST3 Galactose-3-O-sulfotransferase 3 0.214561831 0.014 
  
C16orf30 Chromosome 16 open reading frame 30 0.213297461 0.017 
 
x 
ALDH3A1 Aldehyde dehydrogenase 3 family, memberA1 0.212722554 0 
  
APH1B Anterior pharynx defective 1 homolog B (C. elegans) 0.212651362 0 
  
FBXO44 F-box protein 44 0.212464867 0 
  
ANKDD1A Ankyrin repeat and death domain containing 1A 0.211560778 0 
 
x 
STAP2 Signal transducing adaptor family member 2 0.211557564 0 
  
CRB1 Crumbs homolog 1 (Drosophila) 0.211260864 0.023 
  
SEC31L2 SEC31 homolog B (S. cerevisiae) 0.210806802 0.04 
  
MTSS1 Metastasis suppressor 1 0.210716672 0 
 
x 
RTKN Rhotekin 0.210450445 0.03 
  
SERHL Serine hydrolase-like 0.210364197 0.026 
  
GPR25 G protein-coupled receptor 25 0.210280693 0 
  
FXYD3 FXYD domain containing ion transport regulator 3 0.208717214 0.015 
  
CCDC19 Coiled-coil domain containing 19 0.208457588 0.049 
  
FLJ39599 MPV17 mitochondrial membrane protein-like 0.207319001 0 
  
LAMB3 Laminin, beta 3 0.206753259 0 x x 
LACTB Lactamase, beta 0.206389962 0 
  
SDCBP2 Syndecan binding protein (syntenin) 2 0.20625116 0 
  
HKDC1 Hexokinase domain containing 1 0.20583116 0.014 
  
NR4A1 Nuclear receptor subfamily 4, group A, member 1 0.204840796 0 
  
NDUFS2 
NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa 








FOXD2 Forkhead box D2 0.203879025 0 
  
APCDD1 Adenomatosis polyposis coli down-regulated 1 0.203854304 0 
  
ADORA2A Adenosine A2a receptor 0.203064992 0 
  
LOC349236   0.202228801 0 
  
CRYBA2 Crystallin, beta A2 0.201666542 0.023 
 
x 
TACSTD1 Tumor-associated calcium signal transducer 1 0.201129306 0.04 
  
CLIC6 Chloride intracellular channel 6 0.201080863 0.03 
  
NFKBIB 
Nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, beta 
0.20101736 0 
  
CMTM2 CKLF-like MARVEL transmembrane domain containing 2 0.200457024 0.04 
  
SLC15A2 Solute carrier family 15 (H+/peptide transporter), member 2 0.200430401 0 
  
        n=11 n=32 
        10.4 % 30.2 % 
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Supplementary Table S3 (B) List of the 44 unique genes (P <0.05 and average β-value difference > - 0,20) 
identified as hypomethylated in primary melanoma. 









HLA-DRA Major histocompatibility complex, class II, DR alpha -0,287684014 0 
  
SLC1A2 





MGC35206 Testis expressed 33 -0,265220728 0 
  
PRSS2 Protease, serine, 2 (trypsin 2) -0,262463936 0 
  
SIRPB1 Signal-regulatory protein beta 1 -0,253688211 0 
  
GIMAP7 GTPase, IMAP family member 7 -0,247822312 0,012 
  
GIMAP2 GTPase, IMAP family member 2 -0,240934883 0,014 
  
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) -0,238817512 0 
  
KCNK17 Potassium channel, subfamily K, member 17 -0,238487672 0 
  
NALP12 NLR family, pyrin domain containing 12 -0,238234352 0 
  
TRIM40 Tripartite motif-containing 40 -0,23679714 0 
  
FLJ25773 Chromosome 14 open reading frame 177 -0,233879123 0 
  
ITGAL 
Integrin, alpha L (antigen CD11A (p180), lymphocyte function-
associated antigen 1; alpha polypeptide) 
-0,233231346 0 
  
UNQ3033 V-set and transmembrane domain containing 1 -0,231175937 0 
  
TPM3 Tropomyosin 3 -0,230938917 0 
  
LIFR Leukemia inhibitory factor receptor alpha -0,228878156 0,049 
 
x 
C1orf150 Chromosome 1 open reading frame 150 -0,227742979 0,015 
  
ELSPBP1 Epididymal sperm binding protein 1 -0,227216147 0 
  
FCRL3 Fc receptor-like 3 -0,225753462 0 
  
LILRA2 
Leukocyte immunoglobulin-like receptor, subfamily A (with TM 









K6IRS3 Keratin 73 -0,223643593 0,013 
  
NALP9 NLR family, pyrin domain containing 9 -0,223223861 0 
  
MGAM Maltase-glucoamylase (alpha-glucosidase) -0,220814253 0 
  
FAIM3 Fas apoptotic inhibitory molecule 3 -0,218429252 0,016 
  
AQP5 Aquaporin 5 -0,217565045 0 
 
x 
GIMAP4 GTPase, IMAP family member 4 -0,214211774 0,015 
  
ASGR2 Asialoglycoprotein receptor 2 -0,212790738 0 
  
GIMAP1 GTPase, IMAP family member 1 -0,210846219 0 
  
MGC29671 Spinster homolog 3 (Drosophila) -0,210725154 0 
  
SLA2 Src-like-adaptor 2 -0,210128702 0 
  
PGK2 Phosphoglycerate kinase 2 -0,209436678 0 
  
LILRA1 
Leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 1 
-0,206384966 0 
  
PSMB6 Proteasome (prosome, macropain) subunit, beta type, 6 -0,206295895 0,04 
  
GPR154 Neuropeptide S receptor 1 -0,204509133 0 
  
RBP3 Retinol binding protein 3, interstitial -0,204407391 0,025 
  
C15orf2 Chromosome 15 open reading frame 2 -0,203557247 0,039 
  
PTPN22 Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) -0,203401133 0,03 
  
OR1A1 Olfactory receptor, family 1, subfamily A, member 1 -0,202507508 0,02 
  
KRTAP10-8 Keratin associated protein 10-8 -0,202131896 0 
  
EMR3 Egf-like module containing, mucin-like, hormone receptor-like 3 -0,200710901 0 
 
x 
MRGPRX2 MAS-related GPR, member X2 -0,200622617 0 
  
RUNX3 Runt-related transcription factor 3 -0,200567687 0,034 x x 
MARCO Macrophage receptor with collagenous structure -0,200136166 0 
  
        n=1 n=6 






























































Supplementary Figure S1. CpG islands within gene promoter regions are analyzed for validation of gene 
methylation status. Schematic representation of the first exon, location of the CpG island, the region amplified 
for bisulphite melting curve and sequence analysis (amplicon) and the region corresponding to the CpG probe on 
the Infinium beadchip (cg) of HOXA9, MAPK13, CDH11, PLEKHG6, PPP1R3C and CLDN11. 
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Supplementary Figure S2. Promoter methylation status of HOXA9, MAPK13, CDH11, PLEKHG6, PPP1R3C and 
CLDN11 in metastatic melanoma samples. (A) Bisulphite melting curve profiles of seven cutaneous melanoma 
metastases and 13 early-passage metastatic melanoma cell lines were plotted overlapping in one graph (top) for 
each gene. The overlap of melting curves of the 15 naevi in one graph is included for comparison (bottom). The 
melanoma metastases show a peak in their melting curve patterns at the melting temperature (Tm) for 
methylated DNA, whereas naevi show a peak at the Tm for unmethylated DNA in the absence of a methylated 
DNA peak. Methylated DNA peaks in the melting curve pattern with a height of 0.5 or more relative to the 
unmethylated DNA peaks were considered indicative of methylation for the investigated CpG island amplicon. (B) 
Bisulphite sequencing analysis of CpG dinucleotides in the HOXA9, MAPK13, CDH11, PLEKHG6, PPP1R3C and 
CLDN11 promoter regions in a selected number of metastatic melanoma cell lines (MCL) and naevi (N). An 
unmethylated cytosine of an interrogated CpG dinucleotide is depicted as a white circle, a methylated cytosine 
as a black circle, a partially methylated cytosine as a grey circle. An interrogated CpG island amplicon was 
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Supplementary Figure S3. Restoration of MAPK13 expression in melanoma cells with MAPK13 promoter 
methylation attenuates proliferation, long-term growth curves. (A) Melanoma cell lines 634, 453A0, 93.08, 
9304C and 04.07 were transduced using retroviral vectors (pBABE-puro-HA-MAPK13) expressing MAPK13
WT
 or 




 and selected for succesful integration. Empty 
vectors were used as controls (c). Samples were analyzed for MAPK13 expression by Western blot 9 days post-
infection, α-tubulin served as loading control. (Note that a short exposure was used to detect overexpressed 
MAPK13, explaining the seeming absence of the two corresponding endogenous protein in 9304C and 04.07 
cells). The MAPK13 promoter methylation status is indicated for each cell line; M, methylated (left); U, 
unmethylated (right). (B) Samples of the transduced melanoma cells were seeded at equal numbers and counted 
every three to four days starting at three days post-infection for at least three weeks. Error bars indicate 
standard deviation from triplicate cell counts at each time point; two-tailed t-test was applied for statistical 
analysis. MAPK13 promoter methylation status is indicated; M, methylated (top row); U, unmethylated (bottom 
row). *P <0.05. 
Promoter methylation profiling and epigenetic silencing of MAPK13 
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Supplementary Figure S4. Depletion of MAPK13 does 
not prevent cell cycle arrest induced by BRAF
V600E
 in 
human fibroblasts. (A) TIG-3 human fibroblasts stably 
expressing one of the three independent MAPK13 
shRNAs (#1, #2 or #3) in addition to the ecotropic 





-encoding retrovirus and 
selected for integration of the construct. Empty vectors 
(control) and scrambled shRNA (sh-scr) were included as 
controls. Samples were analyzed for MAPK13 and BRAF 
expression by Western blot nine days post-infection, α-
tubulin served as loading control. The depicted lanes 
originate from a single blot and were re-aligned for 
reading convenience of the figure. (B) Samples were 
seeded at equal densities and stained with crystal violet 
13 days post-infection. Empty vectors were used as 
controls. An shRNA targeting IGFR2 served as positive 
control for bypass of BRAF
V600E
-induced proliferative 
arrest (Thomas Kuilman and D.S.P., unpublished 
results). Data are representative for three independent 
experiments. (C) Samples were seeded at equal 
densities and analyzed for BrdU incorporation 11 days 
post-infection. Empty vector (control) and scrambled 
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The activation of oncogenes in primary cells blocks proliferation by inducing oncogene-
induced senescence (OIS), a highly potent in vivo tumor-suppressing program. A prime 
example is mutant BRAF, which drives OIS in melanocytic nevi. Progression to melanoma 
occurs only in the context of additional alteration(s) like the suppression of PTEN, which 
abrogates OIS. Here, we performed a near-genomewide short hairpin (sh)RNA screen for 
novel OIS regulators and identified by next generation sequencing and functional 
validation seven genes. While all but one were upregulated in OIS, depletion of each of 
them abrogated BRAF
V600E
-induced arrest. With genome-wide DNA methylation analysis, 
we found one of these genes, RASEF, to be hypermethylated in primary cutaneous 
melanomas but not nevi. Bypass of OIS by depletion of RASEF was associated with 
suppression of several senescence biomarkers including senescence-associated (SA)-β-
galactosidase activity, interleukins, and tumor suppressor p15
INK4B
. Restoration of RASEF 
expression inhibited proliferation. These results illustrate the power of shRNA OIS bypass 
screens and identify a potential novel melanoma suppressor gene. 
 
Introduction 
Several tumor-suppressive mechanisms have evolved to prevent malignant transformation 




. Work in recent 
years has uncovered that cells at risk for oncogenic transformation can embark on another 
strategy: in response to obstinate stress signals, they activate signaling networks 
comprising several potent tumor suppressor proteins. In this way, a system is established 
enacting a dominant break that actively halts cell proliferation. This type of cell cycle 
arrest, termed ‘oncogene-induced senescence (OIS)’, can be maintained even in the 
context of persistent oncogenic cues
3
. In recent years, a large body of evidence has shown 
that OIS acts as a pathophysiologic mechanism suppressing cancer in model systems and 
humans alike. Indeed, senescence biomarkers have been reported for a plethora of 
precancerous lesions including melanocytic nevi, pulmonary adenomas, prostate 
intraepithelial neoplasia, and mammary lesions
4
. 
Cellular senescence denotes a state of virtually irreversible withdrawal of cells 
from the proliferative pool. While we have come to realize that its onset can be triggered 
by a plethora of stress-related signals, it was first recognized in cultured human diploid 
fibroblasts (HDFs) following explantation and in vitro culturing. With every cell division, 
telomeres get progressively shorter, causing cells to hit their ‘Hayflick limit’ at the end of 
their replicative life span
5
. Such replicative senescence has correlates in the context of 
other stress signals, most notably the activation of oncogenes or loss of tumor suppressor 
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Next to long-term cell cycle arrest, which is the central characteristic of senescent 
cells, OIS is characterized by the activation of tumor suppressor pathways including-but 




. Conversely, cell cycle 
progression factors such as cyclins A and B and PCNA are inhibited
3
. Oncogene-induced 
senescence is accompanied also by morphological changes, induction of senescence-
associated β-galactosidase activity (SA-β-Gal)
9
, and chromatin condensation into 
senescence-associated heterochromatin foci (SAHF)
10,11
. 
Another characteristic of cells undergoing OIS is the activation of an 
inflammation-associated secretory program called senescence-messaging secretome 
(SMS) as we and others have shown
12-14
 or senescence-associated secretory phenotype 
(SASP), the latter of which is associated with a DNA damage response
15,16
. The physiologic 
relevance of the inflammatory phenotype is reflected by the production of a number of 
interleukins and chemokines in senescent cells in benign murine and human neoplasms
17
. 
But secreted senescence-associated (SA) factors also limit tissue damage
18
 and correlate 
with premature aging
19
. Yet another function of senescence-associated secreted factors is 
to activate the innate immune system, setting up incipient cancer cells for their own 
demise
20,21
. Further supporting a cell non-autonomous role for senescence, it was recently 
shown that this program can be brought about also in a paracrine fashion
22
. 
Lately, we and others have discovered functional connections between the 
cellular metabolism and OIS. Aird et al. (2013)
23
 have demonstrated that stable cell cycle 
arrest in OIS is established and maintained through suppression of nucleotide metabolism. 
Others have highlighted the importance of malic enzyme activity in OIS
24
. We identified 
mitochondrial gatekeeper pyruvate dehydrogenase (PDH) as an enzyme critically 
contributing to OIS
25
. In OIS, PDH is activated upon downregulation of its inhibitory kinase 
PDK1 and simultaneous upregulation of PDH activating phosphatase PDP2. Normalization 
of the levels of these enzymes inactivates PDH resulting in abrogation of OIS. Translating 
these findings to a clinical context, we demonstrated that PDK1 depletion eradicates 
established melanomas, highlighting this metabolic enzyme as a potentially attractive 
therapeutic metabolic cancer target. 
The benign melanocytic nevus was the first human lesion for which evidence was 
shown in favor of the idea that OIS prevents malignant progression
26
. Three years prior to 
that, BRAF
V600E
 was identified as a common mutation in melanoma and other cancer 
types
27
. Remarkably, in spite of the presence of oncogenic mutations in the BRAF (or, in 
some cases, NRAS) gene
28
, nevi are typically associated with an exceedingly low 
proliferative activity. However, while this proliferative arrest can be maintained for 
decades
29
, several studies provide genetic evidence that a fraction of nevi still progresses 
to melanoma
30-32
. As a BRAF
V600E
 mutation alone is insufficient to drive melanomagenesis, 




restraints and become malignant. Several genetic events frequently occurring in 
melanoma have been described, including the loss of CDKN2A and ARF, amplification of 
CCND1 or CDK4
33,34
, alterations in MMP8, GRM3, ERBB4, GRIN2A, MITF 
35-39
, and activation 
of the PI3K pathway
40
. We have demonstrated previously that the latter event, for 
example by reduction in the expression levels of PTEN, reflects a rate-limiting step in OIS 
abrogation on the path to oncogenic transformation
41
. Moreover, recent exome and 
whole genome sequencing studies reported frequent mutations in melanoma of several 
genes including RAC1 and PREX2
42-44
. 
In addition to genetic alterations, tumor suppressor genes can be inactivated by 
epigenetic means. Promoter hypermethylation has emerged as an important epigenetic 
mechanism responsible for transcriptional repression of a multitude of genes in human 
cancer cells. In melanoma, several established tumor suppressor genes have been shown 
to be inactivated secondary to promoter hypermethylation, including CDH1, RASSF1A, and 
SERPINB5
45
. Although the role of some of the above-mentioned genes affected by 
mutation or promoter hypermethylation in melanoma has been demonstrated, the 
mechanistic relationship with OIS is unclear for most. Hence, the molecular mechanism 
and the identity of the factors underlying malignant transformation in relation to OIS and 
OIS bypass are largely unknown. Therefore, we set out to perform a near-genomewide 
(sh)RNA screen for novel OIS factors. Such genes would be predicted to function as tumor 
suppressor genes in tumor cells expressing an activated oncogene, with PTEN serving as a 
prime example
46,47
. We have recently performed a genome-wide analysis of promoter 
methylation in primary melanoma and benign nevus and identified a large number of 
genes, including several tumor suppressor genes, to be hypermethylated in melanoma
48
. 
Here, we have integrated the data from both RNAi screening and methylation analyses.  
 
Methods 
Cell culture, viral transduction, and senescence induction 
The HDF cell line TIG3 expressing the ectopic receptor, hTERT, and sh-p16
INK4A
 as well as 
melanoma cell lines (04.04, 04.07, 05.06, 518A2, 06.24, 607B, 634, 93.08, 94.03C, 94.07, 
94.13, A875, BLM, Mz7.4) were maintained in DMEM, supplemented with 9% fetal bovine 
serum (Sigma, St. Louis, MO) and 2mM glutamine (GIBCO, Carlsbad, CA, USA). 
Melanocytes were maintained as described previously
49
. Lentiviral and retroviral 
infections were performed using HEK293T cells and Phoenix cells, respectively, as 
producers of viral supernatants. For senescence experiments, HDF or melanocytes were 
infected with shRNA-encoding or protein-coding retro- or lentivirus, selected 
pharmacologically (puromycin or blasticidin) and subsequently infected with BRAF
V600E
-
encoding or control virus. After selection, cells were seeded for cell proliferation assay, 
BrdU incorporation assay, SA-β-galactosidase activity and analyzed. 
RNAi screening, BRAF
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Cell proliferation assay 







respectively) and selected pharmacologically. Fixation and staining with crystal violet was 
performed 9–18 days after the BRAF
V600E
-encoding or control virus infection, or 12–16 
days after RASEF-encoding or control eGFP-encoding virus infection. Images of cell 
proliferation assays reflect representative results of at least three independent 
experiments. 
 
BrdU incorporation assay 
BrdU labeling was carried out for 3h followed by fixation. Incorporated BrdU was detected 
by immunostaining as described in Serrano et al., 1997
3
 and FACS analysis. Results are 
represented as mean with SD of at least three independent experiments. 
 
Analysis of SA-β-galactosidase activity 
Senescence-associated β -galactosidase was stained using the ‘Senescence Associated β -
Galactosidase Staining Kit’ from Cell Signaling (Danvers, MA, USA) at pH6 according to the 
manufacturer’s protocol. Images reflect representative results of at least three 
independent experiments. 
 
Trypan blue exclusion assay 
Cells were brought into suspension using trypsin, centrifuged and resuspended in a small 
volume of culture medium. Trypan blue (Sigma) was added to the cell suspension (dilution 
factor = 2), and stained cells were counted as dead. The number of dead cells was 
quantitated, and the values were expressed as the fold change over control. Results are 
represented as mean with SD of at least three independent experiments. 
 
Plasmids 
The human TRC1 shRNA Library was purchased from Sigma-Aldrich. pMSCV-blast-
BRAF
V600E
 and pMSCV-blast, KH1-GFP-shPTEN#1, HIV-CSCG-blast-BRAF
V600E
, and HIV-CSCG-
blast were previously described
13,41
. For the re-expression of RASEF, the pLX304-RASEF-V5 
as well as control pLX304-eGFP-V5 plasmids, both from CCSB-Broad Lentiviral Expression 




The human TRC1 shRNA Library was purchased from Sigma-Aldrich 
(http://www.sigmaaldrich.com/life-science/functional-genomics-and-
rnai/shrna/products/lentiplex.html). Lentiviral knockdown constructs were purchased 
from Sigma-Aldrich in pLKO.1 backbone: 




shUBE2V1#2–TRCN0000033706 – 5’-CCAAGAGCCATATCAGTGCTA-3’ 
shNMRAL1#1–TRCN0000036912 – 5’-GGGACATTCAAGGTTCGAGT-3’ 
shNMRAL1#2–TRCN00000036913 – 5’-CAAGATGACTCCTGAGGACTA-3’ 
shPCDHGA10#1–TRCN0000053343 – 5’-TTTCTATTTCATAGAAACCGG-3’ 
shPCDHGA10#2– TRCN0000053344 – 5’-ATTCCTCAGGAATTGAGTAGG-3’ 
shSLC1A4#1– TRCN0000038641 – 5’-AGAGGATCAGCAGGTTTAT-3’ 
shSLC1A#2– TRCN0000038642 – 5’-CCACCTGAATCAGAAGGCAA-3’ 
shWT1#1– TRCN0000001114 – 5’-AAAGTTTACATTAGCAGACAC-3’ 
shWT1#2– TRCN0000001117 – 5’-AAGTCACACTGGTATGGTTTC-3’ 
shGEMIN6#1– TRCN0000147641 – 5’-TTCATAGTTTCAACAGTCTGC-3’ 
shGEMIN6#2– TRCN0000146917 – 5’-TATACTCATTCTTCTCACTGG-3’ 
shRASEF#1– TRCN0000055624 – 5’-TAATGGGAACAGTCTCATGGG-3’ 
shRASEF#2– TRCN0000055625 – 5’-TTTCCGTGTCTTATGTTCTGC-3’ 
shRASEF#3– TRCN0000055626 – 5’-ATTCTCGTATGTTAAGAAAGC-3’ 
 
Quantitative real-time PCR 
Total RNA was DNase-treated with RQ1 RNase-Free DNase (Promega, Madison, WI, USA). 
Reverse transcription was performed with SuperScript II First Strand Kit (Invitrogen, 
Carlsbad, CA, USA). Quantitative real-time PCR was performed with the SYBR Green PCR 
Master Mix (Applied Biosystems, Carlsbad, CA, USA) on an ABI PRISM 7700 Sequence 
detection System (Applied Biosystems). Primer sets used were as follows: 
UBE2V1: 5’-GGAGAGGTTCAAGCGTCTTACC-3’ and 5’-TTCGAGTTCTTCCAACAGTCG-3’ 
NMRAL1: 5’-GCTTACGCCACCTTCATCG-3’ and 5’-CAGATCAGCGAGCAGCTTCC-3’ 
PCDHGA1’: 5’-CTGCAAGCCATGATCTTGG-3’ and 5’-AGACATTCTGGCGGTAGTCG-3’ 
SLC1A4: 5’-TCCGAAGGAGAAGACCTCATCC-3’ and 5’-CTTCCAACAAGGAACATGATGC-3’ 
WT1: 5’-TACAGCACGGTCACCTTCG-3’ and 5’-CACCGAGTACTGCTGCTCAC-3’ 
GEMIN6: 5’-CGAGTGACAGCCAGTGAGAAG-3’ and 5’-ATCTTCAAGGAAGTTCACAAGG-3’ 
RASEF: 5’-GCTGCTACAGAGGGACAAAAA-3’ and 5’-CAGAATAATGCCCCATACGTC-3’ 
Or 5’-ATCAGACTTCAAAGCACAGAAATGG-3’ and 5’-TTCCTCTTCCAACTCACTCAACTG-3’ 
IL6, IL8, C/EBPβ, and RPL13 (standard) primer sequences were described previously
13
. All 
primer pairs except C/EBPβ span exon-exon borders. RPL13 was used as control. For 




Antibodies used for immunoblotting were BRAF (sc-5284; Santa Cruz, Dallas, TX, USA), 
Hsp90 (4874; Cell Signaling), MAP kinase p44/42 (9102; Cell Signaling); phospho-MAP 
kinase p44/42 (9106; Cell signaling), MEK1/2 (L38C12; 4694; Cell Signaling), phospho- 
MEK1/2 [Ser217/221] [(41G9); 9154; Cell Signaling], PCNA [(PC10); sc-56; Santa Cruz], 
p21
Waf1/Cip1
 [(C19); sc-397; Santa Cruz], p15
INK4B
 (sc-612; Santa Cruz), p53 [(DO-1); sc-126; 
Santa Cruz]; phospho-RB (Ser807/811) (9308; Cell Signaling), total RB (9309; Cell 
Signaling); RASEF (HPA021431; Sigma), V5-tag (R960-25; Invitrogen).  
RNAi screening, BRAF
V600E




Fresh-frozen and paraffin-embedded biopsy specimens were obtained from 76 primary 
cutaneous melanomas and from 15 benign melanocytic nevi, all containing at least 70% 
melanocytic cells (for detailed clinical information, see Table S2). The BRAF and NRAS 
mutation status of a subset of five nevi and 24 primary melanomas was determined using 















 mutations on a CFX384 Real-Time Detection System (Bio-Rad, Hercules, CA). 
DNA was extracted with the Genomic-tip kit (Qiagen, Hilden, Germany) or RecoverAll 
Nucleic Acid kit (Ambion, Carlsbad, CA). 
 
Bisulfite melting curve analysis and BSA 
Bisulfite conversion was performed with the EZ DNA methylation kit (Zymo Research, 
Orange, CA). RASEF bisulfite primers for BMCA and BSA were designed to amplify a 126-
base pair region at +259 from the TSS, located within the CpG island that covers the 
promoter region and first exon of the RASEF gene (5’-GGGATGGAGGCGGATGGG-3’ and 5’-
GGTATTGTGTACGGAGTTGCGG-3’; Figure 3B). Sensitivity of the primer set for BMCA was 
validated using mixtures, 1:1, 1:3, 1:9, and 1:9.5, of completely methylated CpGenome 
universal methylated DNA (Chemicon, Hampshire, UK) and unmethylated semen DNA, 
respectively, showing that methylation could be accurately detected if 10% of the total 
analyzed DNA was methylated. Generated bisulfite melting curves of the RASEF CpG island 
amplicon were scored as previously described
48
. Sequences obtained from BSA were 
considered methylated if the density of methylated CpG dinucleotides within the 
interrogated amplicon was 15% or more, a threshold value that has been previously used 





Melanoma cell lines 634 and 06.24 were seeded at 15% confluency and treated with 2μM 
5-aza-2’-deoxycytidine (Decitabine; Sigma) for 96h. Culture medium was replaced with 
medium containing freshly prepared 5-aza-2’-deoxycytidine every 24h. Cells were 
harvested for RNA extraction with the RNeasy Mini kit (Qiagen), and expression of RASEF 
was analyzed by qRT-PCR. Stable expression of the reference genes TBP and CPSF6 was 





Statistical analyses were done with t-tests, unless stated otherwise. P values of less than 










To identify factors required for BRAF
V600E
 to induce senescence, we performed a function-
based knockdown screen for genes that can rescue this type of cell cycle arrest (Figure 
1A). Human diploid fibroblasts (HDF) were transduced with a near-genomewide lentiviral 
shRNA library targeting approximately 15,000 human genes, organized in 10 pools with 
some five shRNAs per gene target. Transduction was performed at a multiplicity of 
infection (MOI) of 0.5 to ensure that in most cases only a single shRNA integrated per cell. 
The number of cells used for transduction was calculated to obtain a minimum coverage 
of 10. After pharmacological selection, cells were transduced with BRAF
V600E
-encoding 
retrovirus. While cells containing empty vector control underwent cell cycle arrest as 
expected, cells that contained library shRNAs abrogating BRAF
V600E
-induced senescence 
kept growing and formed colonies. These colonies were subsequently picked individually, 
expanded, and their genomic DNA was isolated. To identify hits, gDNAs isolated from 
individual colonies derived from independent shRNA pools were grouped and received a 
unique index. shRNAs were re-amplified and analyzed by deep sequencing. If a particular 
shRNA gave rise to more than one colony, it would be present in more than one group. 
Candidates for validation were selected based on two criteria: (i) the presence of 
at least two shRNAs targeting the same gene to reduce the chance of off-target effects 
and (ii) the extent of senescence abrogation: only shRNAs identified in independent 
colonies were further analyzed (Table S1). On the basis of these criteria, shRNAs targeting 
40 genes were re-evaluated, one by one, for their ability to abrogate BRAF
V600E
-induced 
cell cycle arrest. Seven genes (UBE2V1, NMRAL1, PCDHGA10, SLC1A4, WT1, GEMIN6, 
RASEF) could be validated in multiple rounds each with two shRNAs in cell proliferation 
assays (Figure 1B) and BrdU incorporation assays (Figure 1C). 
We next tested whether the identified shRNAs were on-target, that is, whether 
they deplete the gene of interest. Quantitative real-time (qRT) PCR analysis confirmed that 
in all cases, the expression of the target gene was decreased (Figure 1D–J). We previously 
demonstrated that OIS genes are commonly induced by the oncogenic stressor, for 
example interleukins
13
. Consistent with this notion, the expression of all genes but SLC1A4 
was induced in senescent cells. Taken together, this near-genomewide function-based 
shRNA screen identified seven genes crucial for BRAF
V600E
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Figure 1. Near-genomewide shRNA screen identifies genes required for BRAFV600E-induced senescence. (A) 
Schematic summary of the screen setup. (B) Cell proliferation assay on human diploid fibroblasts transduced 
with vector control or shRNA targeting candidate genes identified in the screen. Cells were fixed and stained 11 
days after exposure to BRAF
V600E
. shRNA targeting IGFR2 was used as a positive control (Kuilman T., Peeper D.S., 
unpublished data). (C) BrdU incorporation of samples described in B, measured 9 days after exposure to 
BRAF
V600E
. Levels are represented as mean of three independent validation rounds. Error bars represent SD. 
Significance was determined by one-way ANOVA comparing OIS cells with cells depleted of the indicated target 
gene. (D–J) Regulation of gene transcripts of the samples described in B as determined by quantitative real-time 
qRT-PCR. Measurements are standardized to the vector-expressing cells. Error bars represent SD from triplicate 





RASEF is a new OIS gene 
Of the seven genes identified in the screen, the expression of RAS and EF-hand domain 
containing (RASEF) transcript, also known as RAB45, was induced by BRAF
V600E
 to the 
highest extent (Figure 1J). Additionally, the RASEF locus was previously shown to be 
associated with predisposition to hereditary melanoma
53
 and epigenetically regulated in 
uveal melanoma
54
. In light of those observations, and because BRAF
V600E
-induced 
senescence prevents nevi from progressing to melanomas
49
, we studied the role of RASEF 
in OIS and OIS abrogation in more detail. 
For this, with the use of an additional shRNA, we confirmed that RASEF depletion 
(Figure 2A) abrogates BRAF
V600E
-induced cell cycle arrest as determined by cell 
proliferation (Figure 2B) and BrdU incorporation assays (Figure 2C). The abrogation of cell 
cycle arrest was seen already at day 10 after introduction of BRAF
V600E
 (around the day 
when senescence is fully established) and was maintained up to at least 18 days (Figure 
2B). Importantly, this could not be explained by loss of BRAF
V600E
 expression or loss of 
activation of downstream MEK/ERK signaling (Figure 2D). The rescue of proliferation by 
RASEF knockdown was associated with restoration of expression of the DNA replication-
associated protein PCNA (Figure 2D). Moreover, RASEF depletion resulted in a profound 
suppression of other common senescence-associated biomarkers (SA)-β-galactosidase 
activity (Figure 2E), expression of the SA p15
INK4B
 tumor suppressor (Figure 2D), and the 
number of SAHF-positive cells (Figure 2F). Whereas RB as expected accumulated in its 
hypo-phosphorylated form in BRAF
V600E
 senescent cells, RASEF depletion reversed its 
phosphorylation status (Figure S1), suggesting cross talk between RASEF and RB signaling. 
In contrast, p53 expression levels remained unaffected. Notably, RASEF depletion also led 
to a marked reduction in IL6 and IL8 transcript levels, typical of cells abrogating OIS (Figure 
2G). We have previously identified C/EBPβ to be a critical mediator in the interleukin 
pathway leading to OIS
13
. Indeed, while the C/EBPβ transcript was highly induced in OIS, 
this was significantly reduced upon RASEF silencing (Figure 2H). From these findings, we 
conclude that RASEF is a new and essential component of OIS. 
 
RASEF is hypermethylated in melanoma 
Recently, we reported a genome-wide analysis of promoter hypermethylation in primary 
cutaneous melanomas and benign nevi, interrogating the methylation status of 14,495 
genes
48
. The identification in the present study of seven genes required for BRAF
V600E
-
induced senescence prompted us to examine whether any of these genes is epigenetically 
silenced in melanoma harboring a mutant BRAF gene. We reanalyzed the epigenomic 
profiling data taking into account the BRAF mutation status of the melanoma and nevus 
samples. From the samples subjected to genome-wide methylation analyses, all five nevi  
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Figure 2. RASEF is a new OIS gene. (A) Regulation of RASEF transcript in human diploid fibroblasts expressing 
vector control or non-overlapping shRNAs targeting RASEF in the presence and absence of oncogenic BRAF
V600E
. 
Level of expression is determined by quantitative real-time qRT-PCR. Measurements are based on three 
independent experiments and standardized to the vector-expressing senescent cells. Error bars represent SD. (B) 
Cell proliferation assay on samples from A. Cells were fixed and stained 13 days after exposure to BRAF
V600E
. (C) 
BrdU incorporation of samples described in A, measured 9 days after infection with BRAF
V600E
-encoding 
retrovirus. Levels are represented as mean of at least three independent experiments. Error bars represent SD. 
(D) Samples from A were analyzed by immunoblotting with antibodies as indicated. Hsp90 serves as loading 
control. (E) Representative images of senescence-associated (SA)-β-galactosidase staining for the cells described 
in A. Quantification of SA-β-galactosidase-positive cells was performed on three independent experiments, with 
SD. (F) Representative images of DAPI staining for the cells described in A. Quantification of SAHF-positive cells 
was performed on two independent experiments, with SD from triplicate. (G, H) Regulation of IL6 and IL8 (G) and 
C/EBPβ (H) transcripts of the samples described in A., as determined by qRT-PCR. Measurements are based on 
three independent experiments and standardized to the BRAF
V600E
-expressing senescent cells. Error bars 
represent SD. P values of less than 0.05 were considered significant. *0.01 < P < 0.05; **0.001 < P < 0.01; ***P < 
0.001. 
and five of 24 melanomas harbored a BRAF
V600E
 mutation, while two had a BRAF
V600K
 
mutation. It appeared that, of the seven genes identified in the shRNA screen, only the 
RASEF gene was differentially methylated in nevi and melanomas. In fact, RASEF was 




whereas its methylation was absent from nevi. Comparative analysis pointed to 
hypermethylation in four of seven BRAF-mutant melanomas with an average β-value 
difference (a measure of differential methylation) of 0.32 (Figure 3A). We proceeded with 
the validation of RASEF promoter hypermethylation in a panel of 76 primary melanoma 
and 15 nevus biopsy specimens using bisulfite melting curve analysis (BMCA). In 16 of 76 
melanoma samples (21%), the RASEF promoter was hypermethylated, whereas none of 
the 15 nevi showed methylation (Figure 3B). Bisulfite sequencing analysis (BSA) of five 
nevi, three primary melanomas, and two early-passage melanoma cell lines further 
confirmed dense RASEF hypermethylation in the primary tumors and melanoma cell lines, 
against a general absence of RASEF methylation in the nevi (Figure 3C). To further assess 
whether an association exists between RASEF promoter methylation and BRAF mutation 
in melanoma, we performed mutation analysis of BRAF and NRAS on a subset of 24 
primary melanomas. In four of these, RASEF was methylated; this included one melanoma 
with a BRAF mutation, no melanoma with NRAS mutation, and three not harboring 
mutations in these melanoma oncogenes (Table S2). This result shows that RASEF 
methylation is not confined to melanomas that carry a BRAF mutation. 
Next, we assessed the correlation between RASEF promoter methylation and 
transcript abundance in a panel of melanoma cell lines. In addition, we analyzed whether 
a relationship exists between RASEF silencing, MAP kinase pathway activation, and the RB 
pathway. RASEF transcript expression was very low to undetectable in the six melanoma 
cell lines with promoter hypermethylation, whereas significantly higher RASEF expression 
was present in several cell lines with absent RASEF promoter methylation (Figure 3D, 
Figure S2). RASEF expression levels neither correlated with MAP kinase pathway activation 
(as judged by lack of differences in ERK and MEK phosphorylation; Figure S3) nor with RB 
phosphorylation (Figure S4). Treatment with 5-aza-20-deoxycytidine of two different cell 
lines derived from melanoma metastases, both positive for RASEF promoter methylation, 
resulted in reactivation of RASEF gene expression with an induction of 7- and 3.5-fold in 
the cell lines 634 and 06.24, respectively (Figure 3E), suggesting that promoter 
methylation of RASEF is correlated with transcriptional silencing. Collectively, these results 
demonstrate that hypermethylation of the RASEF gene affects 21% of primary cutaneous 
melanomas. 
 
RASEF acts as potential tumor suppressor 
The essential role of RASEF in OIS, together with data on its differential methylation in 
nevi and melanomas, would be consistent with a tumor-suppressive role for RASEF. This 
hypothesis would predict that restoration of RASEF expression in cells in which the gene 
has been silenced by methylation acts cytostatically. Therefore, we reexpressed RASEF in  
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Figure 3. RASEF is hypermethylated in melanoma. (A) Hypermethylation of the RASEF promoter in BRAF-mutant 
primary melanoma samples as measured by Infinium’s 27 K genome-wide beadchip assay. Normalized average β-
values represent extent of methylation of probe cg10319505 for five BRAF-mutant nevi and seven BRAF-mutant 
primary melanoma samples. (B) RASEF promoter methylation status by bisulfite melting curve analysis of the 
indicated RASEF CpG island region performed in 15 benign nevi and 76 primary melanoma biopsy samples. (C) 
RASEF promoter methylation analysis by bisulfite sequencing of the indicated CpG dinucleotides in five benign 
nevi, three primary melanomas, and two early-passage melanoma cell lines. (D) RASEF mRNA expression levels in 
early-passage melanoma cell lines with known RASEF promoter methylation status as determined by quantitative 
real-time qRT-PCR. Error bars represent SD from triplicate qRT-PCRs. (E) Reactivation of RASEF mRNA expression 
upon 5-aza-2’-deoxycytidine treatment in early-passage melanoma cell lines 634 and 06.24 with pre-existent 
RASEF methylation. Measurements are representative for treatment experiments performed in duplicate, SD 
from triplicate qRT-PCRs. P values of less than 0.05 were considered significant. *0.01 < P < 0.05; **0.001 < P < 




two BRAF-mutant melanoma cell lines (04.04 and A875) with a hypermethylated RASEF 
promoter and very low RASEF mRNA expression (Figure 3D). We ectopically expressed V5-
tagged RASEF (Figure 4A) and analyzed the effect on cell proliferation and survival. In both 
cell lines, this resulted in the induction of cell cycle arrest as measured by cell proliferation 
and BrdU incorporation assays (Figure 4B, C). This was associated with a decrease in the 
steady state levels of PCNA and an induction in the levels of the SA protein p21
Cip1
 (Figure 
4A). We could not detect p15
INK4B
 protein in these cell lines, possibly owing to a deletion of 
the locus, which is commonly seen in melanoma. The RASEF-induced cell cycle arrest was 
not associated with cell death (Figure 4D,E). Melanoma cell lines in which RASEF was 
methylated were more prone to halt cell cycle progression upon its reintroduction than 
were the RASEF-proficient cells (Figure S5). These observations together are compatible 
with a model in which RASEF has a tumor suppressor function. 
 
 
Figure 4. RASEF acts as potential tumor suppressor. (A) Immunoblotting analysis of two indicated melanoma cell 
lines expressing eGFP as control or RASEF. Hsp90 serves as loading control. (B) Cell proliferation assay on samples 
from A. Cells were fixed and stained 12 days after exposure to RASEF. (C) BrdU incorporation of samples 
described in A, measured 16 days after infection with RASEF-encoding lentivirus. Levels are represented as mean 
of at least three independent experiments. Error bars represent SD. (D) Representative phase contrast images for 
the cells described in A. (E) Cell death induction of cells described in A as measured by trypan blue exclusion 
assay. Results represent mean of at least three independent experiments. Error bars represent SD. P values of 
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RASEF contributes to BRAF
V600E
-induced senescence in melanocytes 
We identified and subsequently validated RASEF in a function-based screen for genes that 
are required for OIS in a model system, cultured HDFs (Figures 1 and 2). The results above 
indicate that this gene is frequently silenced in melanoma (Figure 3). Together, these data 
predict that RASEF plays an important role also in melanocytes, in the context of OIS. We 
therefore validated the key results obtained in fibroblasts in cultured human melanocytes. 
Indeed, RASEF depletion in BRAF
V600E
-expressing melanocytes caused an almost five-fold 
induction of cell proliferation, as measured by BrdU incorporation assay (Figure 5A,B), 
similar to what we previously reported for PTEN
41
. This was associated with a drop in 
several senescence biomarkers, particularly IL6 and IL8, as well as C/EBPβ transcripts 
(Figure 5C–E). We conclude from these results that RASEF is a candidate melanoma 
susceptibility gene that acts, at least in part, by contributing to OIS. 
 
Figure 5. RASEF contributes to BRAF
V600E
-induced 
senescence in melanocytes. (A) BrdU 
incorporation in cultured human melanocytes 
expressing vector control or shRNA targeting 
RASEF in the presence and absence of oncogenic 
BRAF
V600E
. shRNA targeting PTEN was used as a 
positive control. Measurement was performed 15 
days after infection with BRAF
V600E
-encoding 
lentivirus. Levels are represented as mean of two 
independent experiments with SD from triplicate. 
(B) Regulation of RASEF transcript in samples 
described in A, as determined by quantitative 
real-time qRT-PCR. Measurements are based on 
two independent experiments and standardized 
to the vector-expressing senescent cells. Error 
bars represent SD from triplicate qRT-PCRs. (C–E) 
Regulation of IL6 (C), IL8 (D), and C/EBPβ (E) 
transcripts in samples described in A, as 
determined by qRT-PCR. Measurements are 
based on two independent experiments and 
standardized to the BRAF
V600E
-expressing 
senescent cells. Error bars represent SD from 
triplicate qRT-PCRs. P values of less than 0.05 
were considered significant. *0.01 < P < 0.05; 
**0.001 < P < 0.01; ***P < 0.001.  
Discussion 
Over the last decade, OIS has been established as a safeguard program protecting against 
cancer. However, we have only begun to dissect the underlying mechanism. There is 
ample evidence to argue that genes critically required for OIS are endowed with tumor 




, p53, and PTEN serving as paradigms
6,41
. In 







 to induce senescence. We identified seven genes, one of which we 
characterized in more detail, because we found it was frequently methylated in 
melanomas. RASEF depletion prevented the induction of senescence by BRAF
V600E
 both in 
fibroblasts and melanocytes. This was accompanied by the suppression of several 
biomarkers of senescence including (SA)-β-galactosidase activity, expression of p15 tumor 
suppressor protein, and SAHF. Furthermore, RASEF depletion reversed the increase in 




Function-based screens for mediators of OIS have been performed previously, 
too, in several different experimental settings and with gain-of-function libraries as well as 
loss-of-function libraries
14,55-58
. The latter study was carried out in the context of 
BRAFV
600E
-induced senescence; we found an overlap of two genes, BUB1 and NF2. 
Moreover, we identified two genes with an established function in OIS, that is, TSC22 and 
IL6R (albeit with single shRNAs in the primary screen
13,59
). These results show that the 
current screens are not saturating and that multiple approaches ought to be used to draw 
a complete map of critical OIS regulators. 
None of the seven genes identified in our screen have been previously studied in 
the context of BRAF
V600E
-induced senescence. Depletion of RASEF suppressed the 
expression of IL6 and IL8 transcripts via downregulating C/EBPβ, a key controller of the 
SMS/SASP contributing to OIS
13
. It will be interesting to determine the relationship 
between C/EBPβ and RASEF. We have previously identified additional regulators of 
senescence, including the putative tumor suppressor TSC22
59
 and the metabolic enzymes 
PDK1 and PDP2
25
. Interestingly, all these genes are essential to drive the expression of IL6 
and IL8 transcripts in the face of an oncogenic signal. These results not only support model 
in which RASEF controls OIS by regulating components of the senescence secretome, but 
also highlight the central role of specific interleukins in OIS. 
Among the genes identified here, only Wilms Tumor 1 (WT1) has been previously 
associated with tumorigenesis
60
. Moreover, none were found to be among the genes that 
were recently reported to be frequently mutated in melanoma
43,44,61
. We find that, of 
seven genes identified in the screen, only the RASEF gene shows promoter 
hypermethylation in a substantial fraction of primary cutaneous melanomas (21%). Benign 
melanocytic nevi did not show RASEF promoter methylation. Although the results from 
our initial genome-wide methylation analysis suggested selective RASEF hypermethylation 
in mutant BRAF melanomas, we observed in a subsequent assessment of a larger group of 
tumors that RASEF hypermethylation occurred equally in BRAF-mutant and BRAF-wild-
type tumor samples. RASEF hypermethylation was associated with transcriptional 
downregulation and chemical demethylation resulted in transcriptional reactivation of this 
gene. RASEF promoter hypermethylation has previously been reported to occur in uveal 
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melanoma, a melanoma subtype with genetic and clinical features that are distinct from 
cutaneous melanoma
54
. In that study, methylation of RASEF was found in primary uveal 
melanomas and more prominently in uveal melanoma cell lines lacking RASEF expression. 
Only cell lines lacking RASEF methylation were found to express the gene. This pattern of 
correlation between promoter methylation status and gene expression is similar to our 
findings for RASEF in cutaneous melanoma. Interestingly, in another study of three Danish 
families with multiple cutaneous and uveal melanoma cases, a susceptibility locus was 
mapped to a 3 Mb chromosomal region on 9q21.32 harboring the RASEF gene
53
. Although 
the presence of germ-line mutations in the RASEF gene was not analyzed in this study, 
reduced expression of this gene was found in melanoma patients, further supporting 
RASEF as a candidate melanoma susceptibility gene, but this should be explored further. 
To begin delineating such a role for RASEF, we show that its restored expression in a 
limited number of melanoma cells in which this gene is methylated causes cell cycle 
arrest. Clearly, a more definitive characterization of RASEF as a tumor suppressor will 
require in vivo models. Notably, RASEF has been previously reported to have differential 
functions depending on the cancer type; it has been attributed with a tumor-suppressive 
function in myeloid leukemia
62
, while it has an oncogenic function in lung cancer
63
. Our 
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TRCN0000043609 2 3 




    
 
TRCN0000001117 2 3 
NM_006042 HS3ST3A1 2 TRCN0000035837 1 4 
    
 
TRCN0000035836 2 2 
NM_006212 PFKFB2 2 TRCN0000037962 1 3 
    
 
TRCN0000037961 2 2 
NM_006244 PPP2R5B 2 TRCN0000039935 1 4 
    
 
TRCN0000039937 2 2 
NM_152573 RASEF 2 TRCN0000055625 1 2 
    
 
TRCN0000055624 2 3 
NM_000876 IGF2R 2 TRCN0000060254 1 5 
    
 
TRCN0000060253 2 3 
NM_007215 POLG2 2 TRCN0000053055 1 2 
    
 
TRCN0000053054 2 3 
NM_017549 EPDR1 2 TRCN0000055590 1 6 
    
 
TRCN0000055589 2 2 
NM_004875 POLR1C 2 TRCN0000052904 1 2 
    
 
TRCN0000052906 2 3 
NM_139075 TPCN2 2 TRCN0000043921 1 3 
    
 
TRCN0000043920 2 2 
 
Table S2. RASEF methylation status and clinical data of the benign nevi, primary melanomas, and early-passage 
melanoma cell lines used in the study. U, unmethylated; M, methylated. 
Normal naevus 
    
Sample number RASEF methylation status Gender Age (yrs) Mutation status 
N1 U F 29 BRAFV600E 
N2 U F 43 BRAFV600E 
N3 U M 55 BRAFV600E 
N4 U F 40 BRAFV600E 
N5 U F 38 BRAFV600E 
N6 U F 31 - 
N7 U M 46 - 
N8 U F 39 - 
N9 U F 27 - 
N10 U M 21 - 
N11 U M 57 - 
N12 U F 52 - 
N13 U F 24 - 
N14 U F 30 - 
N15 U F 30 - 
 
Primary melanoma 
     
Sample number RASEF methylation status Gender Age (yrs) Mutation status Breslow (mm) 
PM 1 U F 53 wt 1,67 
PM 2 U M 68 BRAFV600E 2,08 
PM 3 U M 65 wt 4,48 
PM 4 U F 65 wt 2,05 
PM 5 M F 60 wt 3,88 
PM 6 U M 58 wt 0,81 
PM 7 U F 42 BRAFV600K 0,91 
PM 8 U F 34 wt 0,94 
PM 9 U M 36 BRAFV600E 1,06 
PM 10 U F 35 BRAFV600E 0,73 
PM 11 U F 59 NRASG12D 1,70 
PM 12 U F 73 wt 3,36 
PM 13 U M 85 wt 15,60 
PM 14 U M 54 wt 3,46 
PM 15 U F 48 NRASQ61K 9,20 
PM 16 M M 82 BRAFV600E 18,00 
PM 17 U F 62 wt 6,29 
PM 18 U F 65 wt 1,28 
PM 19 U M 79 BRAFV600K 17,20 
PM 20 U F 45 wt 3,04 
PM 21 U M 78 wt 2,02 
PM 22 M M 70 wt 12,20 
PM 23 M F 56 wt 10,10 
PM 24 U F 75 BRAFV600E 2,08 
PM 25 M M 64 - 3,00 
RNAi screening, BRAF
V600E
-induced senescence and RASEF 
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PM 26 U M 46 - 2,00 
PM 27 U M 83 - 1,80 
PM 28 U F 73 - 1,40 
PM 29 U M 61 - 6,00 
PM 30 U F 51 - 3,40 
PM 31 U M 64 - 2,20 
PM 32 M F 51 - 5,90 
PM 33 U F 35 - 1,20 
PM 34 U M 62 - 3,50 
PM 35 U F 27 - 2,30 
PM 36 M M 72 - 5,20 
PM 37 U F 42 - 3,90 
PM 38 U F 68 - 1,50 
PM 39 U F 35 - 1,30 
PM 40 U F 29 - 2,60 
PM 41 U M 64 - 4,50 
PM 42 U F 53 - 3,40 
PM 43 U M 64 - 3,00 
PM 44 U M 37 - 2,20 
PM 45 U F 89 - 3,30 
PM 46 M F 57 - 2,00 
PM 47 U F 80 - 2,90 
PM 48 U M 48 - 3,60 
PM 49 U F 34 - 2,10 
PM 50 M F 81 - 3,00 
PM 51 U M 55 - 3,00 
PM 52 U M 70 - 2,20 
PM 53 U F 70 - 2,70 
PM 54 U M 54 - 4,00 
PM 55 U M 67 - 2,00 
PM 56 U M 62 - 4,80 
PM 57 U M 43 - 3,10 
PM 58 U F 74 - 3,30 
PM 59 U F 38 - 2,30 
PM 60 U M 65 - 3,60 
PM 61 M M 74 - 7,00 
PM 62 M M 77 - 6,00 
PM 63 U M 33 - 2,50 
PM 64 U F 26 - 2,50 
PM 65 M M 55 - 2,40 
PM 66 U F 84 - 5,00 
PM 67 U F 59 - 7,00 
PM 68 U F 82 - 2,50 
PM 69 U F 57 - 3,20 
PM 70 M M 88 - 4,20 
PM 71 U F 62 - 2,00 
PM 72 U F 50 - 2,80 
PM 73 M M 58 - 7,50 
PM 74 U F 60 - 2,10 
PM 75 M F 67 - 2,50 
PM 76 M M 85 - 3,20 
 
Melanoma cell lines 
    
Cell line RASEF methylation status Gender Age (yrs) Mutation status 
05.06 U M 59 BRAFV600E 
06.24 M F 60 NRASQ61R 
518A2 U M 19 BRAFV600E 
94.03C U F 37 BRAFV600E 
94.07 M M 39 BRAFV600E 
94.13 U F 47 BRAFV600E 
04.07 U F 59 BRAFV600E 
607B U F 51 NRASQ61K 
93.08 U M 30 BRAFV600E 
Mz7.4 U n/a n/a BRAFV600E 
634 M F 52 NRASQ61R 






Figure S1. Regulation of RB and p53 proteins in cycling, OIS and cells bypassing OIS upon depletion of RASEF. 
HDFs expressing vector control or nonoverlapping shRNAs targeting RASEF in the presence and absence of 
oncogenic BRAF
V600E




Figure S2. RASEF expression in early-passage melanoma cell lines. RASEF mRNA expression levels in early-
passage melanoma cell lines with known RASEF promoter methylation status as determined by qRT-PCR. Bars 
represent mean of normalized RASEF expression in cell lines with hypermethylated RASEF promoter versus cells 
with absent RASEF methylation. Error bars represent S.E.M. 
 
 
Figure S3. Comparison of MAP kinase pathway activation in melanoma cell lines. Melanoma cell lines with and 








Figure S4. Regulation of RB protein in melanoma cell lines. Melanoma cell lines with and without RASEF 
silencing were analyzed by immunoblotting with antibodies as indicated. Hsp90 serves as loading control. 
 
 
Figure S5. Effect of ecotropic expression of RASEF on melanoma cell lines viability. Cell proliferation assay on 
melanoma cell lines with and without RASEF silencing expressing eGFP as control or RASEF. Cells were fixed and 
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Dysplastic naevi are melanocytic lesions that represent an intermediate stage between 
common naevus and melanoma. Histopathological distinction of dysplastic naevus from 
melanoma can be challenging and there is a requirement for molecular diagnostic 
markers. In this study, we examined promoter CpG island methylation of a selected panel 
of genes, identified in a genome-wide methylation screen, across a spectrum of 405 
melanocytic neoplasms. Promoter methylation analysis in common naevi, dysplastic naevi, 
primary melanomas, and metastatic melanomas demonstrated progressive epigenetic 
deregulation. Dysplastic naevi were affected by promoter methylation of genes that are 
frequently methylated in melanoma but not in common naevi. We assessed the diagnostic 
value of the methylation status of five genes in distinguishing primary melanoma from 
dysplastic naevus. In particular, CLDN11 promoter methylation was specific for melanoma, 
as it occurred in 50% of primary melanomas but in only 3% of dysplastic naevi. A 
diagnostic algorithm that incorporates methylation of the CLDN11, CDH11, PPP1R3C, 
MAPK13, and GNMT genes was validated in an independent sample set and helped 
distinguish melanoma from dysplastic naevus (area under the curve 0.81). Melanoma-
specific methylation of these genes supports the utility as epigenetic biomarkers and 
could point to their significance in melanoma development.  
 
Introduction 
Cutaneous melanoma is a malignant tumor that arises from melanocytes residing in the 
skin. The lifetime risk of developing melanoma is approximately 2% in the United States 
and Europe and both incidence and mortality rates continue to rise
1,2
. Early diagnosis is 
important to prevent the formation of lethal metastasis. However, the clinical diagnosis of 
melanoma is challenging in a proportion of cases. This applies to visual assessment of 
pigmented skin lesions and to histopathological examination of biopsied tissue, the 
standard for melanoma diagnosis. A substantial inter-observer discordance rate of 14% in 
the pathological diagnosis of melanoma has been reported
3,4
. In particular, the sensitivity 
for diagnosing early-stage melanomas is low and distinction with dysplastic melanocytic 
naevus can be problematic.  
Dysplastic naevi are irregular in shape and pigmentation and occur in 
approximately 10% of the population
5
. Histologically, these lesions demonstrate random 
cytological atypia, architectural disorder, and stromal changes. The relevance of dysplastic 
naevus to melanoma progression is underscored by observations that dyplastic naevi are 
found in contiguity with melanoma in a significant subset of cases
6,7
. On the basis of 
morphological and biological characteristics, dysplastic naevi have been proposed to 
represent an intermediate lesion between common naevi and malignant melanoma in the 
multistep tumor progression model of melanocytic neoplasia
8
.  
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In the melanoma progression model proposed by Clark, melanocytic cells acquire 
malignant traits in discrete steps, a process driven by accumulation of genetic and 
epigenetic alterations
9
. Although there is limited information about genetic and epigenetic 
alterations in dysplastic naevi, patterns of intragenic mutations, chromosomal aberrations, 
and DNA methylation alterations are assumed to differ from those in melanoma. 
Therefore, detection of these molecular differences could aid in the correct classification 
of those cases in which morphological diagnosis fails to discriminate.  
Systematic characterization of molecular alterations in melanoma has provided a 
wealth of information on acquired DNA alterations in melanoma cells, which could be 
used in the molecular diagnosis of this malignant disease. Recently, we performed a 
genome-wide promoter methylation analysis of 14.495 genes in melanoma and common 
naevus samples and found widespread aberrant promoter methylation in melanoma
10
. 
Among the hundreds of gene promoters that exhibited methylation in melanomas but not 
in common naevi, we identified several tumor suppressor genes, causally implicating 
epigenetic mechanisms in melanoma development.  
The objectives of this study were to gain insight into epigenetic deregulation in 
the different stages of melanocytic neoplasia and to assess the potential diagnostic value 
of genes differentially methylated between melanoma and dysplastic naevus. To this end, 
we examined the methylation status of genes that were previously identified in a genome-
wide methylation screen in a cohort of 251 melanocytic neoplasms and subsequently 
validated a diagnostic algorithm incorporating different gene methylation features in a 
second independent series of 154 dysplastic naevus and primary melanoma samples. The 
combined analysis of promoter CpG island methylation of the five genes proposed in this 





To prioritize the 12 candidate genes, we analyzed an independent set of fresh-frozen or 
boonfix-fixed, paraffin-embedded (BFPE) tissues from patients diagnosed with common 
naevus (n=10), dysplastic naevus (n=20), and primary melanoma (n=15) at Leiden 
University Medical Center (LUMC), the Netherlands. For confirmation of methylation 
frequencies and testing of diagnostic discriminatory value of the final five genes, we 
examined FFPE tissues from patients diagnosed with common naevus (n=62), dysplastic 
naevus (n=72), primary melanoma (n=101), and metastatic melanoma (n=16) at the 
Maastricht University Medical Center (MUMC), the Netherlands, and University Hospitals 
of the University of Leuven (KUL), Belgium (series 1). For validation of the diagnostic 




dysplastic naevus (n=74) and primary melanoma (n=82) at LUMC, MUMC, and KUL (series 
2). The grade of atypia (mild and moderate-severe) of dysplastic naevi was determined by 
an experienced dermatopathologist (VJW), based on criteria formulated by Arumi-Uria et 
al., 2003
11
. Detailed clinicopathological information of all samples is listed in 
Supplementary Table S7. Tissues were processed as previously described
12
; biopsy 
samples contained at least 50% melanocytic cells, as analyzed on hematoxylin and eosin-
stained sections. Patient consent for experiments was not required because French laws 
consider human tissue left over from surgery as discarded material.  
 
DNA isolation and bisulfite conversion 
Genomic DNA from fresh-frozen and BFPE tissues was extracted with the Genomic-tip kit 
(Qiagen, Venlo, The Netherlands) and the RecoverAll Nucleic Acid kit (Ambion, Carlsbad, 
CA), respectively; DNA from FFPE tissues was extracted by macrodissection with 
theQIAamp DNA Micro Kit (Qiagen) or with the Maxwell 16 FFPE Plus LEV DNA Purification 
kit (Promega, Leiden, The Netherlands). Bisulfite conversion was performed using either 
the EZ DNA methylation kit (Zymo Research, Orange, CA; BMCA) or the EpiTect Bisulfite Kit 
(Qiagen; MSP analysis). 
 
Bisulfite melting curve analysis 
Bisulfite primers were designed, and the sensitivity of primer sets was tested as previously 
described
10
 (Supplementary Table S8). Methylation could be accurately detected if 10% of 
the analyzed DNA was methylated. Melting curves were generated for each biopsy 
sample; a sample was considered methylated if the amplicon had at least 10% methylated 
DNA, with the melting curve pattern of a 1:9 methylated to unmethylated DNA mixture 
serving as scoring standard.  
 
Methylation-specific PCR 
MSP analysis using MSP primers on bisulfite-treated DNA was performed as described
13,14
 
(Supplementary Table S8). To facilitate MSP analysis on DNA retrieved from FFPE tissue, 
DNA was first amplified with flanking PCR primers used as template for the PCR. All PCRs 
were performed with controls for unmethylated alleles (DNA from human umbilical vein 
endothelial cells, methylated alleles (normal lymphocyte DNA treated in vitro with Sssl 
methyltransferase (IVD)), and a control without DNA. To ensure reproducibility, MSP 
reactions have been performed in duplicate or triplicate starting from DNA amplification 
with flanking PCR primers. The reproducibility was 493% for all primer sets. Non-
concordant MSP results were analyzed a third time, and two out of three concordance 
was used as the end result. Bands with approximately equal intensity for unmethylated 
and methylated DNA were scored as positive for methylation. Faint methylated bands 
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were considered negative for methylation. Unclear results were analyzed a second time. 
In most cases, methylation levels were clearly negative (no M-band detected) or positive 
(strong M-band detected). 
 
Statistical analysis 
Fisher’s exact test was applied to measure the association between two sample groups 
within a 2x2 contingency table; a two-sided P value <0.05 was considered significant. 
Logistic regression analysis was used to test the diagnostic value of the five genes in the 
training data set. The logistic regression did not converge because of the strong diagnostic 
effect of CLDN11; therefore, we opted for a two-step model: data were filtered for 
samples without CLDN11 methylation, followed by binary logistic regression analysis with 
a single covariate counting how many of CDH11, PPP1R3C, MAPK13, and GNMT were 
methylated. In the resulting diagnostic score, a patient sample was classified as melanoma 
if either CLDN11 was methylated or if at least 1, 2, 3, or 4 of CDH11, PPP1R3C, MAPK13, 
and GNMT were methylated, depending on the chosen cutoff. A receiver operating 
characteristic curve was plotted for this diagnostic score. For this assessment, an 
independent test set was used in order to prevent any optimism bias due to overfit. 
Statistical analyses were performed using SPSS 20 (IBM, Armonk, NY) and R (R Core Team 
(2013) - http://R-project.org/). 
 
Results 
Selection of genes for promoter CpG island methylation analysis in common 
naevus, dysplastic naevus, primary melanoma, and metastatic melanoma 
In a previously performed genome-wide methylation analysis using Infinium 27-k 
beadchips, we identified 106 genes that were significantly and frequently more 
methylated in primary cutaneous melanomas than in common naevi
10
. Here, we set out to 
analyze the methylation status of the 12 most differentially methylated genes in dysplastic 
naevi, next to an independent set of common naevi and primary melanomas (Figure 1A 
and B). Primers for bisulfite melting curve analysis (BMCA) were designed to encompass or 
to be in close proximity of the corresponding 50-mer probe sequence on the beadchip. 
C4orf8 and HIST1H3E were excluded for further methylation analyses owing to suboptimal 
primer design; in their place, PPP1R3C and CLDN11 were included, as we had observed 
that they exhibited notable differential methylation between primary melanoma and 
common naevus samples
10
. In the independent set of 10 common naevus, 20 dysplastic 
naevus, and 15 primary melanoma biopsy samples, BMCA showed that C1orf106, 
MAPK13, CDH11, GNMT, PPP1R3C, and CLDN11 methylation was absent in common and 
dysplastic naevi, whereas frequent methylation (20–67%) was observed in primary 




methylated in 10–80% of common naevi, dysplastic naevi, and primary melanomas. 
Interestingly, PLEKHG6 showed progressively higher levels of methylation with tumor 
progression, that is, in 0% of common naevi, 35% of dysplastic naevi, and 60% of primary 
melanomas, suggesting that transition from a benign melanocytic lesion to a malignant 
tumor can be accompanied by a gradual increase in methylation of certain genes (Figure 
1C). LEP showed mosaic methylation in melanoma and naevi, with only subtle differences 
between these sample groups, whereas the ABCA3 promoter region appeared to be 
unmethylated in melanoma, as well as in naevi (Supplementary Figure S1). Genes showing 
frequent methylation in melanoma, but not, or scarcely, in common and dysplastic naevi, 
were prioritized for further analyses in a large series of samples.  
 
Differential promoter methylation of CLDN11, CDH11, PPP1R3C, MAPK13, and 
GNMT in common naevus, dysplastic naevus, and melanoma 
Promoter methylation of CLDN11, CDH11, PPP1R3C, MAPK13, and GNMT was assessed in 
a large series of 251 formalin-fixed, paraffin-embedded (FFPE) biopsy samples consisting 
of 62 common naevi, 72 dysplastic naevi, 101 primary melanomas, and 16 melanoma 
metastases, designated series 1. We applied nested methylation-specific PCR (MSP) 
because this method is better suited for analysis of FFPE samples than BMCA
14
. To 
compare the results of BMCA and MSP, we subjected 31 samples to methylation analysis 
using BMCA and MSP. This revealed a high concordance rate of 84–97% between both 
techniques, with higher sensitivity for detecting methylation of MSP (Supplementary Table 
S1). C1orf106 was excluded at this stage owing to suboptimal MSP primer design, and 
methylation analysis by MSP was performed for CLDN11, CDH11, PPP1R3C, MAPK13, and 
GNMT. The characteristics of the five genes are detailed in Table 1. The promoter CpG 
island regions of these genes as studied by MSP and BMCA are depicted in Figure 2A. MSP 
was successfully performed in 87–98% of the samples in series 1 (Figure 2B, 
Supplementary Table S2).  
Methylation frequencies of CLDN11, CDH11, PPP1R3C, MAPK13, and GNMT in 
common naevi, dysplastic naevi, and primary and metastatic melanomas are presented in 
Table 2. For further analyses and generation of a diagnostic algorithm, only methylation 
data of samples for which MSP was performed successfully for all five genes (55 common 
naevi, 57 dysplastic naevi, 79 primary melanomas, and 15 metastatic melanomas) are 
included in Table 2 and Figure 3. (Results for all analyzed samples of series 1 are given in 
Supplementary Table S3.) Remarkably, CLDN11 displayed the absence of methylation in 
both common and dysplastic naevi, whereas it was methylated in 48% of primary 
melanomas and 73% of metastatic melanomas in series 1 (Table 2). CDH11 and PPP1R3C 
showed the absence of methylation in common naevi; only 5 and 14% of dysplastic naevi 
harbored methylation for CDH11 and PPP1R3C, respectively. Methylation frequencies in 
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Figure 1. Differential promoter methylation of HOXA9, C1orf106, MAPK13, CDH11, EFCAB1, CNTN1, GNMT, 
PLEKHG6, PPP1R3C, and CLDN11 in common naevi, dysplastic naevi, and primary melanomas. (A) Schematic 
depiction of the workflow used to select candidate genes for methylation analyses in large series of melanocytic 
biopsy samples. (B) The 12 most frequently methylated genes identified by comparative analysis of genome-wide 
methylation data from 24 primary melanomas and five common naevi. (C) Methylation frequency of 10 genes in 
an independent set of 10 common naevi, 20 dysplastic naevi, and 15 primary melanomas as assessed by bisulfite 
melting curve analysis (BMCA). Black triangles indicate the position of the melting curve peak for the respective 




Table 1. Characteristics of five genes that were selected for methylation analysis in common naevus, dysplastic 
naevus, primary melanoma, and metastatic melanoma biopsy samples. 
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GNMT 
Enzyme that catalyzes the conversion of 
S-adenosyl-L-methionine to S-adenosyl-L-
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PPP1R3C 
Regulatory subunit of protein 
phosphatase-1 (PP1) that catalyzes 
reversible protein phosphorylation 
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CLDN11 
Claudin family member that is an integral 
membrane protein and component of 
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primary and metastatic melanomas were 41 and 47% for CDH11, and 52 and 60% for 
PPP1R3C, respectively. GNMT harbored promoter methylation in 4% of common and 11% 
of dysplastic naevi, but yet again higher methylation frequencies were found in primary 
(46%) and metastatic (47%) melanomas. For MAPK13, methylation was observed in 18% 
of common and 26% of dysplastic naevi, with higher methylation frequencies in primary 
(62%) and metastatic (67%) melanomas. The methylation patterns of the five genes, 
showing progressive increase in methylation frequency in different stages of melanocytic 
neoplasia, are depicted in Figure 3A. We noted significantly higher promoter methylation 
frequencies in particular following the transition to melanoma. Methylation of each of the 
five genes was detected only 12 times (4%) in 55 common naevi and 32 times (11%) in 57 
dysplastic naevi, significantly lower when compared to 196 times (50%) in 79 primary 
melanomas (P <0.001) and 44 times (59%) in 15 metastatic melanomas (Figure 3B). 
Complete absence of methylation for all five genes was found in 44 of 55 (80%) common 
naevi, 39 of 57 (68%) dysplastic naevi, 18 of 79 (23%) primary melanomas, and 2 of 15 
(13%) metastatic melanomas (Figure 3C). There was no significant correlation between the 
grade of atypia of dysplastic naevi and promoter methylation frequency. 
Promoter hypermethylation is known to increase with age, and the mean age of 
the melanoma patients was higher (63 years) than of the dysplastic naevus patients (46 
years). The differences in methylation frequencies of CLDN11, CDH11, PPP1R3C, MAPK13, 
and GNMT between melanomas and dysplastic naevi were comparable in the subset of 
patients younger than 50 years and those older than 50 years (Supplementary Table S4A). 
From this it can be concluded that the observed methylation differences between 
melanoma and dysplastic naevus cannot be attributed to age. For gender, similar results 
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were obtained (Supplementary Table S5a). CLDN11, CDH11, PPP1R3C, MAPK13, and 
GNMT promoter methylation has been demonstrated to be associated with transcriptional 
silencing in tumor cell lines (Table 1). Additional pathway analysis specified that the 
products of these five genes and their predicted interactors are part of gene signaling 
networks involved in cell–cell adhesion, cell junction assembly, and adherens junction 















































































Figure 2. Methylation analysis of CLDN11, CDH11, PPP1R3C, MAPK13, and GNMT in large series of common 
naevi, dysplastic naevi, primary and metastatic melanomas. (A) CpG island promoter region of the five genes, 
with the location of the primers used for methylation-specific PCR (MSP) and bisulfite melting curve analysis 
(BMCA) in this study. (B) Electrophoretic analysis of MSP amplification products of CLDN11, CDH11, PPP1R3C, 
MAPK13, and GNMT. N, common naevus; DN, dysplastic naevus; M, melanoma; u, unmethylated; m, methylated; 
IVD, positive control for methylated alleles (lymphocyte DNA treated with Sss1 methyltransferase); HUV, 
negative control for unmethylated alleles (DNA from human umbilical vein endothelial cells); H2Oo, no template 
control for first amplification with flanking primers; H2Oi, no template control for second amplification with 
primers specific for methylated and unmethylated DNA. 
Table 2. Methylation frequency of five candidate genes in biopsy samples of series 1 (55 common naevi, 57 
dysplastic naevi, 79 primary melanomas and 15 metastatic melanomas), together with the specificity and 
sensitivity of each gene for the distinction of primary melanoma samples from dysplastic naevus samples of 
series 1. DN, dysplastic naevus; PM, primary melanoma. 
 





DN n = 57 
PM n = 79  














CLDN11 0% 0/55 0% 0/57 48% 38/79 73% 11/15 100% 48% 
CDH11 0% 0/55 5% 3/57 41% 32/79 47% 7/15 95% 41% 
PPP1R3C 0% 0/55 14% 8/57 52% 41/79 60% 9/15 86% 52% 
MAPK13 18% 10/55 26% 15/57 62% 49/79 67% 10/15 74% 62% 

































































































































































Figure 3. Pattern and frequency of CLDN11, CDH11, PPP1R3C, MAPK13, and 
GNMT promoter methylation in a large series of common naevi, dysplastic 
naevi, primary melanomas, and metastatic melanomas (series 1). (A) 
Heatmap depiction of CLDN11, CDH11, PPP1R3C, MAPK13, and GNMT
promoter methylation status in 55 benign naevi, 57 dysplastic naevi, 79 
primary melanomas, and 15 metastatic melanomas from series 1. White, 
unmethylated; red, methylated. (B) Percentage of methylation events 
(methylated genes) found in each sample within the groups of common 
naevus, dysplastic naevus, primary melanoma, and metastatic melanoma. **P
<0.01 and ***P <0.001 by two-sided Fisher’s exact test. (C) Overview of total 
number of genes that were methylated in each sample within the groups of 
common naevus, dysplastic naevus, primary melanoma, and metastatic 
melanoma. NS, nonsignificant. 
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A diagnostic algorithm combining epigenetic markers to distinguish melanoma 
and dysplastic naevus 
The diagnostic specificities and sensitivities of CLDN11, CDH11, PPP1R3C, MAPK13, and 
GNMT for the distinction of primary melanomas from dysplastic naevi of series 1 are given 
in Table 2. After having determined these characteristics of the five methylation markers 
individually, we continued by examining which combinations of markers could aid in the 
differential diagnosis of primary melanoma and dysplastic naevus. Diagnostic algorithms 
were created using the set of 57 dysplastic naevi and 79 primary melanomas from series 1, 
and the accuracy of these models was subsequently tested in a second sample set 
consisting of 72 dysplastic naevus and 82 primary melanoma biopsy samples, designated 
series 2. In series 1, the three most differentially methylated genes were CLDN11, CDH11, 
and PPP1R3C. A first, simple three-gene diagnostic model was created that considers 
methylation of either of these three genes as indicative of melanoma. This model yielded 
a specificity of 89% and sensitivity of 67% in series 2 used as test set (Figure 4A). 
As CLDN11 methylation occurred exclusively in melanoma in series 1 used as 
training set, this epigenetic event had the highest discriminatory value with a specificity of 
100% and sensitivity of 48% (Table 2). On the basis of a logistic regression model, a 
diagnostic algorithm was constructed consisting of two discrete steps. First, CLDN11 
methylation was evaluated, and, if present, a lesion was classified as melanoma. Second, 
methylation of CDH11, PPP1R3C, MAPK13, and GNMT was taken in consideration for 
samples with no CLDN11 methylation (Figure 4A). Adding methylation information of the 
other four genes generated additional diagnostic value by increasing the sensitivity of the 
model to detect melanoma. This model has a receiver operating characteristic curve with 
an area under the curve of 0.806 (Figure 4B). The condition that a lesion is classified as 
melanoma if CLDN11 or at least two other genes are methylated yields a specificity of 89% 
and sensitivity of 66% in series 2 (Figure 4A). Promoter methylation frequencies and 
patterns of the five interrogated genes in series 2, visualized in Figure 4C and D and 
reported in Supplementary Table S6a, were generally similar to that of series 1. In series 2, 
CLDN11 methylation was detected in 6% of dysplastic naevus samples and 52% of primary 
melanoma samples. Validation of methylation frequencies for the five genes in sample 
series 2 demonstrated that, in addition to CLDN11, also methylation of CDH11, PPP1R3C, 
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Figure 4. Testing and validation of diagnostic models that incorporate CLDN11, CDH11, PPP1R3C, MAPK13, and 
GNMT promoter methylation. (A) Diagnostic value was tested in 57 dysplastic naevi and 79 primary melanomas 
from series 1 (training set), yielding diagnostic scores in the form of a three-gene model and a two-step model, 
followed by validation of these models in 72 dysplastic naevi and 82 primary melanomas from series 2 (test set). 
(B) Receiver operating characteristic curve of the two-step diagnostic model. (C) Percentage of methylation 
events within the dysplastic naevi and primary melanomas of series 2. ***P <0.001 by two-sided Fisher’s exact 
test. (D) Promoter methylation status of the five genes in 72 dysplastic naevi and 82 primary melanomas from 
series 2. White, unmethylated; red, methylated. 




Dysplastic naevi are melanocytic neoplasms with cytonuclear and architectural atypia and 
stromal alterations and are generally considered to constitute an intermediate stage 
between common naevi and melanoma. These lesions have an increased risk of 
developing into melanoma, and it can be difficult to clinically distinguish dysplastic naevus 
from early-stage melanoma
5
. In this study, we examined promoter CpG island methylation 
of 12 genes, previously identified in a genome-wide methylation screen, in metastatic and 
primary melanoma, dysplastic naevus, and common naevus biopsy specimens. We 
observed progressive promoter CpG island hypermethylation of these genes, with the 
methylation frequencies increasing from common naevus to metastatic melanoma. 
Dysplastic naevi, although less commonly than melanoma, demonstrate promoter 
hypermethylation of genes with tumor-suppressive functions, including CDH11. This 
shows that dysplastic naevi may already resemble their malignant counterparts at the 
epigenetic level and suggests that epigenetic instability can occur early, in premalignant 
stages of melanocytic neoplasia. In addition, it reinforces the notion of dysplastic naevus 
as an intermediate step in melanoma progression. 
Promoter CpG island methylation analysis in a first, smaller series of samples 
using BMCA suggested that promoters of the CLDN11, CDH11, PPP1R3C, MAPK13, and 
GNMT genes could be selectively methylated in melanoma. This would render these 
methylation events suitable epigenetic biomarkers to improve the diagnosis of melanoma 
and to allow distinction with dysplastic naevus. Using MSP in a large series of 251 
melanocytic neoplasm samples, we were able to show the discriminatory value of 
detecting promoter methylation of these five genes. Methylation detection by the MSP 
technique is especially suited in this setting, as it yields reproducible results and can 
directly be applied to FFPE-based samples in the clinic. On the basis of a logistic regression 
model analysis, we developed a diagnostic score that incorporates different gene 
methylation features, consisting of assessment of CLDN11 methylation first, followed by 
determination of the methylation frequency of CDH11, PPP1R3C, MAPK13, and GNMT in 
DNA isolated from a biopsy sample. Testing of the diagnostic accuracy of this score in 
another independent series consisting of 82 primary melanoma and 72 dysplastic naevus 
samples revealed a receiver operating characteristic area under the curve of 0.806 in this 
independent test set. A simpler three-gene model that incorporates only CLDN11, CDH11, 
and PPP1R3C as marker of melanoma has a specificity of 89% and sensitivity of 67% in the 
validation sample set. In our analysis, we have pursued methylation events that are 
present in melanoma and do not occur in dysplastic naevus. This has resulted in a panel of 
epigenetic markers with very high specificity for melanoma, but with moderate sensitivity. 
In particular for screening purposes, a sensitive test would be preferred over a more 




genes that are more frequently methylated in melanoma, such as HOXA9, an increase in 
sensitivity can be achieved, but at the expense of specificity. The binary results of 
methylation detection may confer an advantage over comparative genomic hybridization, 
fluorescent in situ hybridization, or combined immune-histochemical detection of 
melanoma markers, where interpretation of results can have higher interobserver 
variability
15-17
. Comparative genomic hybridization and fluorescent in situ hybridization, 
genomic methodologies used primarily in the research setting, may yield higher diagnostic 
accuracy than methylation detection of a few genes. 
Remarkably, methylation of the CLDN11 gene was completely specific for 
melanoma, that is, methylation affected 48% of primary melanoma and 73% of metastatic 
samples, whereas it was absent in common and dysplastic naevi in the first large sample 
series. In the second sample series, used to validate the diagnostic algorithm, CLDN11 was 
found to be methylated in 6% of dysplastic naevus samples. Detection of CLDN11 
methylation might in particular be used clinically to distinguish malignant from benign 
melanocytic lesions. Its methylation was shown previously to be associated with 
transcriptional silencing
18
. CLDN11 encodes a member of the claudin family, components 
of tight junctions that maintain a physical barrier and polarity of cells. CLDN11 
hypermethylation was previously reported in bladder and gastric cancer, where epigenetic 
silencing increased cell motility and invasiveness
18,19
. Interestingly, in mouse skin 
tumorigenesis, changes were found in the distribution pattern of claudin tight-junction 
proteins, where epidermal expression of claudin proteins including CLDN11 decreased 
during tumor progression
20
. We hypothesize that in melanoma development loss of 
CLDN11 expression through promoter hypermethylation facilitates invasive behavior by 
disrupting intercellular cohesion provided by tight-junction structures. In addition, 
methylation of CDH11, PPP1R3C, and GNMT occurred in more than half of melanomas but 
rarely in dysplastic naevi. The results for CDH11 are in line with previous studies showing 
that methylation of this cadherin gene that inhibits tumor growth and metastasis 
preferentially occurs in lymph node metastases of melanoma patients
21
. Tumor-
suppressive properties have also been reported for PPP1R3C and GNMT. 
Thus far, promoter methylation studies in melanoma often used a limited number 
of clinical specimens and lacked examination of non-malignant samples, thereby making it 
impossible to distinguish cancer-specific from tissue-specific methylation events
22
. Only 
few studies analyzed promoter methylation in dysplastic naevi, and most of them 
examined single candidate genes in small sample sets
23-25
. To our knowledge, this is a 
previously unreported study that makes use of a large series of clinical specimens to show 
that promoter methylation of several genes, including tumor suppressor genes, is present 
to a small extent in dysplastic naevi. Using the methylation pattern of five genes, we 
propose a diagnostic algorithm to distinguish melanoma from benign melanocytic lesions. 
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The presence of CLDN11, CDH11, PPP1R3C, and GNMT methylation in a suspicious 
melanocytic lesion might be regarded as an indicator of malignancy. Taken together, the 
findings presented in this study provide insight in the epigenetic changes that occur in 
melanoma development and can aid in the molecular diagnosis of melanocytic lesions. 
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Supplementary Table S1. Percentage of samples that had concordant results when methylation analysis was 
performed using BMCA and MSP on the same set of common naevi (n=11), dysplastic naevi (n=10) and 
melanomas (n=10). 



















100% 11/11 100% 11/11 100% 11/11 64% 7/11 100% 11/11 
Dysplastic 
naevus 
90% 9/10 90% 9/10 80% 8/10 90% 9/10 90% 9/10 
Primary 
melanoma 
80% 8/10 100% 10/10 90% 9/10 100% 10/10 70% 7/10 
Total 90% 28/31 97% 30/31 90% 28/31 84% 26/31 87% 27/31 
 
Supplementary Table S2. Percentage of bisulphite-converted genomic DNA samples that was successfully 
amplified using MSP. In series 1, DNA was obtained from FFPE biopsy specimens of common naevus, dysplastic 
naevus, primary melanoma and metastatic melanoma (n=251). In series 2, DNA was obtained from FFPE, BFPE 
(boonfix-fixed, paraffin-embedded) and fresh frozen biopsy specimens of dysplastic naevus and primary 
melanoma (n=156). 

































Supplementary Table S3. Methylation-specific PCR (MSP) was performed on series 1 consisting of 62 common 
naevus, 72 dysplastic naevus, 101 primary melanoma and 16 metastatic melanoma samples to determine 
methylation frequency of five candidate genes. In this table, all MSP results are presented whereas in Table 2, 
only samples for which MSP data was complete for all five genes were included. 
 CLDN11 CDH11 PPP1R3C MAPK13 GNMT 
  No. of 
samples 
 No. of 
samples 
 No. of 
samples 
 No. of 
samples 




0% 0/61 0% 0/57 0% 0/62 17% 10/58 3% 2/60 
Dysplastic 
naevus 
0% 0/72 5% 3/66 11% 8/71 25% 15/59 8% 6/71 
Primary 
melanoma 
47% 46/98 38% 35/92 45% 43/95 64% 54/85 44% 41/93 
Metastatic 
melanoma 





Supplementary Table S4a. Methylation frequency of five candidate genes in dysplastic naevus and primary 
melanoma biopsy samples from series 1 based on age of the patients. Dysplastic naevus and primary melanoma 
samples for which age was known (n=130) were grouped into patients younger than 50 years (n=57) and those 
that were 50 years or older (n=73). 
 
Supplementary Table S4b. Methylation frequency of five candidate genes in dysplastic naevus and primary 
melanoma biopsy samples from series 2 based on age of the patients. Dysplastic naevus and primary melanoma 
samples (n=154) were grouped into patients younger than 50 years (n=53) and those that were 50 years or older 
(n=101). 
 
Supplementary Table S5a. Methylation frequency of five candidate genes in the dysplastic naevus and primary 
melanoma biopsy samples from series 1 based on gender of the patients. The dysplastic naevus and primary 
melanoma samples for which gender was known (n=130) were grouped into male (n=53) and female (n=77) 
patients. 




























CLDN11 0% 0 41% 7 0.000 0% 0 46% 26 0.000 
CDH11 5% 2 47% 8 0.000 6% 1 34% 19 0.029 
PPP1R3C 13% 5 53% 9 0.002 18% 3 48% 27 0.028 
MAPK13 28% 11 71% 12 0.003 24% 4 57% 32 0.025 
GNMT 10% 4 35% 6 0.051 12% 2 46% 26 0.011 




























CLDN11 3% 1 56% 10 0.000 8% 3 52% 33 0.000 
CDH11 0% 0 50% 9 0.000 8% 3 45% 29 0.000 
PPP1R3C 3% 1 50% 9 0.000 14% 5 56% 36 0.000 
MAPK13 26% 9 61% 11 0.017 38% 14 70% 45 0.002 
GNMT 0% 0 44% 8 0.000 3% 1 52% 33 0.000 




























CLDN11 0% 0 54% 15 0.000 0% 0 40% 18 0.000 
CDH11 0% 0 39% 11 0.000 9% 3 36% 16 0.014 
PPP1R3C 8% 2 61% 17 0.000 19% 6 42% 19 0.047 
MAPK13 16% 4 64% 18 0.000 34% 11 58% 26 0.064 
GNMT 0% 0 61% 17 0.000 19% 6 33% 15 0.199 
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Supplementary Table S5b. Methylation frequency of five candidate genes in the dysplastic naevus and primary 
melanoma biopsy samples from series 2 based on gender of the patients. The dysplastic naevus and primary 
melanoma samples for which gender was known (n=153) were grouped into male (n=76) and female (n=77) 
patients. 
 
Supplementary Table S6a. Methylation frequency of five candidate genes in biopsy samples of series 2 (72 
dysplastic naevi and 82 primary melanomas), together with the specificity and sensitivity of each gene for the 




Dysplastic naevus Primary melanoma 
Dysplastic naevus n = 72 
Primary melanoma n = 82  
Methylation frequency 
Specificity Sensitivity 
 No. of samples  No. of samples 
CLDN11 6% 4/72 52% 43/82 94% 52% 
CDH11 4% 3/72 46% 38/82 96% 46% 
PPP1R3C 8% 6/72 55% 45/82 92% 55% 
MAPK13 32% 23/72 68% 56/82 68% 68% 
GNMT 1% 1/72 50% 41/82 99% 50% 
 
Supplementary Table S6b. Methylation frequency of five candidate genes in biopsy samples of series 1 and 2 
(129 dysplastic naevi and 161 primary melanomas), together with the specificity and sensitivity of each gene for 
the distinction of primary melanoma samples from dysplastic naevus samples. 
Series 1 + 2 
(training set + test set) 
 
Dysplastic naevus Primary melanoma 
Dysplastic naevus n = 129 
Primary melanoma n = 161  
Methylation frequency 
Specificity Sensitivity 
 No. of samples  No. of samples 
CLDN11 3% 4/129 50% 81/161 97% 50% 
CDH11 5% 6/129 43% 70/161 95% 43% 
PPP1R3C 11% 14/129 53% 86/161 89% 53% 
MAPK13 29% 38/129 65% 105/161 71% 65% 
GNMT 5% 7/129 48% 77/161 95% 48% 
 




























CLDN11 10% 3 53% 24 0.000 3% 1 51% 19 0.000 
CDH11 10% 3 53% 24 0.000 0% 0 38% 14 0.000 
PPP1R3C 16% 5 60% 27 0.000 3% 1 49% 18 0.000 
MAPK13 55% 17 73% 33 0.140 15% 6 62% 23 0.000 




Supplementary Figure S1. LEP and ABCA3 promoter methylation status in 20 dysplastic naevi, next to an 
independent set of 10 common naevi and 15 primary melanomas as analyzed by bisulphite melting curve 
analysis (BMCA). Black triangles indicate position of the melting curve peak for the respective positive (fully 
methylated) and negative (fully unmethylated) control. 
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*Only Biological Processes with 4 or more involved genes and p-value < 0.05 are listed 
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Supplementary Figure S2. Interaction network analysis of CLDN11, CDH11, PPP1R3C, MAPK13 and GNMT. 
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Cutaneous melanoma, a type of skin tumor originating from melanocytes, often develops 
from premalignant naevoid lesions via a gradual transformation process driven by an 
accumulation of (epi)genetic lesions. These dysplastic naevi display altered morphology 
and often proliferation of melanocytes. Additionally, melanocytes in dysplastic naevi show 
structural mitochondrial and melanosomal alterations and have elevated reactive oxygen 
species (ROS) levels. For this study we performed genome-wide expression and proteomic 
analysis of melanocytes from dysplastic naevus (DNMC) and adjacent normal skin (MC) 
from 18 patients. Whole genome expression profiles of the DNMC and MC of each 
individual patient subjected to GO-based comparative statistical analysis yielded 
significantly differentially expressed GO classes including “organellar ribosome,” 
“mitochondrial ribosome,” “hydrogen ion transporter activity,” and “prefoldin complex.” 
Validation of 5 genes from these top GO classes revealed a heterogeneous differential 
expression pattern. Proteomic analysis demonstrated differentially expressed proteins in 
DNMC that are involved in cellular metabolism, detoxification, and cytoskeletal 
organization processes, such as GTP-binding Rho-like protein CDC42, glutathione-S-
transferase omega-1 and prolyl 4-hydroxylase. Collectively these results point to 
deregulation of cellular processes, such as metabolism and protein synthesis, consistent 
with the observed elevated oxidative stress levels in DNMC potentially resulting in 
oxidative DNA damage in these cells. 
 
Introduction 
Cutaneous melanoma is a malignant tumor that originates from melanocytes, the pigment 
producing cells of the skin. Melanoma development is a multistep process driven by the 
acquisition of genetic and epigenetic abnormalities. Although a subset of melanomas 
develop in normal skin de novo, in many instances premalignant naevoid pigmented 
lesions can be discerned in melanoma formation. Approximately a third of melanomas 
develop from a precursor naevus that is most commonly dysplastic
1
. Consistently, 
individuals with dysplastic naevi are at increased risk of developing melanoma
2
.  
Dysplastic naevi can progress into radial and subsequently vertical growth phase 
melanomas
3,4
. The complex multistage development process of melanoma is 
characterized by various morphological, cellular, and biochemical alterations. 
Histopathologically dysplastic naevi show characteristic morphological alterations, 
including proliferation and variable atypia of epidermal melanocytes, formation of 
irregular cell nests in the epidermis and basement membrane zone, and the 
interconnection of these nests and layers (bridging). Melanocytes in dysplastic naevi 
(DNMC) furthermore exhibit morphological alterations in melanosomes and mitochondria, 
similar to those observed in melanoma cells
5
. We have previously shown that DNMC in 
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comparison with normal melanocytes show higher pheomelanin, iron, and calcium levels 
resulting in elevated reactive oxygen species (ROS) levels
6,7
. The diminished levels of 
antioxidant enzymes in DNMC further highten ROS levels and reinforce chronic oxidative 
stress in these cells
8,9
.  
In the present study we compared the gene expression and protein expression 
patterns of melanocytes from dysplastic naevus and from normal skin of 18 individuals. 
From a surgically removed dysplastic naevi and adjacent normal skin, melanocytes were 
isolated and briefly cultured for gene expression analysis using whole genome expression 
arrays and proteome analysis by peptide mass fingerprinting. Gene ontology-based gene 
expression analysis and protein expression analysis revealed differentially expressed 
pathways involved in cellular metabolism, detoxification, and cell shape organization. 
These findings appear to signify deregulated processes that all together may contribute to 
an increase in the levels of reactive oxygen species and oxidative stress, as is often 
observed in DNMC. The resultant oxidative DNA damage is an endogenous mutagenic 




After approval by the Medical Review Board of Leiden University Medical Center and 
patient consent, 18 clinically atypical naevi were excised from 18 different patients. All 18 
samples were confirmed after pathologist review as dysplastic naevus. The elliptical 
incision consisted of the dysplastic naevus in the central part and normal skin at the tips. 
To ensure separate isolation of melanocytes from the dysplastic naevus and from adjacent 
normal skin, the central part and tip of each surgical specimen were first divided before 
further processing. For isolation of the melanocytes from the dysplastic naevus and 
normal skin from the epidermal compartment, we used an established protocol described 
previously
6,7
. Briefly, after removal of subcutaneous fat, epidermis and dermis were 
separated by overnight incubation with dispase grade II (Boehringer Mannheim Inc, 
Indianapolis, IN). The epidermis was trypsinized to obtain a single cell suspension using 
0.25% trypsin. The cells from this single cell suspension were plated in Ham’s F10 
melanocyte medium supplemented with penicillin (100 U/mL), streptomycin (100 U/mL), 
L-glutamine (Invitrogen, Breda, The Netherlands), 1% Ultroser G (BioSepra, Fremont, CA), 
Endothelin-1 (5 ng/mL), basic-FGF (5 ng/mL), cholera toxin (30 μg/mL), IBMX (33 μM), and 
TPA (8 nM, Sigma-Aldrich, Zwijndrecht, The Netherlands). This melanocyte medium 
contains ingredients that are toxic to keratinocytes present in the epidermal cell 
suspension. Under these conditions pure melanocyte cultures are obtained at 10 days 
after start of culture. Purity of these melanocyte cultures was confirmed by microscopic 




10 days all cells invariably had the dendritic, star-shaped or spindle-like morphology of 
melanocytes and no cells with epithelioid morphology were present in the culture dish. 
Additional stainings of representative melanocyte cell cultures with melanocytic cell 
markers HMB45 and Melan-A confirmed the purity of these melanocyte cultures. 
Melanocytes isolated from dysplastic naevus (DNMC) and from normal skin (MC) were 
cultured for a maximum of six passages to ensure logarithmic growth and keep the time in 
culture as short as possible. To minimize the variation introduced by cell culture on gene 
and protein expression, all MC and DNMC patient samples underwent identical treatment 
in culture and were harvested at the same passage number with the same harvesting 
methods. 
 
Sample preparation for microarrays and peptide mass fingerprinting 
RNA was isolated from melanocytes with the RNeasy Mini Kit (Qiagen, Venlo, 
Netherlands). Antisense amplified RNA (aRNA) was generated with theMessageAMP II 
aRNA Kit (Ambion, Austin, TX) for hybridization to the Human Genome U133 Plus 2.0 Array 
(Affymetrix, Santa Clara, CA) following manufacturer’s protocol. RNA concentrations were 
determined by nanodrop measurements and RNA quality control was performed prior to 
hybridization by Lab-on-a-chip on Agilent’s Bioanalyzer. RNA quality was further 
confirmed by post-hybridization quality control measurements performed as part of the 
Affymetrix microarray analysis, including normalization scaling factor across the 
microarrays and cRNA transcript integrity as assessed by 3’ to 5’ probe set signal intensity 
ratios, as routinely performed at the Leiden Genome Technology Center. Protein was 
isolated from melanocyte cell pellets using TRIzol reagent (Invitrogen); protein 
concentrations were determined by the Pierce BCA Protein Assay Kit. Protein samples (10 
μg) were labeled with 1000 pmol fluorescence amine-reactive cyanine dyes for two-
dimensional difference gel electrophoresis (2D DIGE) following manufacturer’s protocol 
(Amersham-Pharmacia Biotech). 
 
Statistical analysis of gene expression data 
Probe set signal intensities derived from microarray scans were subjected to the robust 
multi-array average (RMA) algorithm as previously described
10
. This algorithm results in 
background-corrected, quantile normalized and log(base2)-transformed final probe 
intensities that serve as measures of gene expression; this log scale measure of expression 
will be further referred to as “(gene) expression value.” To identify genes that were 
differentially expressed in DNMC when compared to MC, a statistical analysis method 
(random variance model (RVM)-based t-test) suited for detection of gene expression 
differences in microarray experiments comprising relatively smaller sample sizes was 
used
11
, while controlling the number and proportion of false discoveries with a 
multivariate permutation test as described previously
12
. Additional hierarchical clustering 
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based on Euclidean distance was performed; clustering reproducibility was assessed using 




Functional class scoring based on gene ontology annotations 
All gene ontology annotations were obtained through http://www.geneontology.org/. 
Gene ontology (GO) classes with fewer than five and more than 100 genes represented in 
the array data were not considered in order to exclude very small and very large classes. 
The DNMC sample of one individual patient was compared to the paired MC sample, in 
order to assess whether differential expression of GO classes existed across all microarrays 
between the paired melanocyte sample set. Functional class scoring, based on semi-
supervised gene expression data analysis, was performed according to the statistical 
method as previously described
14
. This method does not require prior gene selection and 
P values are assigned based on interrogated genes in a GO class. 
 
2D DIGE and mass spectrometry analysis 
2D DIGE was performed as previously described
15
. Dye swap experiments were performed 
to check for labeling differences between Cy3 and Cy5. Gels were scanned in low-
fluorescent glass plates with a Typhoon 9400 scanner (GE Health care UK Ltd., 
Buckinghamshire, UK). TIFF images of the gels were analyzed with Delta2D v3.4 software 
(Dodecon, Greifswald, Germany). Spots were quantified and normalized based on total 
spot volume of one gel. The matched spot volumes were subsequently normalized across 
the whole set of gels and normalized spot volumes were compared between images in the 
set. Statistical significant differences between normalized spot volumes were determined 
using the Welch-modified Student’s t-test and step-down Westfall and Young method as 
correction for the false discovery rate. Protein spots of interest were excised from the gel 
for analysis on a MALDI-TOF/TOF instrument (Ultraflex, Bruker, Germany). All mass 
fingerprint and MS/MS data were searched against the human protein database with the 
Mascot program (Matrix Science, Boston, MA). 
 
Quantitative real-time PCR 
cDNA was generated from DNase-treated RNA (1μg) with the iScript cDNA synthesis kit 
(BioRad, Hercules, CA). qRT-PCR was performed with iQ SYBR Green Supermix on a MyiQ 
Real-Time PCR Detection System (BioRad). RPS11 served as reference gene in 
experiments. qRT-PCR expression data is presented as mean of two measurements. 
 
Results 
Microarray analysis of melanocytes from dysplastic naevus and normal skin 
Previously it was demonstrated that melanocytes isolated from dysplastic naevus (DNMC) 




melanocytes isolated from normal skin (MC) in culture
7
. For this study paired DNMC and 
MC were obtained from dysplastic naevi and normal skin of 18 patients. Similarly we 
observed that the cultures of dysplastic naevus cells differed in morphology from that of 
normal melanocytes; Figure 1A displays a representative picture from melanocyte cultures 
derived from either normal skin (left, MC) or from dysplastic naevus (right, DNMC), 
showing that the MC have more equally-shaped dendrites as compared to the DNMC that 
consistently show a distinct stretched and thinner dendrite morphology. Microarray gene 
expression profiling was performed on these 18 paired melanocytic cell sets to gain insight 
into differences between these melanocyte sample groups on molecular level. Analysis of 
Affymetrix U133 plus 2.0 microarray data revealed that melanocytes from dysplastic naevi 
and from normal skin expressed 45% of the interrogated genes at a measurable level. 
Figure 1B depicts a scatter plot where the expression ratio’s of a representative sample 
set of DNMC and MC of one patient is plotted, indicating that gene expression differences 
between the DNMC and MC of the same patient were generally modest. Except for two 
samples, hierarchical clustering of the microarray data showed that the DNMC samples 
resembled their autologous normal counterparts more closely than they resemble the 
DNMC of another individual (Figure 1C). Of note, samples 0310B and 0223B clustered 
separately from the remaining samples; this distinction was not reflected in a different 
morphology of these cell samples, since cell morphology across the 18 DNMC samples was 
homogeneous without notable differences between the samples. In addition, all dysplastic 
naevi included in this study were histopathologically very similar and also in this respect 
samples 0310 and 0223 did not significantly differ from other patient samples.  
We considered the possibility that in our melanocyte sample sets, smaller but 
parallel effects among groups or sets of genes may exist that act together within 
pathways. In this way we would not so much identify individual marker genes 
differentially expressed by DNMC, but rather obtain an impression of dysregulated 
biological processes in DNMC. We aimed to uncover genes that were highly relevant when 
placed in a larger network of genes that interact with it, even though showing small 
differential expression individually. We proceeded to analyze for each pair of DNMC and 
MC from a single patient, which functional groups of genes were differentially expressed. 
The top GO classes identified by functional class scoring as differentially expressed in 
DNMCs when compared to MCs, are listed in Table 1A. Among the top represented GO 
classes were “organellar ribosome,” “mitochondrial ribosome,” “hydrogen ion transporter 
activity,” “prefoldin complex,” and “cAMP-dependent protein kinase regulator activity.” 
Table 1B presents the details of the top five GO classes that are differentially expressed 
between 18 sets of DNMCs and MCs. The genes in each GO class all had a P value <0.05. 
Additional comparative statistical analysis of the gene expression data between the entire 
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group of 18 DNMCs and 18 normal MCs did not yield significantly differentially expressed 








Figure 1. (A) Photos (4x magnification) taken from cultures of melanocytes derived from normal skin (left, MC) 
and dysplastic naevus (right, DNMC), representative of the MC and DNMC cultures of all 18 patients from which 
each of the melanocyte cultures were derived. (B) Scatter plot with average-log expression ratio’s within one 
DNMC sample plotted against the average-log ratio’s within the paired MC sample from one representative 
patient sample set. Each dot represents an interrogated probeset. The diagonal lines in the graph are outlier lines 
that indicate a 2-fold difference in the geometric mean of the expression ratio’s between the DNMC and MC 
sample. (C) Clustering dendrogram of the expression values of all melanocyte samples. The vertical axis indicates 
the Euclidean distance with complete linkage as a measure for the extent of similarity between the samples. The 
horizontal axis contains all samples; A-labeled sample numbers, melanocytes derived from normal skin; B-labeled 
sample numbers, melanocytes derived from dysplastic naevus. The calculated R-index (0.997) and D-index (0.02) 












Table 1A. Differentially expressed GO classes resulting from comparative GO-based analysis of paired DNMC and MC sample sets of 18 patients 
1. The 26 GO categories found to be significant at the nominal 0.005 level of the LS permutation test or KS permutation test (sorted by P values of the LS permutation test).  
For each GO category, the table lists the unique identifier, the number of genes in the project gene list that belong to the GO category, and the LS and KS P values.  The 
presented GO categories are ordered by the P value of the LS test (smallest first). 
2. GO-Term: CC = cellular component, BP = biological process and MF = molecular function. 
3. Fisher (LS) statistic is defined as the mean negative natural logarithm of the P values of the appropriate single gene univariate test. 















1 313 CC organellar ribosome 30 1.00E-05 0.0120303 
2 5761 CC mitochondrial ribosome 30 1.00E-05 0.0120303 
3 15078 MF hydrogen ion transporter activity 94 9.22E-05 9.01E-05 
4 16272 CC prefoldin complex 13 0.0003082 0.001475 
5 8603 MF cAMP-dependent protein kinase regulator activity 9 0.0006046 0.0080679 
6 4164 MF diphthine synthase activity 5 0.0006262 9.03E-05 
7 8629 BP induction of apoptosis by intracellular signals 17 0.0006292 0.0060299 
8 79 BP regulation of cyclin-dependent protein kinase activity 30 0.0009682 0.0006918 
9 8022 MF protein C-terminus binding 28 0.0010178 0.0332401 
10 30274 MF LIM domain binding 5 0.0027241 0.0278159 
11 17182 BP peptidyl-diphthamide metabolism 8 0.0031029 0.001998 
12 17183 BP peptidyl-diphthamide biosynthesis from peptidyl-histidine 8 0.0031029 0.001998 
13 18202 BP peptidyl-histidine modification 8 0.0031029 0.001998 
14 8428 MF ribonuclease inhibitor activity 5 0.0031816 0.0130247 
15 45815 BP positive regulation of gene expression, epigenetic 7 0.0032192 0.0187543 
16 43028 MF caspase regulator activity 5 0.0035432 0.3403788 
17 31202 MF RNA splicing factor activity, transesterification mechanism 23 0.0042451 0.0013586 
18 8757 MF S-adenosylmethionine-dependent methyltransferase activity 76 0.0044728 0.0618698 
19 7021 BP tubulin folding 5 0.0046218 0.0028239 
20 8013 MF beta-catenin binding 7 0.0048826 0.0031594 
21 118 CC histone deacetylase complex 38 0.0080248 0.0020909 
22 9897 CC external side of plasma membrane 9 0.0085632 0.0021181 
23 45736 BP negative regulation of cyclin-dependent protein kinase activity 5 0.0182021 0.0028634 
24 3747 MF translation release factor activity 8 0.045947 0.0046691 
25 8079 MF translation termination factor activity 8 0.045947 0.0046691 
































 GO description Probeset Description
2
 Gene symbol Parametric P values 
1 CC organellar ribosome 219220_x_at mitochondrial ribosomal protein S22 MRPS22 0.0001097 
2 CC organellar ribosome 223480_s_at mitochondrial ribosomal protein L47 MRPL47 0.000131 
3 CC organellar ribosome 218558_s_at mitochondrial ribosomal protein L39 MRPL39 0.006304 
4 CC organellar ribosome 224869_s_at mitochondrial ribosomal protein S25 MRPS25 0.0151834 
5 CC organellar ribosome 222775_s_at mitochondrial ribosomal protein L35 MRPL35 0.0171902 
6 CC mitochondrial ribosome 219220_x_at mitochondrial ribosomal protein S16 MRPS16 0.0005530 
7 CC mitochondrial ribosome 223480_s_at mitochondrial ribosomal protein L44 MRPL44 0.000131 
8 CC mitochondrial ribosome 219819_s_at mitochondrial ribosomal protein S28 MRPS28 0.0029398 
9 CC mitochondrial ribosome 217919_s_at mitochondrial ribosomal protein L42 MRPL42 0.0303516 
10 CC mitochondrial ribosome 222993_at mitochondrial ribosomal protein S37 MRPL37 0.003539 
11 MF hydrogen ion transporter activity 213846_at cytochrome c oxidase subunit VIIc COX7C 0.0020774 
19 MF hydrogen ion transporter activity 218484_at NADH dehydrogenase (ubiquinone) 1 NDUFA4L2 0.00585351 
12 MF hydrogen ion transporter activity 238765_at ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 ATP6V1G1 0.0059421 
13 MF hydrogen ion transporter activity 209065_at ubiquinol-cytochrome c reductase binding protein UQCRB 0.0171665 
14 MF hydrogen ion transporter activity 231487_at cytochrome c oxidase subunit 8C COX8C 0.021483 
15 MF hydrogen ion transporter activity 1552286_at ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E2 ATP6V1E2 0.0279023 
16 MF hydrogen ion transporter activity 202698_x_at cytochrome c oxidase subunit IV isoform 1 COX4I1 0.0380242 
17 MF hydrogen ion transporter activity 228142_at ubiquinol-cytochrome c reductase complex (7.2 kD) UCRC 0.0389511 
18 MF hydrogen ion transporter activity 220834_at membrane-spanning 4-domains, subfamily A, member 12 MS4A12 0.0460068 
20 CC prefoldin complex 207132_x_at prefoldin subunit 5 PFDN5 0.0086113 
21 CC prefoldin complex 218336_at prefoldin subunit 2 PFDN2 0.0225808 
22 CC prefoldin complex 222019_at prefoldin subunit 6 PFDN6 0.0326926 
23 CC prefoldin complex 201472_at von Hippel-Lindau binding protein 1 VBP1 0.0345687 
25 CC prefoldin complex 205963_s_at DnaJ homolog, subfamily A, member 3 DNAJA3 0.04568034 
26 MF oxidoreductase activity 207843_x_at cytochrome b5 type A CYB5A 0.01245134 
27 MF oxidoreductase activity 1560609_at crystallin zeta (quinone reductase)-like 1 CRYZL1 0.0496658 
1. Parametric GO-Term: CC = cellular component; MF= molecular function; BP= biological process. 
2. Genes found to be differentially expressed with a parametric P value of less than 0.05 in the top 5 of GO categories. 





Validation of genes from differentially expressed GO Classes 
Not all genes belonging to a certain GO class will necessarily exhibit differential expression 
between the DNMC and MC samples. To subsequently validate and assess whether 
individual genes from the identified GO classes are differentially expressed in DNMC as 
compared to MC, we selected 14 genes that were among the top four GO classes and 
analyzed expression levels by qRT-PCR in the sample groups. Table 2 provides an overview 
of the 14 selected genes for validation and the corresponding qRT-PCR primer sequences. 
Figure 2 shows the qRT-PCR results for five of these validated genes (MRPL42, PSMD10, 
HSPD1, MRPL47, and MRSP22) with expression depicted as the ratio of gene expression in 
the DNMC to the corresponding expression in MC (vertical axis) plotted per sample for all 
18 samples (horizontal axis). Differential gene expression seemed to vary per patient, as 
gene expression was either increased or decreased in DNMC as compared to MC for all 
interrogated paired melanocyte sample sets; this pattern was observed for all five genes. 
Some specific patient samples showed a higher increase in expression than other sample 
sets that also showed increased expression (sample 8018; expression PSMD10 and 
MRPL47), but a consistent differential expression pattern similar for all five genes was not 
observed for individual samples. This heterogeneous differential expression pattern in 
DNMC when compared to MC across the 18 samples seems to be in line with the 
observations from the microarray expression analysis. 
 Table 2. The 14 selected genes for validation of gene expression and qRT-PCR primer sequences 
 
Gene GO description forward primer (5'-3') reverse primer (5'-3') 
1 MRPS22 Organellar ribosome GAACTGAAGCCACCAACCTATAAG GCTGCCTCAACTGCCTGTC 
2 MRPL42 Organellar ribosome TCCAGTCCAAAATGGAGCTT CCACAGAAGGGTGGTAGCAT 
3 MRPL47 Organellar ribosome ACCTGGTGCTTGGAGAAGAGAC CACATAAGGCAAGGCAAAGAATCG 
4 MRPL21 Organellar ribosome GAGCCGAGATAGCTTCCTGA CTCCTTCCCATTGGTTCTCA 
5 MRPL7 Organellar ribosome ACGCTTTGATTGCTCGATCT TTGCCTCTTTGAAGCGTTTT 
6 MRPL10 Organellar ribosome GCAGAACAAGGAGCATGTGA TTTCAGCCACCATGTCTTCA 
7 MRPL17 Organellar ribosome CACTCGTGAAACTGCTCAGG CGTCGGAATGGTACACACTG 
8 NDUFS1 hydrogen ion transporter activity TGCCCTAACCTCTAAGCCCTATG ACTTCCAACCGCATCCATTACATC 
9 NOX1 hydrogen ion transporter activity GCCTCCATTCTCTCCAGCCTATC CACATACTCCACTGTCGTGTTTCG 
10 ACADM Mitochondrial AGCCTTTACTGGATTCATTGTGG ATTCCTCTAGTATCTGAACATCGC 
11 HSPD1 prefoldin complex TACTGGCTCCTCATCTCACTCG TGCTCAATAATCACTGTTCTTCCC 
12 PSMF1 prefoldin complex AACACCTGGGTGACTTCCAC CCCACTGCTCATGGATAGGT 
13 PSMB9 prefoldin complex CGGGCGGGAGCACCAACC GCAGACACTCGGGAATCAGAACC 
14 PSMD10 prefoldin complex AGGTGCTCAAGTGAATGCTGTC TGTAGCCTCATAATGGTCCTTAGC 
 
Proteome analysis of melanocytes from dysplastic naevus and normal skin 
The 18 matched melanocyte sample sets, derived from either dysplastic naevus or normal 
skin, were additionally subjected to mass spectrometry analysis to assess whether protein 
expression differences existed between the melanocyte sample groups. Figure 3 shows a 
representative example of proteins expressed in MC (visualized as green signal-Cy3) and 
the corresponding protein expression in DNMC (visualized as red signal-Cy5). Dye swap  




































































































































































































































































































































































































































































































































































Figure 2. qRT-PCR results across the 18 paired melanocyte sample groups for each of the five validated genes 
of GO-based statistical analysis. Expression was calculated by taking the ratio between DNMC and the 
corresponding MC per patient sample set. RPS11 served as reference gene in qRT-PCR experiments performed in 
duplicate. Values <1: gene expression is lower in DNMCs when compared to normal skin-derived melanocytes. 
 
Figure 3. Representative 2D DIGE image of 
protein analysis. Red signal: overexpressed 
protein in DNMCs. Green signal: overexpressed 
protein in melanocytes from normal skin. Yellow 
signal: equal expression in both melanocyte types 







experiments to control for dye labeling efficiency performed on various samples indicated 
that no large differences in efficiency were present between both dyes (data not shown). 
Each of the 2D DIGE gels contained on average 2205 spots, 90% of these spots were 
reproducible in at least 15 gel sets. Protein spots (n = 99) that were differentially 
expressed between normal and atypical melanocytes in at least 15 gel sets determined by 
statistical analysis were excised and subsequent MALDI TOF/TOF analysis was performed. 
Database mining resulted in the annotation of 70 proteins (see Table 1 available as 
Supplementary Material online at doi:10.1155/2012/981308). Additional statistical 
analysis yielded 16 most differentially expressed proteins (P <0.03, fold-change in 
expression difference ≥2 between DNMC and MC) (Table 3).  
Among these 16 proteins, there was decreased expression of vimentin and 
increased GTP-binding Rho-like protein CDC42 expression in the DNMC; these proteins are 
involved in regulation of cell shape and morphology. In addition, glutathione-S-transferase 
omega and tyrosine 3- monooxygenase, proteins involved in cellular detoxification 
processes, were found to be expressed at lower level in DNMC than in MC. Proteins that 
were involved in protein metabolism (prolyl 4-hydroxylase, eukaryotic translation 
initiation factor 3) we found to be higher expressed in DNMC.  
To assess whether overlap existed between the protein expression data and RNA 
expression data, we asked if for the 16 most differentially expressed proteins a similar 
expression pattern existed on the mRNA level. For each paired sample set of DNMC and 
MC, the corresponding gene expression fold-change was calculated. The fold-change in 
expression values was <1.5 for all probe sets and a consistent pattern in either increase or 
decrease in gene expression for a particular gene across all samples could not be observed 
(data not shown). 
 
Discussion 
In this study we compared the genome-wide gene expression and protein expression 
patterns of melanocytes derived from dysplastic naevus (DNMC) and melanocytes derived 
from adjacent normal skin (MC) from 18 patients. We aimed to find alterations in gene 
and protein expression that could inform us about biological processes underlying the 
earliest stage of melanoma development. Our results indicated that gene expression 
differences as measured using microarrays between melanocytes derived from normal 
skin and dysplastic naevus are rather small. Unbiased gene ontology analysis of the 
expression data of dysplastic naevus and normal melanocytes from a single patient 
enabled us to reveal differentially expressed GO classes; these included “organellar 
ribosome,” “mitochondrial ribosome,” “hydrogen ion transporter activity,” “prefoldin 
complex,” and “cAMP-dependent protein kinase regulator activity.” These GO classes 





















































P value General function 
Q9Y2R9 Ribosomal protein S7 22113 10.09 10 43 0.1310 0.010946 Translational elongation 
P32969 Ribosomal protein L9 21964 9.96 9.96 29 0.22334 0.016167 Translational elongation 
P78417 Glutathione S-transferase omega 1-1 27833 6.23 6.24 21 0.23627 0.013815 
Exhibits glutathione-dependent thiol transferase and 
dehydroascorbate reductase activities 
P62753 Ribosomal protein S6 28842 10.9 10.85 23 0.31890 0.012139 
Controlling cell growth and proliferation through the 
selective translation of particular classes of mRNA 
O75947 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit d 
18537 5.21 5.21 41 0.32135 0.027965 
Mitochondrial membrane ATP synthase that produces 
ATP from ADP 
P04792 Heat shock protein 27 22427 7.83 5.98 57 0.36622 0.023047 Involved in stress resistance and actin organization 
P02794 Ferritin heavy chain 21252 5.3 5.08 46 0.40067 0.006873 
Stores iron in a soluble, nontoxic, readily available 
form. Important for iron homeostasis 
Q59EQ2 
Tyrosine 3-monooxy-genase/tryptophan 
5-monooxygenase activation protein 
28179 4.76 4.73 26 0.41836 0.012436 Oxidoreductase 
P08670 Vimentin 53710 5.06 5.06 43 0.4478 0.023374 Vimentins are class-III intermediate filaments 
P07355 Annexin A2 36631 8.32 7.56 53 0.47142 0.00642 May be involved in heat-stress response 
P47985 Cytochrome b-c1 complex subunit Rieske 29934 8.55 6.3 5 0.47725 0.008578 
Component of the ubiquinol-cytochrome c reductase 
complex 
Q5U0F4 Eukaryotic translation initiation factor 3 36878 5.38 5.38 32 32.155 0.018194 Protein synthesis 
O94844 GTP-binding Rho-like protein cdc42 20123 5.25 4.83 55 288.699 0.017896 
The protein may play a role in small GTPase-mediated 
signal transduction and the organization of the actin 
filament system 
P07237 Prolyl 4-hydroxylase 57480 4.76 4.69 46 279.651 0.009987 
This multifunctional protein catalyzes the formation, 
breakage, and rearrangement of disulfide bonds 
Q6IBR6 Platelet-activating factor acetylhydrolase 25569 5.57 5.57 
 
246.963 0.008975 Lipid metabolic process 
Q9UBS4 DnaJ (Hsp40) homolog, subfamily B 40774 5.81 5.81 30 233.737 0.011076 
Binds directly to both unfolded proteins that are 
substrates for ERAD and nascent unfolded peptide 
chains 
1 Calculated molecular mass of the protein in Dalton (Da). 2 Isoelectric point (pI) observed in this study. 
3  p I calculated according to the Mascot database.  4 Percentage peptide coverage. 




factor that could contribute to the accumulation of cellular ROS levels.  
We also aimed to determine differences in protein expression between the 
DNMC and melanocytes derived from normal skin. Comparison of the protein profiles 
between the two melanocyte sample groups resulted in 16 significantly differentially 
expressed proteins. Lower expression of cytoskeletal proteins such as vimentin and 
annexin in DNMC was observed, which is possibly associated with morphological 
alterations of DNMC observed in culture when compared to melanocytes derived from 
normal skin
7
. Proteins that were higher expressed in DNMC included eukaryotic 
translation initiation factor 3, GTP-binding Rholike protein CDC42, prolyl 4-hydroxylase, 
platelet-activating factor acetylhydrolase, and DnaJ homolog subfamily B. These proteins 
are involved in protein synthesis, protein folding, and metabolism as well as lipid 
metabolism and cell shape organization
16,17
. 
We did not observe an overlap of the 16 differentially expressed proteins with 
the microarray gene expression data, as a clear pattern in mRNA expression across all 18 
sample sets was not found. This could be related to the overall small gene expression 
differences found in the microarray data. Dissimilarity between mRNA and protein 
abundance has been found in many combined genomic and proteomic studies. 
Nonetheless, among the differentially expressed proteins there were several involved in 
translation and growth, a functional class of proteins also identified in gene expression 
analysis.  
For this study, melanocytes were isolated from patient biopsy samples and 
expanded in culture to obtain sufficient material for gene expression and proteome 
profiling. Cell culture, although short, will have impacted on mRNA and protein levels in 
these cells. However, the relative number of melanocytes present in the epidermis would 
be too small and variable across naevus and normal skin samples to allow for similar 
comparative analysis of whole tissue samples. Microdissection of the dysplastic naevus 
and normal skin biopsy samples prior to RNA and protein isolation would ensure isolated 
melanocyte populations, but it would not yield sufficient material for the type of 
microarray and proteomic analysis performed in the described study. The technology to 
isolate single melanocytic cells and perform whole transcriptome and proteome analyses 
is not yet available to us, if at all feasible currently. Evidently, a subset of pre-existing 
biological differences in the transcriptomes and proteomes between the DNMC and MC 
may not be detected with the approach employed in this study, as the impact of culturing 
may overwhelm more subtle distinctions in expression. Any gene and protein expression 
differences however that may be induced by culturing will be comparable between MC 
and DNMC since identical culture procedures have been followed for all DNMC and MC 
cultures, in addition to harvesting cultures at the same passage numbers with the same 
harvesting methods. Moreover, we have compared DNMC and MC from the same patient
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from a single lesion and body site to maximize comparability. In spite of the impact of 
short-term culture on both types of cells, comparisons between these cells may be 
expected to yield meaningful results therefore. 
For many gene and protein expression profiling studies established tumor cell 
lines and benign primary cells have often been comparatively analyzed. For this study 
early-passage cultures were used and comparisons were performed with benign cells of 
the same patient isolated from the vicinity of the lesional dysplastic cells. This approach, 
combined with the fact that expression patterns of dysplastic instead of malignant cells 
were compared to those of benign cells, probably also provides an explanation for the 
relatively limited range of expression differences we observed.  
For the melanocyte cultures, we made additional observations of representative 
MC and DNMC cultures in order to find out whether differences existed between the two 
melanocyte groups. Directly after plating of the epidermal single cell suspensions, the 
melanocytes from dysplastic naevus did not display differences in the rate of cell death or 
plate adherence as compared to the melanocytes from normal skin. In addition, DNMC 
and MC did not display significant differences in proliferation rate when seeded at equal 
densities at passage four in 6W plates and counted every day for seven days. However, 
the DNMC cultures underwent senescence after prolonged periods in culture where 
normal MC cultures continued to proliferate. In addition modest but consistent 
differences in cellular morphology between DNMC and MC were observed, in particular 
pertaining to the shape of the dendrites. Together these findings are in agreement with 
previous electron microscopic studies revealing bloated mitochondria in DNMC and not in 
the MC as well as elevated ROS level measurements in DNMC when compared to MC
6,7
.  
Until now, very little comparative gene expression and protein expression studies 
have focused on dysplastic naevi. Usually, melanocytes from either dysplastic naevi or 
normal skin are included in large expression studies aimed at later stages of melanoma 
development, involving melanoma samples
18-20
. In a comprehensive gene expression study 
that included biopsies from normal skin and dysplastic naevus, in addition to radial and 
vertical growth phase melanomas and melanoma metastases, it was observed that 
dysplastic naevi do not differ to a large extent from normal naevi based on gene 
expression profiles
21
. Even though the dysplastic naevi showed higher expression of 
proliferation-related genes compared to normal naevi and displayed similar molecular 
features to vertical growth phase melanomas, they displayed significant heterogeneity in 
gene expression profiles. Our results now indicate that differences between melanocytes 
from dysplastic naevus compared to melanocytes from normal skin are also modest.  
Protein expression studies are to a similar extent often aimed at identifying 
changes occurring in late melanoma development stages; recently, it was found that 6.1% 




mini chromosome maintenance (MCM) protein 2, a polypeptide belonging to the MCM 
family of proteins that are involved in DNA replication and are assumed to be 
prognostically useful as cell proliferation marker similar to Ki-67
22
. In comparison, 49.1% 
nuclei of primary cutaneous melanomas stained positive. In addition, an earlier study 
found positive cyclin D1-nuclei staining in 0.34%, 5%, and 7.75% and positive cyclin D3-
nuclei staining in 1.8%, 6.4%, and 17.8% in normal naevi, dysplastic naevi and melanoma 
biopsy sections, respectively
23
. These observations together indicate that expression 
differences of proteins that mark proliferating cells may also be limited in DNMC 
compared to MC whereas the most significant differences in protein expression remains 
when comparing dysplastic naevi with the primary melanoma stage.  
A recent study however, found that the HLA class I heavy chain β2m and HLA 
class IIβ chain were expressed in 8.6% of the investigated normal, benign naevi and in 72% 
of atypical melanocytic lesions, where the level of expression correlated with degree of 
cytologic atypia and morphological disorder
24
. Further validation of a selected number of 
targets from our list of differentially expressed proteins could further confirm whether 
specific proteins also show significant difference in expression in DNMC compared to 
melanocytes from normal skin.  
Since some dysplastic naevi bear more molecular similarity to their normal 
counterparts, whereas other dysplastic naevi more closely resemble more advanced 
primary melanoma in gene expression patterns
21
, it may be not surprising that overall 
expression patterns of DNMC are heterogeneous. Differences that do occur between 
DNMC and melanocytes from normal skin tissue may be specific and exclusive for only a 
subset of dysplastic naevus and potentially associated with the grade of atypia. The 
occurrence of such expression differences may also partially depend on history of 
formation of the original benign naevus; melanocytes from a dysplastic naevus that readily 
progresses to melanoma may have been more “primed” for transformation even before 
the initial naevus formation stage compared to melanocytes that may display 
characteristics of dysplasia, but are more restricted in their potential to progress to 
malignancy. It will be a challenge to design experimental approaches that can more 
accurately delineate gene expression alterations typical of dysplastic naevi, given the 
heterogeneity of their cellular composition and gene expression patterns. Novel single cell 
sequencing methodologies or sequencing of microdissected lesions may partially address 
some of these challenges.  
Melanocytic cells are especially prone to oxidative DNA damage due to cellular 
metabolism processes such as melanin biosynthesis specific to these cells and exposure to 
UVA radiation. Deregulated expression of proteins involved in crucial oxidative stress 
management pathways in melanocytes of a dysplastic naevus can be detrimental and may 
contribute to their further progression towards malignancy. Recently exome analysis of 
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melanoma has demonstrated that approximately 9% of driver mutations are G > T 
transversions reflecting the relevance of oxidative DNA damage as a mutagenic force in 
melanoma development
25
. Via a proteomic approach, we found several proteins 
differentially expressed in melanocytes from dysplastic naevus when compared to 
melanocytes from normal skin. Notably, proteins involved in the mitochondrial respiratory 
electron transport chain and overall oxidative phosphorylation process showed a decrease 
in expression in DNMC. A decrease in expression of proteins involved in oxidation 
reduction, cytoskeletal organization, and protein folding was also observed. Some of the 
proteins that showed significant higher level of expression in the DNMC were involved in 
protein metabolism, lipid oxidation, positive regulation of inflammatory responses, and 
protein refolding. The pattern of differential protein expression that our comparative 
analysis has yielded, may indicate that DNMC are indeed exposed to elevated levels of 
oxidative stress due to their own deregulated cellular metabolic processes, particularly 
mitochondrial oxidative phosphorylation, additionally suffering from faulty protein 
folding, and cytoskeletal organization. Which (epi)genetic alterations are causing oxidative 
stress to occur in melanocytes within a dysplastic naevus and whether these sets of 
alterations can serve to identify the dysplastic naevus cells are important issues that 
remain to be elucidated. 
 
Conclusion 
Genome-wide expression profiling of melanocytes derived from dysplastic naevus (DNMC) 
and melanocytes from normal skin (MC) resulted in significantly differentially expressed 
“organellar ribosome,” “mitochondrial ribosome,” “hydrogen ion transporter activity,” 
and “prefoldin complex”Gene Ontology classes, with overall gene expression differences 
between both melanocyte groups being relatively small. MRPL42, PSMD10, HSPD1, 
MRPL47, and MRSP22 were among the top GO classes; validation of these genes showed a 
heterogeneous differential expression pattern across the DNMC and MC samples. 
Proteomic analysis revealed differentially expressed proteins in DNMC compared to MC 
with a role in cellular metabolism, detoxification, and cytoskeletal organization processes. 
Together these results indicate possible deregulated processes such as metabolism and 
protein synthesis in the melanocytes from dysplastic naevus; this is in line with the 
observed elevated oxidative stress levels that can potentially result in oxidative DNA 
damage in these cells. Further studies are needed to validate the identified differentially 
expressed proteins. Furthermore, investigations into which set of (epi)genetic alterations 
underlie the deregulated cellular processes that lead to increased oxidiatve stress, and 
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Supplementary Table 1. Differentially expressed proteins in DNMC and MC. Melanocytes derived from 
dysplastic naevus (DNMC) and normal adjacent skin (MC) of 18 different patients were subjected to mass 
spectrometry analysis. Mass fingerprint and MS/MS data were searched against the human protein database and 
resulted in annotation of 70 proteins. 
1) Calculated molecular mass of the protein (Da) 
2) Isoelectric point (pI) observed in this study 
3) pI calculated according to the Mascot database 
4) Percentage peptide coverage 
 

































































































































































































































































































































































































Promoter CpG island hypermethylation of MCHR1 and SYNPO2 in 
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Cutaneous melanoma is characterized by its propensity to metastasize. Once 
metastasized, the overall survival of patients is generally poor. The molecular alterations 
that confer melanoma cells the capacity to disseminate and colonize distant body sites 
remain to be defined. DNA methylation constitutes an important mechanism that 
contributes to the aberrant expression of genes involved in metastasis. Previously we have 
obtained genome-wide DNA methylation data from 24 primary cutaneous melanoma 
biopsy samples using beadchip technology interrogating 14,495 genes. We retrieved 
follow-up data and re-analysed these data comparing DNA methylation patterns of 13 
melanoma patients who had subsequently developed metastatic disease with those of 11 
patients who had not experienced recurrence after surgical removal. This re-analysis 
revealed six genes that were more frequently methylated in primary melanoma with 
metastatic behavior. Validation in an independent sample set confirmed that promoter 
hypermethylation of MCHR1 and SYNPO2 occurred more frequently in melanoma with 
metastatic behavior, supporting their application as prognostic biomarkers. Kaplan-Meier 
survival analysis of TCGA genome-wide methylation data of metastasized melanoma 
revealed that MCHR1- and SYNPO2-methylated metastasized melanomas had poorer 
survival rates compared to the non-methylated metastasized melanomas. Additional 
genome-wide methylation profiling of melanoma metastasis biopsy specimens revealed a 
loss of MAGEA3 and MAGEA6, members of the melanoma-antigen family A, in the 
melanoma metastases when compared to primary melanomas. Our findings warrant 
further investigation into the prognostic potential of MCHR1 and SYNPO2, and suggest a 




Cutaneous melanoma is a type of skin cancer that originates from melanocytes residing in 
the skin. Melanoma has a propensity to metastasize and once this occurs, the prognosis of 
patients is generally poor in spite of the introduction of targeted approaches to therapy. 
The central clinical factor predicting metastatic disease is tumor thickness. In addition, 
presence of tumor ulceration, mitotic activity, age, gender and tumor location have 
prognostic significance. In selected patients sentinel lymph node biopsy is performed for 
prognostic lymph node staging. The majority of patients are diagnosed early and present 
with a thin primary tumor which is curable by surgical excision. However, even in the 
group of patients with thin melanoma, a minority harbors lethal metastasis 
1
. Patients at 
increased risk of metastatic disease could benefit from more extensive surgery and 
adjuvant treatment.  
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Metastasis results from a complex cascade of events where melanoma cells 
acquire multiple molecular alterations that confer metastatic capacity. Gene expression 
signatures have been defined that are associated with metastatic capacity and survival of 
primary melanoma 
2,3
. Also metastatic melanomas were found to separate into subtypes 
with different prognosis based on their gene expression signatures 
4,5
. Systemic 
characterization of melanoma has revealed a diversity of recurrent genetic alterations, 
some of which were shown to drive the tumorigenic process 
6
. Still, the underlying 
molecular changes in melanoma that confer the capacity to migrate and colonize distant 
body sites remain to be defined. 
Epigenetic alterations have been recognized as important contributors to the 
malignant phenotype of melanoma cells. Recent findings suggest that promoter CpG 
island hypermethylation constitutes a major mechanism responsible for the inappropriate 
expression of genes involved in metastasis. Findings in breast cancer revealed DNA 
methylation signatures that were associated with metastatic risk and surivival outcome 
7
. 
Genes epigenetically silenced in melanoma and implicated in metastatic progression 
identified by us and others include SerpinB1 (Maspin), CDH11 and RASSF1A 
8-12
. As an 
epigenetic biomarker for metastasis, promoter hypermethylation has the advantage that 
it is generally stable and can reliably be detected in clinical samples. 
In a recent genome-wide analysis of promoter methylation in primary melanomas 
and melanocytic naevi interrogating 14,495 genes, we demonstrated widespread changes 
in DNA methylation patterns. For this study, we obtained clinical survival data for the 
interrogated samples and re-analyzed the results of the genome-wide analysis to identify 
DNA metylation alterations associated with metastatic behavior. In addition, we 
performed genome-wide methylation analysis on melanoma metastatic lesions to 
examine promoter methylation events occurring late in melanoma progression. 
 
Methods 
Melanoma biopsy specimens and patient information  
Fresh-frozen (FF) or fixed-in-boonfix and paraffin-embedded (BFPE) biopsy samples from 
72 patients diagnosed with primary melanoma and 28 patients with melanoma 
metastases (cutaneous, lymph node or visceral) were used (Supplementary Table S1a, S1b 
and S2). For the primary melanoma tumors, follow-up ranged from 60 months to 204 
months (median 132 months, mean 129 months). Excised tumor biopsies were reviewed 
by an expert dermatopathologist as previously described 
9
. DNA was extracted using 
either the Genomic-tip kit (Qiagen, Hilden, Germany) or RecoverAll Nucleic Acid kit 
(Ambion, Carlsbad, CA), followed by bisulphite conversion with the EZ DNA methylation kit 





Bisulphite melting curve analysis (BMCA) 
Bisulphite primer sequences were designed, sensitivity of primer sets was tested, and 




Analysis of Illumina Infinium HumanMethylation27K Beadchip promoter 
methylation data and BMCA data 
β-values resulting from the genome-wide Illumina Infinium HumanMethylation27K 
Beadchip, ranging from 0 to 1, were quantile normalized to correct for unequal 
distributions within and between samples due to technical variation. Average β-values 
were calculated for each sample group (metastatic primary melanomas (M+), non-
metastatic primary melanomas (M-) and melanoma metastases). Absolute average β-
value differences were calculated to represent the extent of differential methylation 
between different sample groups. Fisher’s Exact Test was applied to measure the 
association of promoter methylation frequency obtained by BMCA between two sample 
groups in IBM SPSS Statistics 20 (IBM Corp, Armonk, NY, USA); a two-sided P value <0.05 
was considered significant. 
 
Kaplan-Meier survival analysis of The Cancer Genome Atlas (TCGA) Illumina 
Infinium HumanMethylation450K data 
Illumina Infinium HumanMethylation450K Level 3 DNA methylation data and clinical 
follow-up information of 229 metastasized melanoma specimens (stage IV) were obtained 
via the TCGA dataportal (https://tcga-data.nci.nih.gov/). The HumanMethylation 450K 
Beadchip contains nine cg-probes for MCHR1 and 32 cg-probes for SYNPO2 that map to 
the promoter region, gene body and 3’UTR. Since we were interested in promoter 
methylation status, we selected a single representative probe (MCHR1 probe: 
cg14701072, SYNPO2 probe: cg24326232) that was located in the gene promoter region, 
at the same time located in proximity of the interrogated cg-probe on the 
HumanMethylation27K Beadchip, and that did not overlap with the other MCHR1 or 
SYNPO2 probes on the HumanMethylation 450K beadchip. Melanoma specimens with a 
cg-probe β-value >0.5 were considered methylated. Kaplan-Meier survival analysis was 
performed and survival curves were plotted in IBM SPSS Statistics 20, a logrank test P 
value <0.05 was considered significant.  
 
5-aza-2’-deoxycytidine treatment and quantitative real-time PCR 
Melanoma cell lines 06.24 and 94.13 were treated with 5-aza-2’-deoxycytidine as 
previously described 
9
. qRT-PCR was performed with iQ SYBR Green Supermix on a CFX384 
Touch™ system (Bio-Rad). qRT-PCR primers were designed to span exon-exon barriers; 
expression of the reference genes TBP and CPSF6 was validated using geNorm analysis
13
. 




Re-analysis of genome-wide data to identify promoter methylation events 
associated with metastatic behavior 
Our objective was to identify differential methylation events occurring in primary 
melanoma with metastatic behavior (M+) when compared to primary melanoma without 
metastatic behavior (M-). To this end, the clinical follow-up status of 24 patients with 
primary melanoma whose tumors had been previously subjected to genome-wide Illumina 
Infinium HumanMethylation27K profiling was obtained
9
. Thirteen of 24 patients 
diagnosed with primary melanoma had developed visceral or lymph node metastases 
during their disease course after a period of at least 60 months following diagnosis. In 11 
of 24 primary melanoma patients, no metastasis had occurred during a follow-up period 
of at least 60 months. The metastatic (M+) primary melanomas had an average Breslow 
thickness of 8.0 mm, with an average patient age of 67 years and 69% (9/13) showing 
ulceration. The non-metastatic (M-) primary melanomas had an average Breslow thickness 
of 1.8 mm, average patient age of 53 years, with 18% (2/11) demonstrating ulceration 
(Supplementary Table S1a). 
The difference in the extent of promoter methylation, expressed as the absolute 
difference in average β-value, was used to rank individual genes according to most 
differentially methylated in the primary melanomas with metastatic behavior (M+) 
compared to those without metastatic behavior (M-). The small group sizes limited 
meaningful statistical analysis of the genome-wide methylation data. A threshold value of 
0.20 was applied; genes with an average β-value difference higher than 0.20 were 
considered more frequently hypermethylated. From this re-analysis six genes emerged as 
more frequently hypermethylated in the primary melanomas with metastatic behavior 
(M+): MCHR1, SYNPO2, C1orf106, HIST1H3G, ZNF35 and GNMT (Figure 1a). We did not 
find genes with an average β-value difference less than -0.20 that were indicative of more 
frequent methylation in the primary melanomas without metastatic behavior (M-). 
 
Validation of frequent MCHR1 and SYNPO2 promoter hypermethylation in 
primary melanoma with metastatic behavior 
Bisulphite melting curve analysis (BMCA) of the seven genes on 21 of the 24 primary 
melanomas subjected to genome-wide methylation profiling, confirmed a significant 
difference in promoter methylation between M+ and M- primary melanoma tumors (*P 
<0.05 by two-sided Fisher’s exact test) of MCHR1, SYNPO2, C1orf106, ZNF35 and GNMT 
(Table 1a). HIST1H3G did not show significant differential methylation between both 
groups (Table 1a). To get an impression of MCHR1 methylation in the different stages of 




naevus and seven melanoma metastasis biopsy specimens was examined in addition. This 
showed that MCHR1 promoter methylation in the common naevi is at comparable level to 
the melanoma tissues (Figure 1b). Examination of SYNPO2 methylation in a similar way 
showed near absence of SYNPO2 methylation in the common naevi compared to the 
melanomas (Figure 1c); overall SYNPO2 methylation levels were notably lower than 






















































































Figure 1. (A) Re-analysis was performed of available genome-wide methylation data that was generated by 
subjecting 24 primary melanoma tumors to Illumina Infinium HumanMethylation27K profiling. Clinical follow-up 
status was retrieved of the 24 patients from which the primary melanomas were derived; 13 of 24 patients had 
primary melanoma tumors that developed metastasis (with metastatic behavior), 11 of 24 patients had primary 
melanoma with no occurence of metastasis during a follow-up period of at least 60 months (no metastatic 
behavior). (B) MCHR1 (probe: cg21342728) promoter methylation as obtained by genome-wide methylation 
profiling of common naevi, primary melanomas with and without metastatic behavior and metastatic melanoma. 
(C) SYNPO2 (probe: cg02519806) promoter methylation as obtained by genome-wide methylation profiling of 
common naevi, primary melanomas with and without metastatic behavior and metastatic melanoma. (D) 
Melanoma cell lines 06.24 and 94.13 were treated with 2μM 5-aza-2′-deoxycytidine for 96hrs and harvested for 
RNA isolation on day 5. qRT-PCRs were performed in triplicate, results are representative for treatment 
experiments performed in duplicate. * P <0.05 by two-sided t-test. 
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Table 1a. Methylation status of six candidate genes in the Illumina Infinium HumanMethylation27K set of 




- metastatic behavior 
Primary melanoma 
+ metastatic behavior Fisher’s exact 
P value   No. of 
samples 
 No. of 
samples 
MCHR1 44% 4/9 100% 12/12 0.006 
SYNPO2 33% 3/9 83% 10/12 0.032 
C1orf106 0% 0/9 75% 9/12 0.007 
HIST1H3G 44% 4/9 75% 9/12 0.203 
ZNF35 0% 0/9 58% 7/12 0.007 
GNMT 0% 0/9 67% 8/12 0.005 
 
Table 1b. Methylation status of six candidate genes in an independent set of primary melanomas with metastatic 




- metastatic behavior 
Primary melanoma 
+ metastatic behavior Fisher’s exact 
P value   No. of 
samples 
 No. of 
samples 
MCHR1 52% 13/25 90% 18/20 0.006 
SYNPO2 40% 10/25 65% 13/20 0.096 
C1orf106 26% 6/23 37% 7/19 0.453 
HIST1H3G 52% 12/23 70% 14/20 0.233 
ZNF35 32% 7/22 30% 6/20 0.899 
GNMT 25% 5/20 32% 6/19 0.648 
 
BMCA of MCHR1, SYNPO2, C1orf106, HIST1H3G, ZNF35 and GNMT was performed on an 
independent set of 20 metastatic primary melanomas (M+) and 25 non-metastatic primary 
melanomas (M-). This showed that MCHR1 promoter methylation occurred significantly 
more frequently in the metastatic primary melanomas (*P <0.05 by two-sided Fisher’s 
exact test; Table 1b). Differential methylation of SYNPO2 was not significant (P=0.096) but 
still substantial compared to the remaining genes (Table 1b). It should be noted that our 
analysis is restricted by the small size of the sample groups and we cannot exclude 
significant association with metastatic behavior for these hypermethylated genes. In our 
independent sample set, the metastatic primary melanomas (M+) had an average Breslow 
thickness of 4.0 mm with an average patient age of 62 years, while the non-metastatic 
primary melanomas (M-) had an average Breslow depth of 3.8 mm and an average patient 
age of 64 years (Supplementary Table S1b). The observation that MCHR1 promoter 
hypermethylation occurred significantly more frequently in the primary melanomas with 
metastatic behavior (M+), while the clinical prognostic factors Breslow thickness and age 
were similar for the M+ and M- primary melanoma groups, suggests that promoter 
methylation of this gene represents an independent factor predicting metastatic 
dissemination. 
To examine whether MCHR1 methylation was correlated with expression, BMCA 




status (data not shown). Two melanoma cell lines that were positive for MCHR1 promoter 
methylation, 06.24 and 94.13, were selected for 5’-azadeoxycytidine treatment. qRT-PCR 
analyses showed that demethylation of 06.24 and 94.13 resulted in a modest but 




Figure 2. (A) Kaplan-Meier survival analysis was performed with TCGA genome-wide methylation data of 229 
metastasized melanoma samples for MCHR1. (B) Kaplan-Meier survival analysis was performed with TCGA 
genome-wide methylation data of 228 metastasized melanoma samples for SYNPO2. 
Evaluation of prognostic significance in metastasized melanoma (stage IV) of 
MCHR1 and SYNPO2 promoter methylation 
In addition to predicting metastatic outcome of primary melanoma, we asked whether 
patients diagnosed with melanoma metastasis (stage IV) would differ in survival rate 
based on a difference in MCHR1 or SYNPO2 methylation status. Publicly available TCGA 
Illumina Infinium HumanMethylation450K Beadchip methylation data was subjected to 
Kaplan-Meier survival analysis in a TCGA cohort of 229 melanoma metastases samples 
with known clinical outcome (http://cancergenome.nih.gov/). For analysis, a single 
representative probe was selected for MCHR1 (cg14701072) and SYNPO2 (cg24326232). 
As cut-off, a normalized β-value of 0.50 was chosen; samples with β-value higher than 
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0.50 were considered methylated, samples with β-value lower than 0.50 were considered 
unmethylated. Kaplan-Meier survival analysis of MCHR1 showed that metastasized 
melanomas with cg-probe β-value < 0.50 had a significantly higher survival rate than 
metastasized melanomas with cg-probe β-value > 0.50 (*P<0.05 by logrank test) (Figure 
2a). Similarly, SYNPO2-unmethylated metastasized melanomas showed an overall better 
survival rate than SYNPO2-methylated metastasized melanomas, however this difference 
failed to reach statistical significance (P=0.051 by logrank test) (Figure 2b). 
 
Loss of MAGEA3 and MAGEA6 promoter methylation in melanoma metastases 
Next to genome-wide methylation profiling of the 24 primary melanomas using the 
Illumina Infinium HumanMethylation27K Beadchip as mentioned earlier in this chapter, 
we also generated genome-wide methylation data for seven melanoma metastasis tissues 
in order to evaluate whether further epigenetic alterations would occur in later stages of 
development following metastatic colonization. We were interested in comparing the 
methylation data of the primary melanomas and melanoma metastases for differential 
methylation events. Similar to the comparative analysis as mentioned earlier, the absolute 
difference in average β-value was used to rank genes according to most differentially 
methylated. From this analysis, five genes with an average β-value lower than -0.20 
emerged: KCNJ15, A2M, MAGEB6, MAGEA6 and MAGEA3. The methylation status of 
MAGEA3, MAGEA6 and MAGEB6 was assessed in an independent set of 15 primary 
melanomas and 21 melanoma metastases using BMCA (patient information can be found 
in Supplementary Table S1b and S2). KCNJ14 and A2M were excluded from further 
analysis since the CpG density (0.76%) in both promoter regions was too low to perform 
reliable BMCA. MAGEA3 and MAGEA6 are both located on chromosome Xq28 in separate 
locations; MAGEA3 and MAGEA6 promoter methylation was interrogated using the same 
primer set since both genes share 99% similarity in DNA sequence for the +1450bp to -
1000bp TSS region. BMCA on the independent sample set revealed a significant decrease 
of MAGEA3 and MAGEA6 promoter methylation in the melanoma metastasis tissues 
(Table 2). 
Table 2. Methylation status of MAGEA3, MAGEA6 and MAGEB6 in an independent cohort of primary melanoma 
(n=15) and metastatic melanoma (n=21) samples. 
 
Primary melanoma Melanoma metastasis Fisher’s exact 
P value   
No. of samples 
 
No. of samples 
MAGEA3/MAGEA6 100% 15/15 67% 14/21 0.027 






In order to identify CpG promoter island methylation events that are associated with 
metastatic behaviour of melanoma, we have performed re-analysis of genome-wide 
Illumina Infinium HumanMethylation27K Beadchip data followed by bisulphite melting 
curve analysis (BMCA) in independent sample sets of metastatic (M+) and non-metastatic 
(M-) primary melanomas. We observed increased MCHR1 and SYNPO2 promoter 
methylation in the metastatic primary melanomas compared to the non-metastatic 
primary lesions; for MCHR1 the increased methylation frequency was statistically 
significant but not for SYNPO2. Methylation analyses in larger sample sets may show a 
significant association with metastic behaviour for SYNPO2 and the remaining genes that 
we observed as hypermethylated in metastatic primary melanoma, C1orf106, HIST1H3G 
and GNMT. Although metastasis-associated hypermethylation of these genes was not 
replicated in the second sample set, prognostic value of these methylation events is still 
possible given the relatively small size of the independent sample set. The observation of 
MCHR1 hypermethylation in our set of metastatic primary melanomas suggests that the 
event of MCHR1 promoter methylation may be an independent factor predicting 
metastatic dissemination. Detection of MCHR1 promoter methylation status might 
therefore be useful clinically in predicting the risk of metastasis in patients diagnosed with 
primary melanoma. Confirmation studies in large cohorts of metastatic and non-
metastatic primary melanomas will be needed, with an assessment of the extent of 
association between MCHR1 methylation with established clinical prognostic factors such 
as Breslow thickness, ulceration, mitotic index and age. Compared to the investigated 
naevi, a slight decrease in MCHR1 methylation in the non-metastatic primary melanomas 
was observed, suggesting a hypomethylated state of MCHR1 in primary melanomas with a 
good prognosis and a hypermethylated state of this gene in primary melanomas with poor 
prognosis. Our observation of the presence of MCHR1 methylation in benign melanocytic 
tissue indicates that the differences in MCHR1 methylation as detected in this study are 
based on differences in methylation density of the CpG promoter region, rather than 
based on a complete presence or absence of methylation. Further investigation will be 
needed to establish the effect of promoter CpG island methylation density on MCHR1 
expression.  
In addition to finding methylation events associated with metastatic behaviour of 
melanoma, it would be informative to establish an association of individual methylation 
events with survival outcome of primary melanomas. In the TCGA Infinium 
HumanMethylation450K data set of 229 metastasized (stage IV) melanoma samples, a cg-
probe β-value higher than 0.50 for MCHR1 was significantly associated with a poorer 
survival rate. It is striking that, in addition to a significant association with metastatic 
behaviour observed in a set of primary melanomas, MCHR1 methylation is also correlated 
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to survival outcome of metastasized melanomas. These findings indicate that epigenetic 
events that determine metastatic capacity and tumor malignancy occur in the course of 
primary tumor development. MCHR1 (melanin-concentrating hormone receptor 1) has 
been identified as an auto-antigen that is targeted by auto-antibodies in vitiligo, an auto-
immune disease that results from the loss of melanocytes in the skin 
14
. Downregulation of 
MCHR1 may give melanoma cells the advantage to evade the body’s immune response. In 
our study we have found SYNPO2 to be a good candidate gene as well. SYNPO2 
(synaptopodin 2 or myopodin) was found as a tumor suppressor in prostate cancer that 
suppresses motility and invasion of prostate cancer cells, with frequent deletion in 
aggressive prostate cancer 
15,16
. Notably SYNPO2 methylation was found to associate with 
poorer disease-specific survival in bladder and colon cancer 
17,18
. Additional methylation 
analyses in larger sample sets are needed to confirm whether methylation of this gene is 
significantly associated with metastatic behavior in melanoma. 
The MAGE (melanoma-antigen family A) genes MAGEA3 and MAGEA6 encode 
antigens that are presented by members of the major histocompatibility complex, class I 
family, recognized by cytolytic T-lymphocytes and expressed by melanoma tumors while 
rarely being expressed in normal human tissue 
19-22
. MAGEA3 gene expression was found 
to be regulated by methylation in melanoma, with correlating high expression levels and 
MAGEA3 hypomethylation in melanoma cells 
23
. In line with this, we observed in our 
independent set of melanoma metastases MAGEA3 and MAGEA6 hypomethylation 
compared to the primary melanoma lesions. The finding that hypomethylation of these 
cancer/testis antigens occurs late in the metastatic progression of melanoma is novel and 
may have relevance for the design of immunotherapeutic approaches directed towards 
MAGE proteins in melanoma. 
In conclusion, the findings described in this chapter provide a starting point for 
further investigation into the potential of MCHR1 and SYNPO2 methylation status as 
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Supplementary Table S1. (A) Patients (primary tumor) used for re-analyses of Illumina Infinium 
HumanMethylation27K promoter methylation data. 
 
Metastatic Metastasis type Site Breslow Ulcer Mitoses Clark Diagnosis Gender Age Mutation 
1 - n/a Lower leg 1.67 - 3 IV SSMM F 53 wildtype 
2 - n/a Lower leg 2.08 + 6 IV SSMM M 68 BRAFV600E 
3 - n/a Foot 4.48 + 13 V ALMM M 65 wildtype 
4 - n/a Trunk 2.05 - 2 IV SSMM F 65 wildtype 
5 - n/a Foot 3.88 - 5 IV ALMM F 60 wildtype 
6 - n/a Ear 0.81 - 1 III SSMM M 58 wildtype 
7 - n/a Back 0.91 - 0 IV SSMM F 42 BRAFV600K 
8 - n/a Shoulder 0.94 - 2 IV SSMM F 34 wildtype 
9 - n/a Back 1.06 - 2 IV SSMM M 36 BRAFV600E 
10 - n/a Buttock 0.73 - 0 III SSMM F 35 BRAFV600E 
11 - n/a Back 1.28 - 1 IV SSMM F 65 wildtype 
12 + brain, lymph node, skin Nailbed Toe 1.70 + 2 IV ALMM F 59 NRASG12D 
13 + lymph node, skin Foot 3.36 + 6 IV ALMM F 73 wildtype 
14 + skin, lung, bone Neck 15.6 - 2 V Desmopl MM M 85 wildtype 
15 + local recurrence Scalp 3.46 - 4 IV SSMM M 54 wildtype 
16 + lymph node Thigh 9.20 + 10 V SSMM F 48 NRASQ61K 
17 + lymph node Lower leg 18.0 + 12 V SSMM M 82 BRAFV600E 
18 + liver, bone Buttock 6.29 + 8 IV SSMM F 62 wildtype 
19 + Unknown Scalp 17.2 + 9 V NMM M 79 BRAFV600K 
20 + Unknown Back 3.04 + 4 IV SSMM F 45 wildtype 
21 + Unknown Lower leg 2.02 + 4 IV SSMM M 78 wildtype 
22 + Unknown Axilla 12.2 - 7 V SSMM M 70 wildtype 
23 + Unknown Vulva 10.1 + 8 IV SSMM F 56 wildtype 
24 + Unknown Foot 2.08 - 7 IV SSMM F 75 BRAFV600E 
 
Supplementary Table S1. (B) Patients (primary tumor) used for independent validation by BMCA. 
 
Metastatic Metastasis type Site Breslow Gender Age Validation of* 
1 - n/a back 6.0 M 74 1, 2 
2 - n/a lower leg 2.2 M 77 1, 2 
3 - n/a upper arm 5.9 F 65 1, 2 
4 - n/a neck 1.2 F 49 1, 2 
5 - n/a back 3.5 M 76 1, 2 
6 - n/a back 2.3 F 40 1, 2 
7 - n/a back 5.2 M 85 1, 2 
8 - n/a upper leg 3.9 F 55 1, 2 
9 - n/a shoulder 1.3 F 47 1, 2 
10 - n/a back 2.2 M 37 1 
11 - n/a upper arm 2.0 F 57 1 
12 - n/a back 3.0 F 81 1 
13 - n/a trunk 2.2 M 70 1 
14 - n/a lower arm 4.0 M 54 1 
15 - n/a shoulder 4.8 M 62 1 
16 - n/a neck 3.3 F 74 1 
17 - n/a upper arm 3.6 M 65 1 
18 - n/a head 6.0 M 77 1 
19 - n/a back 2.5 F 26 1 
20 - n/a lower leg 2.5 F 82 1 
21 - n/a head 4.2 M 88 1 




23 - n/a back 2.1 F 60 1 
24 - n/a lower leg 2.5 F 67 1 
25 - n/a trunk 3.2 M 85 1 
26 + Visceral shoulder 3.0 M 76 1, 2 
27 + nnll_toilet_k lower leg 1.4 F 86 1, 2 
28 + spinal cord lower leg 1.5 F 80 1, 2 
29 + Cutaneous back 4.5 M 64 1 
30 + Visceral back 3.0 M 64 1 
31 + Cutaneous lower leg 3.3 F 89 1 
32 + Cutaneous upper leg 2.9 F 80 1 
33 + Visceral back 2.1 F 34 1 
34 + Visceral back 3.0 M 55 1 
35 + Visceral upper leg 2.7 F 70 1 
36 + Visceral head/neck 2.0 M 67 1 
37 + Parotis upper leg 3.1 M 43 1 
38 + Brain abdomen right 2.3 F 38 1 
39 + Visceral back 7.0 M 74 1 
40 + Brain neck left 2.5 M 33 1 
41 + Brain thorax left 2.4 M 55 1 
42 + Cutaneous back 7.0 F 59 1 
43 + Visceral labia left 3.2 F 57 1 
44 + Cutaneous back 2.0 F 62 1 
45 + Cutaneous lower arm 7.5 M 58 1 
46 unknown n/a trunk 2.0 M 46 2 
47 unknown n/a knee 1.8 M 83 2 
48 unknown n/a lower leg 3.4 F 51 2 
*Sample was used for validation of the candidate gene set: 
1 = MCHR1, SYNPO2, C1orf106, HIST1H3G, ZNF35, GNMT 
2 = MAGEA3, MAGEA6, MAGEB6 
 
Supplementary Table S2. (A) Melanoma metastasis biopsy specimens (n=7) used for genome-wide Illumina 
Infinium HumanMethylation27K Beadchip profiling. 
Characteristics  No. of Specimens % 
Metastasis type     
cutaneous 7 100 
 
Supplementary Table S2. (B) Melanoma metastasis biopsy specimens (n=21) used for independent validation by 
BMCA of MAGEA3, MAGEA6 and MAGEB6. 
Characteristics  No. of Specimens % 
Metastasis type     
cutaneous 6 29 
lymph node 8 38 
visceral 1 5 

























The development of melanoma is driven by an accumulation of molecular aberrations in 
melanocytes. These aberrations can be genetic and epigenetic events as research has 
shown over the years.  Epigenetic events such as DNA methylation alterations and histone 
modifications are involved in chromatin organization and regulation of gene expression. 
Promoter CpG island hypermethylation of tumor suppressor genes has also been found in 
melanoma. Until now, DNA methylation studies have focused on selected genes and were 
mostly limited to metastatic melanoma cell lines (described in Chapter 1). Our aim was to 
obtain a genome-wide view of promoter methylation in primary melanoma biopsy tissue 
in order to identify melanoma suppressor genes, and to identify diagnostic and prognostic 
biomarkers. 
 
Promoter hypermethylation in primary melanoma 
In this thesis, we report the first genome-wide profiling of DNA methylation alterations in 
primary cutaneous melanoma and common naevus biopsy specimens. Genome-wide DNA 
methylation profiling identified 106 genes as significantly and frequently hypermethylated 
in primary melanoma when compared to common naevus. Among the genes most 
frequently hypermethylated in melanoma were HOXA9, MAPK13, CDH11, PLEKHG6, 
PPP1R3C and CLDN11. Aside from HOXA9, for which methylation was found in a sizeable 
proportion of common naevi, promoter methylation of the other genes was almost absent 
in naevi but occurred frequently in melanomas (Chapter 2). Of the 106 most frequently 
methylated genes, 11 genes have been reported as methylated in melanoma and 32 genes 
as methylated in other cancer types. The PPP1R3C, CDH11 and HOXA9 gene promoters 
have previously been reported to be hypermethylated in melanoma cell lines and 
metastatic samples
1-4
. Methylation of the MAPK13, PLEKHG6 and CLDN11 gene 
promoters, occurring in up to 67% of primary melanoma cases as detected by bisulphite 
melting curve analysis, has not been reported in melanoma yet. From the 106 identified 
genes, one gene (RNF43) was listed in the Cancer Gene Census as a putative tumor 
suppressor gene
5
. The Cancer Gene Census has 54 genes (8%) that overlap with the tumor 
suppressor gene database (TSGene) that consists of 716 human genes up to date. From 
the 106 genes SERPINB5 (Maspin), CHFR and RARβ were listed in TSGene as known tumor 
suppressors based on multiple independent studies in literature. CDH11, GNMT, NR4A1 
and MTSS1 were listed as putative tumor suppressors
6
. 
Genome-wide methylation profiling has revealed the presence of widespread and 
frequent DNA methylation alterations in primary melanoma. Based on further methylation 
analyses in sets of common naevi, dysplastic naevi, primary and metastatic melanomas, 
we have begun to obtain a view of the onset of methylation events that may be important 
in the development of melanoma (Figure 1). We have observed the presence of HOXA9, 
MAPK13 and CNTN1 promoter methylation in a subset of common and dysplastic naevi, 
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and in 40% - 80% of primary melanomas. Interestingly, genes such as CDH11, PPP1R3C and 
PLEKHG6 were progressively hypermethylated in dysplastic naevi, primary and metastatic 
melanomas, with almost absent methylation in common naevi (Chapter 3). This suggests a 
potential role of these genes in suppressing the onset of dysplastic features in melanocytic 
lesions.  
The promoter hypermethylation frequency of a selected panel of genes appeared 
to increase gradually from the common naevus to the dysplastic naevus stage. In primary 
melanoma samples however, the number of methylated genes demonstrated a sharp 
increase, indicating that malignant transformation is associated with epigenetic 
deregulation. Using this approach, we have identified CLDN11 as a potential biomarker to 
distinguish dysplastic naevi from primary melanoma (Chapter 3). CLDN11 encodes a 
member of the claudin family, components of tight junctions that maintain a physical 
barrier and the polarity of cells. Loss of CLDN11 expression through promoter 
hypermethylation during melanoma development may facilitate invasive behavior by 
disrupting intercellular cohesion provided by tight junction structures
7
. 
Genome-wide methylation profiling was performed using Illumina’s Infinium 
HumanMethylation27K platform that interrogates 27,578 CpG sites located within the 
promoter regions of a total of 14,495 genes. Recently, beadchips have become available 
that allow examination of methylomes with an even higher resolution; the 450K beadchip 
interrogates more than 480.000 cytosines distributed over the whole genome inside and 
outside of gene promoter regions. Whole-genome bisulphite sequencing, based on next-
generation sequencing of bisulphite-treated DNA, has made it possible to analyze the 
approximately 30 million CG-dinucleotides in the human genome. These more recent 
techniques can aid in the identification of additional differentially methylated CpG sites 
that hold potential diagnostic or prognostic value, since they enable interrogating an 
extensive number of CpG sites at once. The additional value of methylation analyses using 
these high-resolution platforms, however, may be limited. One reason is that promoter 
CpG island methylation remains the most relevant when it comes to direct implications in 
gene transcription regulation. Approximately 50% of all 30.000 human gene promoters 
contain a CpG island, methylation of which is often associated with transcriptional 
repression. The 14,495 gene promoters interrogated by Illumina's 27k beadchip covers 




Figure 1. A melanoma progression model with the 
hypothesized timing of the most frequently 
occurring epigenetic events in the different stages 









MAPK13 and RASEF, candidate melanoma suppressor genes 
Promoter CpG island methylation is believed to contribute to the development and 
progression of cancer by transcriptional repression of tumor suppressor genes, providing a 
selective advantage to tumor cells. Established tumor suppressor genes that are often 
inactivated in cancer such as CDKN2A and PTEN have been found to be affected by 
aberrant promoter methylation in melanoma. We hypothesized that among the 106 most 
frequently methylated genes could be potential novel genes with a tumor suppressive role 
in melanoma. MAPK13, encoding p38δ, belonged to the five most frequently 
hypermethylated genes in primary melanoma that were identified. Due to its suggested 
tumor suppressive function and the potential involvement of p38 MAPK proteins in 
oncogene-induced senescence, we have performed additional experiments focused on 
MAPK13. To evaluate tumor suppressive properties, MAPK13 expression was restored in 
several melanoma cell lines affected by promoter hypermethylation of this gene; we 
observed that this resulted in a significant decrease of proliferative capacity of these cells 
(Chapter 2). Together with the finding of MAPK13 promoter methylation in a proportion 
of common naevi, our data suggests that MAPK13 silencing by methylation might be an 
early event that has a role in melanoma development. Similar to our findings but in a 
different cancer type, MAPK13 has been suggested to be involved in the suppression of 
oesophageal squamous cell carcinoma (OESCC) through observations of decreased cell 
proliferation and migration, and altered anchorage-independent growth when MAPK13 
was introduced in OESCC cells that did not have endogenous MAPK13 expression, with an 
even greater effect when the active phosphorylated form of MAPK13 was used
8
. Mouse 
embryonic fibroblasts lacking MAPK13 were previously found to have diminished cell 
contact inhibition and to proliferate and migrate faster than their wildtype counterparts
9
. 
Another study observed that phosphorylation of p53 by members of the p38 and JNK 
family of MAP-kinases, including p38δ, upon depletion of SEPW1 mediated a transient G1 
cell cycle arrest in epithelial cells
10
. For keratinocytes it was found that PKCδ suppressed 
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proliferation via activation of MAPK13, leading to an increase in p53 levels and increased 
expression of p21
Cip1,11
. Together these findings point to potential tumor suppressive 
properties of MAPK13 that involves stabilization and activation of p53. 
In the process of malignant transformation towards cancer, oncogene-induced 
senescence (OIS) has been identified as a mechanism to protect against the onset of 
cancer in response to aberrant oncogenic activity. We were not able to observe a bypass 
of BRAF
V600E
-induced senescence upon MAPK13 depletion. This can be due to redundancy 
in function of the four p38 MAPK isoforms in melanoma cells and therefore depletion of 
MAPK13 was not sufficient to bypass senescence. Recently it was shown that RAS-
activated p38 induced the pro-senescent function of Tip60 via phosphorylation of both 
Tip60 and PRAK, providing evidence for a signaling pathway involving p38 that mediated 
oncogene-induced senescence. Upon activation by oncogenic RAS only two isoforms, 
p38α (MAPK14) and p38δ (MAPK13), were observed to mediate phosphorylation of Tip60 
at Thr158/106 in senescent cells, while all four p38 isoforms (p38α, MAPK14; p38β, 
MAPK11; p38γ, MAPK12; p38δ, MAPK13) phosphorylated Tip60 in vitro. These results 
indicate potentially overlapping functions for the p38α and p38δ isoforms in mediating 
senescence
12
. Another study however found that p38δ was able to mediate RAS-induced 
senescence, with enhancement of p38δ expression during senescence via induction of the 
RAF1-MEK-ERK pathway by oncogenic RAS
13
. Since these studies found p38δ involved in 
senescence induced by oncogenic RAS, it may be mainly involved in the response induced 
by this oncogene and not by mutant BRAF. Differences exist between the four p38 
isoforms in terms of different cofactors that regulate phosphorylation, and different 
accessibility to phosphorylation targets. Insight into how the phosphorylation activity of 
each p38 isoform is regulated and how it affects signaling downstream, may aid in further 
understanding the role of the p38 kinases in mutant BRAF-induced senescence. 
In Chapter 2, bisulphite melting curve analysis (BMCA) was used to assess the 
promoter methylation status of fresh-frozen biopsy specimens. Here, no significant 
MAPK13 promoter methylation was observed in the investigated common naevi. In 
Chapter 4 MAPK13 methylation was observed in 18% of investigated formalin-fixed 
paraffin-embedded (FFPE) biopsy samples using methylation-specific PCR (MSP). The MSP 
as applied in Chapter 4 is able to detect one methylated allele in a background of at least 
1000 unmethylated alleles
14
. Therefore MSP has been more sensitive than BMCA in 
detecting methylation even in a tiny fraction of cells. At least 5% of methylated DNA was 
required in order for BMCA to detect methylation. MAPK13 methylation assessment using 
BMCA and MSP on a set of naevi and melanomas showed 84% concordance (described in 
Chapter 4). Cases that did not have concordant results between the BMCA and MSP 
techniques were all specimens that were considered as ‘unmethylated’ using BMCA, and 




with BMCA and MSP, we assume that small subpopulations of melanoma cells exist that 
are positive for methylation of MAPK13 that are not detectable by BMCA.  
In order to identify novel genes required for induction of senescence following 
expression of mutant BRAF, a functional shRNA screen was performed targeting 
approximately 15.000 genes. Primary analysis yielded 40 genes and from secondary 
validation seven genes essential for BRAF-induced senescence emerged, including the 
RASEF gene. Upon reanalysis of genome-wide methylation profiles RASEF was among the 
genes most frequently methylated in BRAF-mutant melanoma. Subsequent analysis in a 
larger series of melanoma samples demonstrated that RASEF was methylated in 21% of 
primary melanomas. Upon validation, RASEF methylation appeared not to be restricted to 
tumors with BRAF mutation. (Chapter 3). Depletion of RASEF mediated a bypass of 
BRAF
V600E
-induced senescence and the suppression of senescence biomarkers including 
senescence-associated (SA)-β-galactosidase activity, interleukins and tumor suppressor 
p15
INK4B
. In addition, a growth-restrictive effect was observed in melanoma cells where 
epigenetically silenced RASEF expression was restored. These findings suggest the 
identification of a potential new tumor suppressor gene in melanoma (Chapter 3). RASEF 
promoter hypermethylation and a correlation between RASEF methylation and expression 
have been previously described in uveal melanoma, a melanoma subtype that differs in 
genetic and clinical characteristics from cutaneous melanoma
15
. The chromosomal region 
on 9q21.32 where RASEF is located has been proposed previously as a susceptibility locus 
in members of three Danish families with cases of cutaneous and uveal melanoma
16
. 
Together with our findings, these results indicate that RASEF inactivation may be 
important for both cutaneous and uveal melanoma development, suggesting a common 
ground that may underlie tumorigenesis of both melanoma subtypes. We propose that 
RASEF is a melanoma suppressor gene, inactivation of which prevents the onset of a 
senescence response that normally occurs upon expression of mutant BRAF. 
For MAPK13 and RASEF, we have made a start in Chapter 2 and Chapter 3 of this 
thesis to characterize their potential tumor suppressive function in melanoma. An 
assessment of MAPK13 and RASEF function using in vivo assays will be needed for a more 
definitive demonstration that MAPK13 and RASEF are tumor suppressors
17
. MAPK13 
mutation was found in 2 of 319 (0.6%) melanoma tissues in the Catalogue of somatic 
mutations in cancer (COSMIC), and RASEF mutation was found in 3 of 314 (1.0%) of 
melanoma tissues. This may be an indication that inactivation of MAPK13 and RASEF 
function is mainly brought about by promoter methylation. Also other genes, such as the 
HIC1 tumor suppressor gene are known to be primarily inactivated by promoter 
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Promoter methylation and gene expression in dysplastic naevus 
The dysplastic naevus is considered an intermediate stage of melanocytic lesion between 
a common naevus and a primary melanoma. Clinically the distinction between dysplastic 
naevus and early-stage melanoma remains challenging for a proportion of cases. We set 
out to examine the promoter methylation status of a selection of genes that were 
identified using genome-wide methylation profiling, in a total of 405 melanocytic 
neoplasms (Chapter 4). Promoter methylation analysis in common naevi, dysplastic naevi, 
primary melanomas and metastatic melanomas demonstrated progressive epigenetic 
deregulation. We also observed that dysplastic naevi were affected by promoter 
methylation of genes that were frequently methylated in melanoma but not in common 
naevi. CLDN11 promoter methylation was the most selective for melanoma as it occurred 
in 50% of primary melanomas and only 3% of dysplastic naevi. Promoter methylation of 
CLDN11 has been previously reported in bladder and gastric cancer and was shown to be 
associated with transcriptional silencing
19,20
 Next we assessed the diagnostic value of the 
methylation status of five genes in distinguishing primary melanoma from dysplastic 
naevus. A diagnostic model that incorporated methylation of CLDN11, CDH11, PPP1R3C, 
MAPK13 and GNMT was validated in an independent sample series and helped distinguish 
melanoma from dysplastic naevus (AUC 0.81). We did not find a single gene methylation 
event that could completely distinguish melanoma from naevus samples in all cases. 
However the combined detection of CLDN11, CDH11 and PPP1R3C promoter methylation 
yielded a specificity of 89% and sensitivity of 67%. 
In addition to DNA methylation, we have also examined differences in gene 
expression of the melanocytes derived from dysplastic naevus and melanocytes from 
adjacent normal skin. To gain insight into the molecular pathways that may underlie the 
elevated oxidative stress levels in dysplastic naevus melanocytes, we compared the gene 
and protein expression patterns of cultured melanocytes derived from dysplastic naevus 
and melanocytes from adjacent normal skin. Our findings indicate that gene expression 
patterns from cultured melanocytes derived from dysplastic naevi are largely similar to 
those of melanocytes derived from normal skin. The main differences were observed with 
genes involved in cellular metabolism, detoxification and cytoskeletal organization. 
Melanocytes derived from dysplastic naevi also differed in morphology and proliferation 
rate from the melanocytes derived from adjacent normal skin (Chapter 5). However 
overall, the differences between the two melanocyte types were small. The initially 
existent expression differences may have been subtle due to artefacts introduced by short 
culturing of the melanocytes; it is possible that we were subsequently not able to detect 
significant differential mRNA levels between the melanocytes derived from dysplastic 
naevi and melanocytes derived from adjacent normal skin. Previous mRNA and protein 




melanomas observed that expression differences between normal melanocytes and 
melanocytes from dysplastic naevi are relatively small
21-24
. Our findings in Chapter 5 are in 
line with these observations. Dysplastic naevi were also previously found to display 
significant heterogeneity in their gene expression profiles, where some dysplastic naevi 
resembled their normal counterparts while other dysplastic naevi more closely resembled 
primary melanomas when comparing gene expression patterns. The existence of this 
heterogeneity can make it more difficult to correctly identify differential gene expression 
patterns in our microarray analysis and requires approaches that can more accurately 
determine differential expression in a more defined, small number of dysplastic naevus 
cells. 
Taken together the observations made in Chapter 4 and 5 show that dysplastic 
naevi, also those with severe atypia, resemble common naevi more than primary 
melanoma on the epigenetic and gene expression level. We found no overlap upon 
comparison of the differentially methylated genes between common naevi and dysplastic 
naevi as observed in Chapter 4, with the differentially expressed genes and proteins found 
in Chapter 5. In Chapter 4, the identified genes were obtained by initially comparing 
common naevi with primary melanomas. The most frequently methylated genes from that 
comparison were subsequently analyzed in common naevi and dysplastic naevi. These 
genes were HOXA9, C1orf106, MAPK13, CDH11, EFCAB1, CNTN1, GNMT, PLEKHG6, 
PPP1R3C and CLDN11 (Table 1). Out of these ten genes HOXA9, MAPK13, CNTN1, 
PLEKHG6 and PPP1R3C were also observed to be hypermethylated in dysplastic naevi 
(Table 1). The possibility remains that if the initial promoter methylation profiling was 
performed using common naevi and dysplastic naevi as the initial comparison, genes 
different than those listed in Table 1 would have been identified. In addition the 
comparison in Chapter 5 was performed between melanocytes from dysplastic naevi and 
melanocytes derived from normal skin. Altogether this can explain why no overlap was 
found between the identified gene candidates in Chapter 4 and 5. 
 
Prognostic biomarkers for primary melanoma with metastatic capacity 
The acquisition of metastatic capacity is a crucial step in melanoma progression as 
metastatic melanoma is often fatal whereas a localized tumor can be cured by excision. It 
remains a challenge to correctly predict those patients that are at high risk for metastatic 
disease and to determine the prognosis for patients diagnosed with melanoma, in spite of 
the availability of several clinical prognostic factors such as tumor thickness. Current 
understanding about the role of epigenetic alterations that underlie the capacity of 
melanoma cells to invade deeper skin regions and disseminate from the primary tumor is 
limited. In order to identify genes that were differentially methylated between primary 
melanoma with and without metastatic capacity, a re-analysis of genome-wide methyla- 
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Table 1. Hypermethylated genes in dysplastic naevi and primary melanomas. Genes observed as 
hypermethylated in either dysplastic naevus compared to common naevus (left column) or primary melanoma 
compared to common naevus (right column). Genes were considered hypermethylated in dysplastic naevi when 
more than 5% of the number of analyzed dysplastic naevi showed methylation compared to the number of 





















-tion data followed by validation in an independent set of primary melanomas was 
performed (Chapter 6). This showed that MCHR1 was significantly hypermethylated in 
primary melanomas with metastatic capacity. SYNPO2 was the second gene that showed 
substantial, but not significant, hypermethylation. Kaplan-Meier survival analysis was 
performed using methylation data from the TCGA database containing 
HumanMethylation450K Beadchip methylation data of 48 primary melanoma and 229 
metastasized melanoma biopsy specimens. Due to the limited amount of patient 
information on metastatic capacity of the primary melanomas, the number of primary 
melanomas with known metastatic capacity was too small to analyze the value of 
potential prognostic factors. Instead, Kaplan-Meier survival analysis was carried out on the 
229 metastasized melanomas from the TCGA database. This showed that a cg-probe β-
value higher than 0.50 for MCHR1 was significantly associated with a poorer survival rate 
(Chapter 6). It is interesting that in addition to a significant association with metastatic 
behavior observed in a set of primary melanomas, MCHR1 methylation is also correlated 
to survival outcome of metastasized melanomas. Further comparative analysis of genome-
wide methylation data between melanoma metastasis and primary melanoma biopsy 
specimens also showed significant hypomethylation of MAGEA3 and MAGEA6 in the 
melanoma metastasis samples. 
Not surprisingly, the methylation differences that we observed in the 
comparative analysis of primary melanomas with and without metastatic behavior were 
relatively small. It is likely that methylation differences, if present will be smaller than 
when distinct stages of melanoma progression are compared (for example naevus to 
melanoma). The observation of MCHR1 methylation in benign melanocytic tissue indicates 




differences in methylation density of the CpG promoter region, rather than a complete 
presence or absence of methylation. Since the comparative analysis was performed on a 
small group of primary melanomas with known metastatic capacity, it is possible that 
upon comparison between larger sample series, more genes will be identified with 
significant differential methylation. 
Our findings in Chapter 6 suggest that the methylation status of MCHR1 and 
perhaps also SYNPO2 may be useful in predicting the metastatic behavior of a primary 
melanoma. However we have only started with a first methylation analysis. Because of the 
small sample sets, some methylation events may be random occurrences within the 
specific tumor samples used. Additional validation involving large sample sets of primary 
melanoma biopsies with known clinical information on metastatic capacity is necessary to 
determine the prognostic value of MCHR1 and SYNPO2.  Especially the question whether 
these genes have prognostic value independent of existing clinical parameters used to 
predict prognosis such as Breslow’s thickness, ulceration, mitotic index, gender and age 
will be important. 
We have identified MCHR1 as a novel gene that is differentially methylated 
between primary melanoma with and without metastatic behavior. MCHR1 promoter 
methylation has not yet been previously described in cancer. MCHR1 was found to be an 
auto-antigen, normally expressed by human melanocytes and is thought to serve as a 
target for auto-immune responses in certain cases
25
. Additional analyses will be needed to 
establish the effect of promoter CpG island methylation density on MCHR1 expression. In 
line with our findings for SYNPO2, a commonly deleted region in prostate cancer was 
mapped to the encoding sequence of SYNPO2 (also known as Myopodin) on chromosome 
4q25. Complete or partial deletion correlated with prostate cancer invasiveness and was 
found in 80% of the investigated invasive prostate cancer cases. SYNPO2 
hypermethylation has also been observed in colon cancer cells and colorectal tissue where 
it was found to correlate with overall survival in two independent validation series
26,27
. 
From the candidates in our diagnostic marker panel in Chapter 4, genes such as CLDN11 
and CDH11 can also be considered for testing their value as prognostic biomarkers since 
these genes are frequently methylated in melanoma, in which they are more frequently 
methylated in metastatic melanoma than in primary melanoma lesions, and they have 
been implicated in the processes of invasion and metastasis. 
 
Future perspectives 
Cancer cell genomes generally exhibit a global loss of methylation (hypomethylation) 
together with an aberrant increase in methylation (hypermethylation) at CpG islands, GC-
rich regions present in approximately half of all human gene promoters. Using promoter 
CpG island methylation profiling we have generated a comprehensive view of promoter 
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hypermethylation in primary melanoma and have found that aberrant methylation is 
widespread in melanoma when compared to common naevi. Questions still remain on 
what causes the widespread promoter hypermethylation in melanoma. This relates to the 
question on how in normal cells, CpG islands remain protected from DNA methylation. A 
challenge remains to further elucidate what causes epigenetic deregulation in cutaneous 
melanoma. Recently, ten-eleven translocation (TET) family of enzymes that oxidize 5-
methylcytosine to 5’-hydroxymethylcytosine were discovered and led to the insight that 
DNA hydroxymethylation is important in the process of dynamic cytosine modification, 
where 5’-methylcytosines can undergo active demethylation and are reversed back to 
cytosine
28,29
. This implicates a more complex regulation of gene expression than initially 
thought in both normal and cancer cells. 
The genetic lesions underlying cutaneous melanoma are becoming increasingly 
well understood. However an overview of the epigenetic alterations that underlie 
melanoma and the combined interaction between genetics and epigenetics to induce 
gene expression changes in the development of cutaneous melanoma is still lacking.  Full 
insight into these molecular events and their interactions will certainly emerge in the near 
future. It seems that integrating data generated by new genomic and epigenomic profiling 
techniques is necessary to achieve this. The delineation of not only the pattern of DNA 
methylation, but also the pattern of histone modifications and chromatin remodeling will 
provide insight into the contribution of each of these epigenetic mechanisms to 
melanoma initiation and progression. An understanding of these underlying molecular 
events will aid in the search for new diagnostic and prognostic biomarkers and improve 
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De studies in dit proefschrift zijn gericht op het in kaart brengen van promoter CpG eiland 
methylatie patronen in cutaan melanoom, ter identificatie van epigenetische 
veranderingen die van belang zijn bij de ontwikkeling van melanoom, en die kunnen 
dienen als diagnostische en prognostische biomarkers. 
Cutaan melanoom is een agressieve vorm van huidkanker die uitgaat van de 
pigmentcellen (melanocyten) van de huid. Waar melanoom beperkt tot de huid genezen 
kan worden door chirurgische excisie, is melanoom met metastasen op afstand vaak 
fataal. Het ontstaan en de progressie van melanoom wordt veroorzaakt door 
veranderingen in het erfelijk materiaal (het DNA) van de melanocyten. Een gen is een 
regio in het DNA die de code bevat voor het maken van een eiwit. Eerst vindt transcriptie 
van een gen naar messenger RNA (mRNA) plaats, vervolgens wordt de code van dit mRNA 
afgelezen voor productie van het eiwit; op deze manier wordt een gen tot expressie 
gebracht door de cel. Het optreden van een verandering in het DNA kan tot gevolg hebben 
dat een gen foutief tot expressie komt. Het foutief tot expressie komen van genen leidt tot 
een verstoring in het normaal functioneren van de cel. Foutieve expressie van een 
toenemend aantal genen heeft geleidelijke ontsporing van normale cellen naar 
kankercellen tot gevolg. Niet alleen genetische veranderingen, maar ook epigenetische 
veranderingen leiden tot foutieve expressie van genen die de transformatie van normale 
cellen naar kankercellen induceren. 
In elke cel is het DNA op een speciale manier verpakt in de celkern. Elk DNA 
molecuul is gewikkeld rondom speciale eiwitten (histon eiwitten) en verpakt in clusters in 
de celkern; bij elkaar wordt de organiserende DNA-eiwit structuur aangeduid als 
chromatine. Hoe dicht het chromatine verpakt is heeft effect op welke genen wanneer 
afgeschreven worden. Bij epigenetische veranderingen gaat het om een verandering in de 
chromatine structuur, en niet een feitelijke verandering in het DNA zelf, die veranderingen 
in de expressie van een gen teweeg brengt. Een bekend epigenetisch mechanisme is 
methylatie. Bij methylatie van het DNA in een menselijke cel wordt een methylgroep 
vastgemaakt aan een cytosine nucleotide die zich naast een guanine nucleotide in het 
DNA bevindt. Een cytosine en guanine nucleotide naast elkaar in het DNA wordt ook 
aangeduid als een CpG dinucleotide. In het menselijk DNA zijn er afzonderlijke regio’s met 
een groot aantal CpG dinucleotiden, de zogenaamde CpG eilanden. Meer dan de helft van 
alle menselijke genen bevat CpG eilanden aan het begin van het gen, in het gebied  waar 
ook de promoter van het gen zit. De promoter is een regio in het DNA die de transcriptie 
van DNA naar RNA reguleert. Methylatie van CpG eilanden in de genpromoter leidt tot 
een verandering van het chromatine naar een gesloten conformatie. Tevens induceert de 
methylatie van CpG eilanden binding van eiwitcomplexen die transcriptie van het DNA 




veelal geen methylgroep, ze zijn zeer beperkt gemethyleerd. In kankercellen echter, vindt 
abnormale methylatie (hypermethylatie) plaats op deze CpG eilanden. In kankercellen 
gaat deze promoter CpG eiland hypermethylatie vaak gepaard met verminderde of 
afwezige transcriptie van genen getroffen door deze epigenetische verandering. Op deze 
manier kan hypermethylatie leiden tot inactivatie van tumor suppressor genen. Een tumor 
suppressor gen codeert voor eiwitten die de groei van een cel onderdrukken. Deze tumor 
suppressors spelen vaak een cruciale rol in de controle van celdeling, want in tegenstelling 
tot normale cellen, zijn verscheidene tumor suppressor eiwitten afwezig of defect in 
kankercellen. Zo is ook promoter hypermethylatie van genen die bekende tumor 
suppressor eiwitten coderen, zoals CDKN2A, CDH1 en PTEN, gevonden in melanoom. 
Onderzoek naar methylatie veranderingen in cutaan melanoom heeft zich tot nog toe 
beperkt tot analyse van een klein aantal genen, waarbij het onderzochte materiaal 
beperkt bleef tot melanoom cellijnen of weefsel van metastatisch melanomen. In de 
studies opgenomen in dit proefschrift is gebruik gemaakt van bioptweefsel van normale 
naevi, dysplastische naevi, primaire melanomen en metastatische melanomen. 
In hoofdstuk 2 beschrijven we het in kaart brengen van promoter CpG eiland 
methylatie patronen in primaire cutaan melanomen en normale naevi met behulp van 
Beadchip array. Deze array analyseert 27.578 CpG dinucleotiden verspreid over 14.495 
van de naar schatting 30.000 humane genen, d.w.z. bijna alle genen met een CpG eiland in 
de promoter. Wij vonden 106 genen met een significante toename in promoter mehylatie 
ten opzichte van normale naevi, onder deze genen bevonden zich HOXA9, MAPK13, 
CDH11, PLEKHG6, PPP1R3C and CLDN11. Het MAPK13 gen was in 67% van de primair 
melanomen gemethyleerd. MAPK13 codeert voor de isoform van een eiwit dat lid is van 
de p38 MAP kinase familie, p38δ. MAPK13 promoter methylatie was geassocieerd met 
verminderde p38δ expressie. Daarnaast zagen we, wanneer we in melanoomcellen met 
MAPK13 hypermethylatie die geen expressie van het gen meer hadden, de expressie van 
dit gen terugbrachten, dat deze melanoomcellen een afname in proliferatie vertoonden. 
Deze bevindingen zijn de eerste indicatie van een mogelijke tumor suppressieve rol voor 
MAPK13 in melanoom. Daarnaast suggereren deze bevindingen, samen met de 
aanwezigheid van MAPK13 promoter methylatie in een deel van de normale naevi, dat 
uitschakeling van MAPK13 door methylatie een vroege gebeurtenis is in de ontwikkeling 
van melanoom. 
Een belangrijk tumor suppressief mechanisme bij het ontstaan van melanoom is 
oncogen-geïnduceerde senescentie. Senescentie is het fenomeen waarbij een cel na een 
aantal celdelingen in een permanente groeistop raakt. Dit treedt op wanneer een normale 
cel wordt blootgesteld aan bepaalde vormen van stress. Een vorm van stress die 
senescentie kan induceren is activatie van een oncogen, zoals BRAF. In hoofdstuk 3 wordt 




beschreven. shRNA screening gericht op 15.000 genen gevolgd door validatie resulteerde 
in zeven genen, waaronder RASEF. Uit reanalyse van genoom-wijde methylatie data was 
RASEF één van de genen die onderhevig was aan frequente hypermethylatie in BRAF-
mutante melanomen. In een onafhankelijke groep primaire melanomen en normale naevi 
was de methylatie frequentie van RASEF 21%, hier bleek RASEF methylatie niet beperkt tot 
lesies met BRAF mutatie. Opvallend was dat depletie van RASEF resulteerde in het 
uitblijven van een BRAF
V600E
-geïnduceerde senescentie respons, en suppressie van 
senescentie biomarkers zoals (SA)-β-galactosidase activiteit, IL-6 en tumor suppressor 
p15
INK4B
. Daarnaast leidde het terugbrengen van RASEF expressie in melanoomcellen waar 
expressie van dit gen door promoter methylatie was uitgeschakeld, tot een vertraging in 
celgroei. Samen suggereren deze bevindingen dat RASEF een potentieel nieuw tumor 
suppressor gen is in melanoom, dat werkt door het voorkomen van verder ontsporen van 
beginnende melanoomcellen door activatie van oncogen-geïnduceerde senescentie en het 
afremmen van celgroei. 
Dysplastische naevi zijn een type moedervlek die er anders uit zien dan een 
normale moedervlek. Een dysplastische naevus kan groter zijn dan een normale 
moedervlek en verschillen in een aantal met het oog waarneembare kenmerken zoals 
kleur, symmetrie, oppervlakte en rand van de moedervlek. Onderscheid tussen een 
dysplastische naevus en een vroeg-stadium primair melanoom kan moeilijk zijn op grond 
van waargenomen veranderingen in de weefselarchitectuur en aspect van de 
melanocyten. Er bestaat behoefte aan moleculair-pathologische methoden om met 
zekerheid de diagnose melanoom te kunnen stellen. Voor de zoektocht naar potentiële 
diagnostische biomarkers zijn we uitgegaan van de 12 meest frequent in melanoom 
gehypermethyleerde genen. Dit betrof de genen HOXA9, C1orf106, MAPK13, CDH11, 
EFCAB1, CNTN1, GNMT, PLEKHG6, PPP1R3C en CLDN11. Het methylatiepatroon van deze 
12 genen is in biopten van dysplastische naevi onderzocht en vergeleken met het 
methylatiepatroon van normale naevi, primaire melanomen en metastatische 
melanomen. In hoofdstuk 4 worden de resultaten van dit onderzoek beschreven. 
Promoter methylatie analyse liet een progressief toenemende methylatie frequentie zien 
van genen zoals CDH11, PPP1R3C en PLEKHG6, met minimale methylatie in normale 
naevus, een geleidelijke toename van methylatie in dysplastisch naevus, en een scherpe 
toename in methylatie frequentie in primair en metastatisch melanoom. Dysplastische 
naevi vertoonden tevens aanwezigheid van methylatie van genen die  frequent 
gemethyleerd waren in melanoom maar niet in normale naevi, zoals het C1orf106 en 
GNMT gen. HOXA9, MAPK13 en CNTN1 promoter methylatie was aanwezig in een subset 
normale en dysplastische naevi en in 40% - 80% van de onderzochte primaire melanomen. 
CLDN11 was bijzonder specifiek voor melanoom met promoter methylatie in 50% van de 




methylatie status van een panel bestaande uit vijf genen CLDN11, CDH11, PPP1R3C, 
MAPK13 en GNMT werd getest op onafhankelijke series van melanomen en dysplastische 
naevi. Hieruit bleek dat de methylatie status van CLDN11 in combinatie met dat van 
CDH11, PPP1R3C, MAPK13 en GNMT kon helpen met een onderscheid maken tussen 
primair melanoom en dysplastische naevus. Een gecombineerde detectie van CLDN11, 
CDH11 en PPP1R3C promoter methylatie resulteerde in een specificiteit van 89% en 
sensitiviteit van 67%. De melanoom-specifieke methylatie van deze genen wijst op 
mogelijk toekomstige toepasbaarheid als diagnostische biomarker. 
Volgend op DNA methylatie patronen in dysplastische naevi, is hoofdstuk 5 
gericht op identificatie van verschillen in gen- en eiwitexpressie van melanocyten 
afkomstig van dysplastische naevus, en melanocyten afkomstig van aangrenzende 
normale huid. Melanocyten zijn onderhevig aan oxidatieve stress, waarbij in de cel meer 
reactieve zuurstofverbindingen aanwezig zijn dan normaal. In melanocyten afkomstig van 
dysplastische naevi is een verhoogde toestand van oxidatieve stress gevonden. Om inzicht 
te verkrijgen in moleculaire signaleringspaden die ten grondslag liggen aan de verhoogde 
oxidatieve stress levels in dysplastisch naevus melanocyten, zijn het gen- en eiwitexpressie 
patroon van melanocyten afkomstig van dysplastische naevus en van normale huid met 
elkaar vergeleken. Teneinde dit te onderzoeken zijn melanocyten uit dysplastische naevi 
en melanocyten uit aangrenzende normale huid geïsoleerd en opgekweekt. Uit de 
opgekweekte melanocyten is RNA en eiwit verkregen voor respectievelijk genexpressie 
analyse middels Affymetrix array en massaspectrometrie analyse. Tijdens de studie kon in 
de melanocyt celkweken een verschil in morfologie en delingssnelheid worden 
waargenomen tussen melanocyten afkomstig uit dysplastische naevus en melanocyten 
afkomstig van normale huid. Hoewel de genexpressie profielen van beide melanocyt typen 
overeenkomstig waren, waren er ook verschillen in signaleringspaden betrokken bij de 
volgende cellulaire processen: metabolisme, detoxificatie en organisatie van het 
cytoskelet. Over het algemeen vertoonden melanocyten afkomstig van dysplastische naevi 
vergelijkbare gen- en eiwitexpressie patronen in vergelijking tot melanocyten afkomstig 
van aangrenzende normale huid. 
Een deel van de melanomen zaait uit (metastaseert) en het is moeilijk om te 
voorspellen welk melanoom dat zal doen. De voornaamste klinische factor die wordt 
gebruikt om een voorspelling over mogelijk metastaseren van een melanoom te doen, is 
de dikte van de tumor. Het vinden van prognostische biomarkers waarmee een goede 
voorspelling over metastasering kan worden gedaan is noodzakelijk voor een optimale 
behandeling van de patiënt. Ter identificatie van methylatie patronen met potentiële 
prognostische waarde en die mogelijk ter grondslag liggen aan het verkrijgen van 
invasieve en metastatische capaciteit, is in hoofdstuk 6 gezocht naar aanwezigheid van 




Een analyse van genoom-wijde methylatie data werd uitgevoerd, met daaropvolgend 
validatie in een set biopten bestaande uit primaire melanomen met en zonder 
metastatisch gedrag. Hieruit kwamen MCHR1 en SYNPO2 naar voren als meer frequent 
gemethyleerd in melanomen met metastatisch gedrag. Vervolgonderzoek liet zien dat 
metastatische lesies met MCHR1 methylatie een significant slechtere overleving hadden 
dan metastatische melanomen zonder MCHR1 methylatie. Interessant aan deze bevinding 
is dat MCHR1 methylatie  naast een significante associatie met metastatisch gedrag van de 
primaire lesie, ook correleert met de overlevingskans van patiënten met reeds 
gemetastaseerd melanoom. Dit kan erop duiden dat methylatie van MCHR1 een algemene 
indicator is voor agressief gedrag van melanoom. 
Het onderzoek naar promoter methylatie in melanoom heeft laten zien dat 
tijdens de ontwikkeling van melanoom er abnormale methylatie plaatsvindt van vele 
tientallen genen. Waar normale naevi geringe promoter methylatie laten zien, vindt een 
duidelijke toename in de frequentie van promoter methylatie plaats in melanomen. 
Geïdentificeerde genen met frequente hypermethyatie in melanoom kunnen potentiële 
tumor suppressieve functies hebben. Wat de oorzaak is van de uitgebreide toename in 
promoter methylatie tijdens de ontwikkeling van melanoom is nog onduidelijk. De invloed 
van genetische mechanismen en de wisselwerking tussen epigenetische en genetische 
mechanismen in de totstandkoming van de veelvuldig aberrant gemethyleerde genen in 
melanoom ten opzichte van een melanocytaire benigne laesie hebben meer onderzoek 
nodig. Het ontrafelen hiervan zou mogelijk nieuwe aanknopingspunten voor de 
behandeling van cutaan melanoom kunnen bieden. Verder hebben we tijdens ons 
onderzoek gevonden dat de methylatiestatus van CLDN11 in combinatie met vier anderen 
genen, PPP1R3C, CDH11, MAPK13 en GNMT kan bijdragen aan het onderscheid tussen 
dysplastische naevus en een vroeg-stadium melanoom. Hoewel melanoom niet in alle 
gevallen door analyse van de methylatie van een enkel gen met zekerheid kan worden 
gediagnosticeerd, kan de detectie van een combinatie van differentieel gemethyleerde 
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